Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Validation of senofilcon A with new UV / HEV Filter
Protocol CR-6470Version: 2.0Date: 14 September 2021
Investigational Products: senofilcon A with new UV / HEV Filter
Keywords: Sphere platform, Test lens: senofilcon  A with new UV / HEV blocker, Control 
lens: senofilcon A without new UV / HEV bl ocker (ACUVUE OASYS 1-Day), daily wear, 
daily disposable, dispensing, Revitalens,  logMAR visual acuity, biomicroscopy, fit 
acceptance, CLUE vision, situational visual pe rformance (indoors and digital devices), CLUE 
handling, CLUE comfort.
Statement of Compliance to protocol, GC P and applicable regulatory guidelines:
This trial will be conducted in comp liance with the protocol, ISO 14155:2020,
1the 
International Council for Harmonization G ood Clinical Practice E6(R2) (ICH GCP),2the 
Declaration of Helsinki,3and all applicable regulatory requirements.
Confidentiality Statement:
This document contains confide ntial information, which should not be copied, referred to, 
released or published without written approval from Johnson & Johnson Vision Care, Inc. The 
information may not be disclosed to others except to the extent necessary to obtain Institutional Review Board/Independent Ethics Committee a pproval and informed consent, or as required 
by International, Federal and State Laws, as a pplicable. Persons to whom this information is 
disclosed must be informed that this informatio n is privileged and confidential and that it 
should not be further disclosed without the written permission of Johnson & Johnson Vision 
Care, Inc. Any supplemental information that may be added to this document is also 
confidential and proprieta ry to Johnson & Johnson Vision Care, Inc. and must be kept in 
confidence in the same manner as the contents of this document.
CR-6470, v 2.0  
 
Page 1 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
TABLE OF CONTENTS
PROTOCOL TITLE, NUMBER, VERSION AND DATE...................................................... 7  
SPONSOR NAME AND ADDRESS....................................................................................... 7  
MEDICAL MONITOR............................................................................................................. 7  
AUTHORIZED SIGNATURES............................................................................................... 8  
CHANGE HISTORY................................................................................................................ 9  
SYNOPSIS....................................................................................................................... ....... 10  
COMMONLY USED ABBREVIATIONS, ACRONYMS AND DEFINITIONS OF TERMS
............................................................................................................................... .................. 16  
1. INTRODUCTION AND BACKGROUND ................................................................... 17  
1.1. Name and Descriptions of Investigational Products ................................................ 17  
1.2. Intended Use of Investigational Products................................................................. 17  
1.3. Summary of Findings from Nonclinical Studies...................................................... 17  
1.4. Summary of Known Risks and Bene fits to Human Subjects................................... 18  
1.5. Relevant Literature References and Prior Cl inical Data Relevant to Proposed Clinical 
Study 18  
2. STUDY OBJECTIVES, ENDPOINTS AND HYPOTHESES ...................................... 18  
2.1. Objectives................................................................................................................. 18  
2.2. Endpoints.................................................................................................................. 19  
2.3. Hypotheses ............................................................................................................... 20  
3. TARGETED STUDY POPULATION........................................................................... 21  
3.1. General Characteristics ............................................................................................ 21  
3.2. Inclusion Criteria...................................................................................................... 21  
3.3. Exclusion Criteria..................................................................................................... 22  
3.4. Enrollment Strategy.................................................................................................. 23  
4. STUDY DESIGN AND RATIONALE .......................................................................... 23  
4.1. Description of Study Design .................................................................................... 23  
4.2. Study Design Rationale............................................................................................ 24  
4.3. Enrollment Target and Study Duration .................................................................... 24  
5. TEST ARTICLE ALLOCATION AND MASKING..................................................... 24  
5.1. Test Article Allocation............................................................................................. 24  
5.2. Masking.................................................................................................................... 25  
5.3. Procedures for Maintaining and Breaking the Masking........................................... 25  
6. STUDY INTERVENTION............................................................................................. 26  
CR-6470, v 2.0  
 
Page 2 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
6.1. Identity of Test Articles............................................................................................ 26  
6.2. Ancillary Supplies/Products..................................................................................... 27  
6.3. Administration of Test Articles................................................................................ 27  
6.4. Packaging and Labeling ........................................................................................... 27  
6.5. Storage Conditions ................................................................................................... 28  
6.6. Collection and Storage of Samples .......................................................................... 28  
6.7. Accountability of Test Articles ................................................................................ 28  
7. STUDY EVALUATIONS.............................................................................................. 29  
7.1. Time and Event Schedule......................................................................................... 29  
7.2. Detailed Study Procedures ....................................................................................... 30  
VISIT 1 ........................................................................................................................... 30  
VISIT 2 ........................................................................................................................... 36  
FINAL EVALUATION.................................................................................................. 38  
7.3. Unscheduled Visits................................................................................................... 39  
7.4. Laboratory Procedures ............................................................................................. 41  
8. SUBJECTS COMPLETION/WITHDRAWAL.............................................................. 41  
8.1. Completion Criteria.................................................................................................. 41  
8.2. Withdrawal/Discontinuation from the Study ........................................................... 41  
9. PRE-STUDY AND CONCOMITANT INTERVENTION/MEDICATION ................. 42  
9.1. Systemic Medications .............................................................................................. 42  
10. DEVIATIONS FROM THE PROTOCOL .................................................................. 44  
11. STUDY TERMINATION ........................................................................................... 45  
12. PROCEDURE FOR HANDLING PRODUCT QUALITY COMPLAINTS.............. 46  
13. ADVERSE EVENTS................................................................................................... 47  
13.1.  Definitions and Classifications............................................................................. 47  
13.2.  Assessing Adverse Events.................................................................................... 50  
13.2.1.  Causality Assessment.................................................................................... 50  
13.2.2.  Severity Assessment...................................................................................... 50  
13.3.  Documentation and Follow-Up of Adverse Events.............................................. 51  
13.4.  Reporting Adverse Events .................................................................................... 52  
13.4.1.  Reporting Adverse Events to Sponsor .......................................................... 52  
13.4.2.  Reporting Adverse Events to the Res ponsible IEC/IRB and Health Authorities
53 
13.5.  Event of Special Interest....................................................................................... 53  
CR-6470, v 2.0  
 
Page 3 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
13.6.  Reporting of Pregnancy ........................................................................................ 54  
14. STATISTICAL METHODS........................................................................................ 54  
14.1.  General Considerations......................................................................................... 54  
14.2.  Sample Size Justification...................................................................................... 54  
14.3.  Analysis Populations ............................................................................................ 58  
14.4.  Level of Statistical Significance........................................................................... 59  
14.5.  Primary Analyses.................................................................................................. 59  
14.6.  Secondary Analyses.............................................................................................. 62  
14.7.  Other Exploratory Analysis.................................................................................. 63  
14.8.  Interim Analysis ................................................................................................... 63  
14.9.  Procedure for Handling Missing Data and Drop-Outs ......................................... 63  
14.10.  Procedure for Reporting Deviations from Statistical Plan ................................... 64  
15. DATA HANDLING AND RECORD KEEPING/ARCHIVING................................ 64  
15.1.  Electronic Case Report Form/Data Collection ..................................................... 64  
15.2.  Subject Record...................................................................................................... 64  
15.3.  Trial Registration on ClinicalTrials.gov............................................................... 65  
16. DATA MANAGEMENT............................................................................................. 65  
16.1.  Access to Source Data/Document ........................................................................ 65  
16.2.  Confidentiality of Information.............................................................................. 65  
16.3.  Data Quality Assurance ........................................................................................ 65  
16.4.  Data Monitoring Committee (DMC).................................................................... 66  
17. CLINICAL MONITORING ........................................................................................ 66  
18. ETHICAL AND REGULATORY ASPECTS ............................................................ 66  
18.1.  Study-Specific Design Considerations ................................................................. 66  
18.2.  Investigator Responsibility................................................................................... 67  
18.3.  Independent Ethics Committee or Institutional Review Board (IEC/IRB) .......... 67  
18.4.  Informed Consent ................................................................................................. 68  
18.5.  Privacy of Personal Data ...................................................................................... 68  
19. STUDY RECORD RETENTION................................................................................ 70  
20. FINANCIAL CONSIDERATIONS ............................................................................ 70  
21. PUBLICATION........................................................................................................... 71  
22. REFERENCES ............................................................................................................ 71  
APPENDIX A: PATIENT REPORTED OUTCOMES (STUDY QUESTIONNAIRES) ..... 73  
APPENDIX B: PATIENT INSTRUCTION GUIDE ............................................................. 84  
CR-6470, v 2.0  
 
Page 4 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
APPENDIX C: PACKAGE INSERT (APPROVED PRODUCT)......................................... 85  
APPENDIX D: ................................ ....114 
 Limbal & Conjunctival (Bulbar) Redness ................................ ........................... 115 
 Expanded Sodium Fluorescein Corneal Staining ................................ ................ 122 
 Lens Fitting Characteristics ................................ ................................ ................. 129 
 Subject Reported Ocular Symptoms/Problems ................................ ................... 135 
Front and Back Surface Lens Deposit Grading Procedure ................................ .137 
 Determination of Distance S pherocylindrical Refractive Error .......................... 142 
 Biomicroscopy Scale ................................ ................................ ........................... 148 
 Keratometry Procedure ................................ ................................ ....................... 154 
 Distance and Near Snellen V isual Acuity Evaluation ................................ ......... 156 
 Distance LogMAR Visual Acuity Measurement Procedure ............................... 161 
 Patient Reported Outcomes ................................ ................................ ................. 165 
 White Light Lens Surface Wettability ................................ ................................ 167 
 Visual Acuity Chart Luminance and Room Illumination Testing ...................... 169 
APPENDIX E: IRIS COLOR SCALE ................................................................................. 178  
APPENDIX F: STARTING LENS POWER GUIDANCE.................................................. 179  
APPENDIX G: GUIDELINES FOR COVID-19 RISK MITIGATION .............................. 180  
PROTOCOL COMPLIANCE INVESTIGATOR(S) SIGNATURE PAGE ........................ 192  
 
LIST OF TABLES
Table 1: Enrollment Strategy Overall ..................................................................................... 23  
Table 2: Duration of Study Visits ........................................................................................... 24  
Table 3: Test Articles.............................................................................................................. 26  
Table 4: Ancillary Supplies .................................................................................................... 27  
Table 5: Time and Events ....................................................................................................... 29 
Table 6: Disallowed systemic medications............................................................................. 43  
Table 7: Disallowed systemic antihistamines......................................................................... 44  
Table 8: Examples of major and minor protocol deviations................................................... 44  
Table 9: Descriptive Summary and Adjusted Means of LogMAR Visual Acuity and CLUE 
Scores from ,  and  (Interim) ................................ ....................... 55 
Table 10: Descriptive Summary and Adjusted Proportion Estimates for Two Situational Visual 
Performance Items at 2 -week Follow -up from  and  (Interim) .................. 55 
Table 11: Sample Size Estimation for the Primary Endpoints ............................................... 58  
CR-6470, v 2.0  
 
Page 5 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Table 12: Power Estimation for the Secondary Endpoints ..................................................... 58  
 
LIST OF FIGURES
Figure 1: Study Flowchart ...................................................................................................... 15 
 
CR-6470, v 2.0  
 
Page 6 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
PROTOCOL TITLE, NUMBER, VERSION AND DATE 
Title: Validation of senofilcon A with new UV / HEV Filter
Protocol Number: CR-6470Version: 2.0Date: 14 September 2021
SPONSOR NAME AND ADDRESS 
Johnson & Johnson Vision Care, Inc. (JJVC)
7500 Centurion Parkway Jacksonville, FL 32256
MEDICAL MONITOR 
The Medical Monitor must be notified by the clinical institution/site by e-mail or telephone 
within 24 hours of learning of a Serious Adverse Ev ent. The Medical Monitor may be contacted 
during business hours for adverse event questions. G eneral study related questions should be 
directed towards your assigned clinical research associate.
The Medical Monitoring Plan is maintained as a separate document and included in the Trial 
Master File.
 
CR-6470, v 2.0  
 
Page 7 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
AUTHORIZED SIGNATURES 
The signatures below constitutes the approval of this protocol and the attachments and provide 
the necessary assurances that this trial will be conducted according to all stipulations of the 
protocol, including all statement s regarding confidentiality, and according to local legal and 
regulatory requirements and applicable U.S. federal regulations,4ISO 14155:2020,1ICH 
guidelines2, and the Declaration of Helsinki.3
Author / Study Responsible Clinician
See Electronic Signature Report 
DATE
Clinical Operations Manager
See Electronic Signature Report
DATE
Biostatistician See Electronic Signature Report
DATE
Biostatistical Review See Electronic Signature Report
DATE
Data Management See Electronic Signature Report
DATE
Medical Safety Officer See Electronic Signature Report
DATE
Approver See Electronic Signature Report
DATE
 
CR-6470, v 2.0  
 
Page 8 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
CHANGE HISTORY 
Version Originator Description of Change(s) and 
Section Number(s) AffectedJustification 
for ChangeDate
1.0 New Protocol NA 07 Sep 2021
2.0 Update Section 7.2, Step 1.8: 
remove GSI Background questionnaireQuestionnaire 
is not being used14 Sep 2021
CR-6470, v 2.0  
 
Page 9 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
SYNOPSIS  
Protocol Title Validation of senofilcon A with new UV / HEV Filter
Sponsor JJVC, 7500 Centurion Parkway, Jacksonville, FL  32256
Clinical Phase Clinical trial phase: confirmatory
Design control phase: Confirmatory phase, phase 3
Trial Registration This study will be registered on ClinicalTrials.gov by the 
Sponsor
Test Article(s) Investigational Products: senof ilcon A with new UV / HEV 
filter
Approved Products: senofilcon A without new UV / HEV 
filter (ACUVUE OASYS 1-Day)
Wear and Replacement 
SchedulesWear Schedule: daily wear
Replacement Schedule: daily disposable
Objectives This study is being conducted to  validate that the Test lens 
meets the customer requirements.
Primary Objectives : The Test lens will meet the safety and 
efficacy requirements of the Design Validation Requirements.
Secondary Objectives : The Test l ens will meet the Market 
Preference Requirements.
Study Endpoints Primary endpoint(s): logMAR acuity, biomicroscopy, fit 
acceptance, CLUE vision
Secondary endpoint(s): CLUE handling, CLUE comfort, 
situational visual performance –digital devices , and 
situational visual performance - indoors
Study Design This is a bilateral, dispen sing, randomized, controlled, 
subject -masked, 2-arm parallel study. Each subject will be 
bilaterally fitted with one of the two study articles during the 
course of the study .
There will be a total of 2v i s i t s :
1.Visit 1: Screening, baseline evaluation and lens fit #1
2. Visit 2: Follow-up to lens fit #1. Final evaluation
See the flow chart at the end of the synopsis table for the 
schematic of the study visits and procedures of main observations (
Figure 1).
CR-6470, v 2.0  
 
Page 10 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Sample Size Approximately 320 subjects in total (enrolling a160 in the 
Test lens group and 1 60 in the Control lens group with the aim 
to complete approximately 2 86 subjects ( a143in each of the 
2 lens groups).
Study Duration Subject enrollment will last 4 weeks per site. Once enrolled, 
subjects will be in the study for approximately 2 weeks, 
making the entire study approximately 6 weeks in duration.
Anticipated Study 
PopulationSubjects will be male and fe male of any race and ethnicity, 
age 18 through 39, habitual wearers of spherical silicone 
hydrogel contact lenses within the power range of -1.00 
through -6.00 D. Subjects will be targeted in a 7:3 ratio based 
on hab itual lens wear (7 h abitual daily disposable wearers 
versus 3 habitual daily wear reusable wearers) within each 
lens group.
CR-6470, v 2.0  
 
Page 11 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Eligibility Criteria -
InclusionPotential subjects must satisfy all of the following criteria to 
be enrolled in the study:
Inclusion Criteria after Screening
The subject must:
1.Read, understand, and sign the STATEMENT OF 
INFORMED CONSENT and receive a fully executed 
copy of the form.
2.Appear able and willing to adhere to the instructions 
set forth in this clinical protocol.
3. Be between 18 and 39 (inclusive) years of age at the 
time of screening.
4. By self- report, habitually wear spherical silicone 
hydrogel soft contact lenses in both eyes in a daily 
reusable or daily disposable wear modality (i.e. not 
extended wear modality). Habi tual wear is defined as 
a minimum of 6 hours of wear per day, for a minimum 
of 5 days per week during the past 30 days.
5. Have a habitual contact lens prescription that is 
current within the prior 6 months, and they must have 
worn that prescription for at le ast 2 weeks prior to 
entering the study. 
Inclusion Criteria at Baseline Evaluation
6.The subject’s vertex correc ted spherical equivalent 
distance refraction must be in the range of -1.00
through -6.00 D in both eyes.
7.The subject’s refractive cylinder must be 1.00 D or 
less.
8.The subject must have best corrected visual acuity of 
20/25 or better in each eye.
CR-6470, v 2.0  
 
Page 12 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Eligibility Criteria –
ExclusionPotential subjects who meet any of the following criteria will 
be excluded from participating in the study:
Exclusion Criteria after Screening:
The subject must not:
1. Be currently pregnant or lactating.
2.Have any ocular or systemic allergies or diseases that 
may interfere with contact lens wear. 
3.Have any autoimmune disease or use of medication, 
which may interfere with con tact lens wear.  Habitual 
medications used by successful soft contact lens 
wearers are considered acceptable.
4.Have any previous, or planned, ocular or interocular 
surgery (e.g., radial keratotomy, PRK, LASIK, etc.).
5.Be currently wearing lenses in a monovision, multi-
focal, toric, or extended wear modality.
6. Have participated in a contact lens or lens care 
product clinical trial within 14 days prior to study 
enrollment
7.Be an employee (e.g., Investigator, Coordinator, 
Technician) or immediate family member of an employee (including partner, child, parent, 
grandparent, grandchild or sibling o f the employee or 
their spouse) of the clinical site.
8.Have a history of binocular vision abnormality or 
strabismus.
9. Have any infectious disease (e.g., hepatitis, 
tuberculosis) or contagious immunosuppressive 
diseases (e.g., HIV) by self-report.
Exclusion Criteria at Baseline Evaluation
The subject must not:
10.Have any Grade 3 or greater slit lamp findings (e.g., 
edema, corneal neovascularization, corneal staining, 
tarsal abnormalities, conjunctival injection) on the 
FDA classification scale, any previous history or 
signs of a contact lens- related corneal inflammatory 
event (e.g., past peripheral ulcer or round peripheral 
scar), or any other ocular abnormality that may 
contraindicate contact lens wear.
11. Have any ocular infection.12. Have any corneal distortion re
sulting from previous 
hard or rigid gas permeable contact lens wear.
CR-6470, v 2.0  
 
Page 13 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
13. Have entropion, ectropion, extrusions, chalazia, 
recurrent styes, glaucoma, history of recurrent corneal 
erosions, or aphakia.
Disallowed 
Medications/Interventions Use of any prescription or over-the-counter (OTC) 
medications that may affect contact lens wear from 24 hours prior to receiving the study product through the study period 
of
a14 days. Habitual medications taken by suc cessful soft 
contact lens wearers are generally considered acceptable.  
Note that habitual medications should be taken throughout the 
study period .
See section 9.1for details regarding disallowed systemic 
medications.
Measurements and 
ProceduresLogMAR visual acuity, biomicroscopy, fit acceptance, 
GSI/MRD and CLUE questionnaire items.
Microbiology or Other 
Laboratory TestingNone.
Study Termination The occurrence of an Unanticip ated Adverse Device Effect 
(UADE) or Serious Adverse Event (SAE) for which a causal 
relationship to a test article cannot be ruled out, will result in 
stopping further dispensing investigational product. In the 
event of a UADE or SAE, t he Sponsor Medical Monitor may 
unmask the treatment regimen of subject(s) and may discuss 
this with the Principal Investig ator before any further subjects 
are enrolled.
Ancillary Supplies/ Study-
Specific MaterialsPreservative free rewetting drops/artificial tears or saline.  
ACUVUE RevitaLens will be used to transport any 
problematic lenses back to the Sponsor. logMAR visual 
acuity charts.
Principal Investigator(s) 
and Study Institution(s)/Site(s)A full list of Principal Investigators, clinical sites, and 
institutions is kept separately from the Study Protocol and is 
included in the study Trial Master File.
CR-6470, v 2.0  
 
Page 14 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Figure 1: Study Flowchart
286-320 Subjects
x Available powers:  -1.00 to -6.00 in 0.25 D steps
x Habitual wearers of spherical silicone soft contact lenses worn as daily wear
x CL Rx current within prior 6 months, and worn for at least 2 weeks
x t 18 and < 40 years of age. 
Informed Consent
Eligibility Criteria
Baseline Information
¾ Baseline questionnaires
¾ Habitual lens type, modality
¾ Keratometry
¾ Iris color
¾ Subjective refraction
¾ Physiology
Test Group
Trial Period 1
¾ Subjects will be randomly assigned, and fit, a Test or 
Control lens on both eyes
¾ Modify powers to obtain a 0.00 D spherical over-refraction
10-Minute Evaluation
¾ Symptoms
¾ Fitting characteristics, VA
¾ For further testing, the lenses must provide:
¾ Appropriate fitting characteristics on both eyes
¾ 20/30 or better vision in both eyes
¾ Investigator approval
Follow-up 1
(13-15 Days)
¾ Compliance
¾ Patient reported outcomes (Questionnaires), Preference to Habitual
¾ logMAR acuity
¾ Surface characteristics, physiologyControl Group
Trial Period 1
¾ Subjects will be randomly assigned, and fit, a Test or 
Control lens on both eyes
¾ Modify powers to obtain a 0.00 D spherical over- refraction143-160 Subjects 143-160 Subjects
Final Evaluation
¾ Keratometry
¾ Subjective refraction
CR-6470, v 2.0  
 
Page 15 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
COMMONLY USED ABBREVIATIONS, AC RONYMS AND DEFINITIONS OF 
TERMS 
ADE Adverse Device Effect
ADHD Attention Deficit Hyperactivity DisorderAE Adverse Event/Adverse ExperienceBSCVA Best Spectacle Corrected Visual AcuityCFR Code of Federal RegulationsCLUE Contact Lens User ExperienceCOM Clinical Operations ManagerCOVID-19 Coronavirus Disease 2019CRA Clinical Research AssociateCRF Case Report Form
CRO Contract Research Organization
D Diopter
DMC Data Monitoring CommitteeeCRF Electronic Case Report FormEDC Electronic Data CaptureETDRS Early Treatment D iabetic Retinopathy Study
FDA Food and Drug AdministrationGCP Good Clinical PracticeHEV High Energy Visible lightHIPAA Health Insurance Portability and Accountability ActHIV Human Immunodeficiency VirusIB Investigator’s Brochure
ICH International Council for HarmonizationIDE Investigational Device ExemptionIEC Independent Ethics Committee
IRB Institutional Review Board
ISO International Organization for StandardizationITT Intent-to-TreatJJVC Johnson & Johnson Vision Care, Inc.LASIK Laser-Assisted in Situ KeratomileusisLogMAR Logarithm of Minimal Angle of ResolutionOD Right EyeOS Left EyeOU Both Eyes
PIG Patient Instruction Guide
PQC Product Quality ComplaintPRK Photorefractive KeratectomyPRO Patient Reported OutcomeQA Quality AssuranceSAE Serious Adverse Event/Serious Adverse Experience
SAP Statistical Analysis Plan
SAS Statistical Analysis System
CR-6470, v 2.0  
 
Page 16 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
SD Standard Deviation
UADE Unanticipated Adverse Device Effect
UV Ultraviolet radiation
USADE Unanticipated Serious Adverse Device Effect
VA Visual Acuity
1. INTRODUCTION AND BACKGROUND 
The range of high energy visible (HEV) light  is roughly defined in the literature, with 
references stating 380-500 nm5, 400-500 nm6and others stating 430-510 nm.7This region of 
the electromagnetic spectrum has special meaning to the eye. It is light that we can see, but
yet can have negative and positive effects on th e eye. At the shorter wavelength end of the 
range, around 435r 20 nm,8the light has enough energy to cause premature damage to the 
retinal pigment epithelium and has being linked to macular degeneration. The shorter 
wavelengths are also scattered more than longer wavelengths (Ray leigh scattering), which 
create the blue sky and “blue haze” that we see when looking at dist ant objects. At the longer 
wavelength end of the range, around 480 r20 nm,9the light is responsible for regulating our 
circadian rhythms and pupillary light reflexes.
Ophthalmic devices that block the shorter HEV wavelengths while transmitting the longer 
wavelengths might experience an immediate visual improvement through better chromatic 
contrast, while benefitting in the long-term through enhanced retinal protection. This study 
will investigate the clinical performance of th e prototype Test lenses against an otherwise 
similar Control.
1.1. Name and Descriptions of Investigational Products  
This study will evaluate a senofilcon A design prototype with new UV/HEV blocker against a commercially available marketed product ACUVUE OASYS
®Brand Contact Lenses 1-Day 
with HydraLuxe™ Technology (AO1D).  Further details about the test articles are found in 
section  of this protocol.  Note that the new UV/HEV blocker was previously identified as 
Theia I.
1.2. Intended Use of Investigational Products 
The intended use of the investigative product is for correcting myopia and for improving the 
visual experience by improving contrast. During the study, each test article will be worn bilaterally in daily wear, daily disposable mod ality for at least 6 hours per day and 5 days per 
week for approximately two weeks. The subject will wear both test articles in a cross-over 
study design.
1.3. Summary of Findings from Nonclinical Studies 
All previous pre-clinical findings were deemed satisfactory prior to proceeding with clinical 
trials on humans. For the most comprehensiv e nonclinical information regarding senofilcon A 
with new UV / HEV filter, refer to the latest version of the Investigator’s Brochure.
CR-6470, v 2.0  
 
Page 17 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
1.4. Summary of Known Risks and Benefits to Human Subjects 
The risks of wearing soft contact lenses are well  known and are described in the Investigator’s 
Brochure and Informed Consent. The material safety testing/lens release criteria was 
determined based on the Risk Asse ssment. Benefits to the subjects include the correction of 
their refractive error with the potential of improved contrast in HEV environments.
For the most comprehensive risk and bene fit information regarding senofilcon A with new UV 
/ HEV filter, refer to the latest version of the Investigator's Brochure.
1.5. Relevant Literature References and Pr ior Clinical Data Relevant to Proposed 
Clinical Study 
The package insert for the AO1D Control lens ca n be found in the appendices.  Prior clinical 
data of the new UV/HEV- blocker is summarized in the Investigator’s Brochure.
The literature is absent of any articles pert aining to soft contact lenses containing 
HEV-blocker. Articles that pert ain to “blue -blocking” spectacles and intraocular lenses do 
exist with a sampling shown here:
1. Mainster, Martin A. "Violet and blue light blocking intraocular lenses: 
photoprotection versus photoreception." British journal of ophthalmology. 90.6
(2006): 784-792.
2. Braunstein, Richard E., and Janet R. Sparrow. "A blue-blocking intraocular lens 
should be used in cataract surgery." Archives of ophthalmology 123.4 (2005): 547-
549.
3. Glazer-Hockstein, Carolyn, and Joshua L. Dunaief. "Could blue light –blocking lenses
decrease the risk of age-relate d macular degeneration?" (2006): 1-4.
4. Kimberly, Burkhart, and Phelps James R. "A mber lenses to block blue light and 
improve sleep: a randomized trial." Chronobiology international 26.8 (2009): 1602-
1612.
5. Hayashi, Ken, and Hideyuki Hayashi. "Vis ual function in patients with yellow tinted 
intraocular lenses compared with vision in patients with non-tinted intraocular lenses." British journal of ophthalmology 90.8 (2006): 1019-1023.
6. Schmoll, Conrad, et al. "New light for old eyes: comparing melanopsin-mediated 
non-visual benefits of blue-light and UV-blocking intraocular lenses." British Journal of Ophthalmology (2013): bjophthalmol-2013.
2. STUDY OBJECTIVES, ENDPOINTS AND HYPOTHESES 
2.1. Objectives  
This study is being conducted to validate that  the Test lens meets the customer requirements 
prior to launch.  Senofilcon A with a new HEV / UV filter (Test) and without a new UV / HEV 
filter (Control) will be evaluated on se veral safety and efficacy measures.
CR-6470, v 2.0  
 
Page 18 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Primary Objective(s)
The primary objective is todemonstra te that the Test lens meets all of the safety and efficacy 
requirements of the Design Valida tion Requirements as defined by 
Secondary Objective(s)
The secondary objective is to demonstrate that th e Test lens meets all of the Market Preferences 
as defined in 
2.2. Endpoints  
Primary Endpoint(s) :  The following endpoints are defined in 
Primary Safety Endpoints:
Biomicroscopy 
Biomicroscopy (slit lamp findings) will be assessed for each subject eye across all study visits 
(including scheduled and unscheduled visits). FDA Sl it Lamp Classification Scale will be used 
to grade the findings. The percentage of eyes with  clinically significant slit lamp findings (i.e.,
Grade 3 or higher, or significant corneal infiltrates) will be analyzed.
Lens Fit Acceptance
Lens fitting will be assessed at dispensing a nd follow-up visits for each subject eye. The 
percentage of eyes with unacceptable lens fitting will be analyzed.Primary Efficacy Endpoints :
Distance Monocular LogMAR Visual Acuity (VA)
Distance monocular logMAR VA will be assessed for each subject eye at the two-week follow-
up evaluation using ETDRS charts at 4 meters under high luminance high contrast (HLHC)
condition.
CLUE Overall Quality of Vision
Subjective overall quality of vision will be assessed using Contact Lens User Experience 
(CLUE) questionnaire.10CLUE is a validated patient-re ported outcomes questionnaire to 
assess patient-experience attributes of soft , disposable contact lenses (comfort, vision, 
handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived 
CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher  scores indicate a more favorable/positive 
response. A 5-point increase in an average CL UE score translates into 10% shift in the 
distribution of scores for population of soft disposable contact lens wearers.
Secondary Endpoint(s) :  The following endpoints are defined in 
Secondary Efficacy Endpoints:CLUE Overall Handling
Overall handling will be assessed using Con tact Lens User Experien ce (CLUE) questionnaire.
CR-6470, v 2.0  
 
Page 19 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
CLUE Overall Comfort 
Overall comfort will be assessed using Con tact Lens User Experience (CLUE) questionnaire.
Situational Visual Performance –Indoors
Situation visual performance –indoors will be assessed using the individual item “ Clarity of 
vision indoors in bright light ”() .This item uses a 5 -point Likert response scale, 1: 
Excellent, 2: Very Good, 3: Good, 4: Fair and 5: Poor.
Situational Visual Performance –Digital Devices
Situation visual performance –digital devices will be assessed using the individual item 
“Overall preference while using computer screens & digital devices ”( ).The 
response set for this preference item include: Stron gly prefer my habitual lenses , Slightly prefer 
my habitual lenses , No preference, Slightly prefer the study lenses, and Strongly prefer the 
study lenses.  
2.3. Hypotheses 
All the following primary hypotheses must be met for the objectives of this study to be 
satisfied:
Primary Hypotheses
Safety
1. The JJVCI investigational contact lens is non-inferior to the control lens with 
respect to the proportion of eyes with clin ically significant slit lamp findings across 
all study visits. A non-inferiorit y margin of 5% will be used.
2. The JJVCI investigational contact lens is non-inferior to the control lens with 
respect to the proportion of eyes with una cceptable lens fitting at dispensing and 
follow up visit. A non-inferiority margin of 10% will be used.
Efficacy
1. The JJVCI investigational contact lens is non-inferior to the control lens with 
respect to monocular high luminance, high contrast distance visual acuity at the 
follow-up visit. A non-inferiority margin of 0.05 logMAR will be used.
2. The JJVCI investigational contact lens is non-inferior to the control lens with 
respect to overall CLUE vision score at the follow up visit. A non-inferiority margin 
of -5 points on the CLUE scale will be used.
CR-6470, v 2.0  
 
Page 20 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Secondary Hypotheses
Efficacy
1. The JJVCI investigational contact lens is non-inferior to the control lens with 
respect to overall CLUE handling score at  the follow-up visit. A non-inferiority 
margin of -5 points on the CLUE scale will be used.
2. The JJVCI investigational contact lens is non-inferior to the control lens with 
respect to overall CLUE comfort score at  the follow-up visit. A non-inferiority 
margin of -5 points on the CLUE scale will be used.
3.The JJVCI Investigational contact lens will be non -inferior to the Control lens with 
respect to the proportion of subjects with Excellent responses to the statement 
“Clarity of Vision indoors in bright light ( )” at the follow -up visit. A 
non-inferiority margin of 0.67 for odds ratio will be used.
4. The JJVCI Investigational contact lens will be superior to the Control habitual lens 
with respect to overall preference while using computer screens & digital devices 
at the follow up visit.
3. TARGETED STUDY POPULATION 
3.1. General Characteristics  
Approximately 160 subjects will be targeted to  the Test Group and approximately 160 will be 
targeted to the Control Group.  Within each lens g roup, the intent is to complete 143 (286 total 
subjects).  Enrolled subjects will be habitual  wearers of silicone hydrogel spherical contact 
lenses.  All subjects will be the age of t18 and <40.  Subjects will wear the study contact lenses 
approximately two weeks each on a daily wear (DW) daily dispos able (DD) basis for a total 
study duration of approximately 14 days (2 weeks) per subject.
3.2. Inclusion Criteria 
Potential subjects must satisfy all of the following criteria to be enrolled in the study:
Inclusion Criteria after Screening
The subject must:
1. Read, understand, and sign the STA TEMENT OF INFORMED CONSENT and 
receive a fully executed copy of the form.
2. Appear able and willing to adhere to the instructions set forth in this clinical protocol.
3. Be between 18 and 39 (inclusive) years of age at the time of screening.
4. By self-report, habitually wear spherica l silicone hydrogel soft contact lenses in both 
eyes in a daily reusable or daily disposab le wear modality (i.e. not extended wear 
modality). Habitual wear is defined as a minimum of 6 hours of wear per day, for a minimum of 5 days per week during the past 30 days.
5. Have a habitual contact lens prescription that is current within the prior 6 months, and 
they must have worn that prescription for at least 2 weeks prior to entering the study. 
CR-6470, v 2.0  
 
Page 21 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Inclusion Criteria following Baseline Evaluation
6.The subject’s vertex corrected spherical equ ivalent distance refraction must be in the 
range of -1.00 through -6.00 D in both eyes.
7.The subject’s refractive cylinder must be 1.00 D or less.
8. The subject must have best corrected visual acuity of 20/25 or better in each eye.
3.3. Exclusion Criteria 
Potential subjects who meet any of the following criteria will be excluded from participating 
in the study:
Exclusion Criteria after Screening:
The subject must not:
1. Be currently pregnant or lactating.
2. Have any ocular or systemic allergies or di seases that may interfere with contact lens 
wear. 
3. Have any autoimmune disease or use of me dication, which may interfere with contact 
lens wear.  Habitual medications used by successful soft contact lens wearers are considered acceptable.
4. Have any previous, or planned, ocular or  interocular surgery (e.g., radial keratotomy, 
PRK, LASIK, etc.).
5. Be currently wearing lenses in a monovision, multi-focal, toric, or extended wear 
modality.
6. Have participated in a contact lens or lens  care product clinical trial within 14 days 
prior to study enrollment
7. Be an employee (e.g., Investigator, Coordina tor, Technician) or immediate family 
member of an employee (including partner, ch ild, parent, grandparent, grandchild or 
sibling of the employee or their spouse) of the clinical site.
8. Have a history of binocular vision abnormality or strabismus.9. Have any infectious disease (e.g., hepa titis, tuberculosis) or contagious 
immunosuppressive diseases (e.g., HIV) by self-report.
Exclusion Criteria at Baseline EvaluationThe subject must not:
10. Have any Grade 3 or greater slit lamp findings (e.g., edema, corneal 
neovascularization, corneal staining, tarsal abnormalities, conjunctival injection) on 
the FDA classification scale, any previous history or signs of a contact lens-related 
corneal inflammatory event (e.g., past periphe ral ulcer or round peripheral scar), or 
any other ocular abnormality that ma y contraindicate contact lens wear.
11. Have any ocular infection.
12. Have any corneal distortion resulting from previous hard or rigid gas permeable 
contact lens wear.
CR-6470, v 2.0  
 
Page 22 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
13. Have entropion, ectropion, extrusions, chalaz ia, recurrent styes, glaucoma, history of 
recurrent corneal erosions, or aphakia.
3.4. Enrollment Strategy 
Study subjects will be recruited from the Inst itution/clinical site’s subject database and/or 
utilizing Independent Ethics Committee (IEC) or Institutional Review Board (IRB) approved 
materials. 
The overall goal is to enroll approximately 320 eligible subjects and complete 286 that are 
evenly distributed between the Test Group and the Control Group (Table 1).Table 1: Enrollment Strategy Overall
Overall Enrollment Strata Test Group Control Group Total
RandomizedOverall 143-160 143-160 286-320
Habitual Daily 
Disposable~112 ~112 ~ 224
Habitual Daily Wear 
Reusable~48 ~48 ~96
CompletedOverall 143 143 286
Habitual Daily 
Disposablea100 a100 a200
Habitual Daily Wear 
Reusablea43 a43 a86
Approximately 16 sites are expected to e nroll approximately 20 subjects each with 
approximately 10 subject wearing the Test len s and approximately 10 wearing the Control lens 
during the study. Habitual wearers of daily dispos able lenses will be prefe rentially targeted in 
a 7:3 ratio over habitual wearers of daily wear reusable lenses in each lens group within each 
site (i.e., 7 habitual wearers of daily disposable lenses versus 3 habitual wearers of daily wear 
reusable lenses). 
4. STUDY DESIGN AND RATIONALE 
4.1. Description of Study Design 
This study is a controlled, randomized, subject -masked, 2-arm parallel, 2-week dispensing, 
bilateral evaluation where the study lenses are worn for a minimum of 5 days per week and 6 
hours per day.  At study closure, pa rticipants will have no further access to the Test lenses.
The study begins with an initial visit (Visit 1). If a subject is found to meet all eligibility criteria, 
then they will be randomized and fit with eith er the Test or Control lenses in both eyes; 
otherwise, a subject will be deemed ineligible for this study. If the subject is dispensed study 
CR-6470, v 2.0  
 
Page 23 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
lenses at the initial visit, a follow-up visit will be conducted. The follow-up visit will occur 
approximately 2 weeks after the initial visit. Unscheduled visits may occur during the study.
4.2. Study Design Rationale 
The purpose of this study is to evaluate the performance of a new UV/HEV-filter in a 2-arm 
parallel design. In this parallel design, subject s are randomized to one of the two study arms 
and after randomization each participant will st ay in their assigned treatment arm for the 
duration of the study. Randomization eliminates the selection bias and balances both the known
and unknown confounding factors that may affect the study outcomes.
4.3. Enrollment Target and Study Duration 
This study will have an enrollment target of 320 subjects, with a target of at least 286 to
complete. The study will be conducted at up to 16 clinical sites, where the enrollment target 
for each site will be approximately 20 subjects.  A subject will be considered enrolled upon 
signing of the informed consent form. 
There will be 2 visits in total per subject; total study duration including the enrollment period 
is expected to be approximately 6 weeks. Subj ects who are discontinued prior to the final 
evaluation may be replaced at the discretion of the study sponsor. The investigation will end 
at the time that the study data is hard locked.
Table 2: Duration of Study Visits
Visit Description ||Duration
1Informed consent, eligibility criteria, baseline data, trial fitting 1, 
dispense lenses. Study lenses to be worn 13- 15 days to first follow-
up visit.2.0 hours
313-15 day follow-up for the study lens, subjective responses, 
preference to habitual lenses, VA, fitting characteristics, surface 
characteristics, physiology, Final Evaluation.1.0hours
5. TEST ARTICLE ALLOCATION AND MASKING 
5.1. Test Article Allocation  
Use of the test articles will be randomized us ing a lens fitting schedule supplied by the study 
biostatistician. The clinical site will follow the lens fitting schedule provided and will complete
enrollment according to the randomization list and will not pre-select or pre-assign subjects.Randomly-permuted block randomization will be used to avoid bias in the assignment of 
subjects to treatment and to enhance the vali dity of statistical comparisons across treatment 
groups. A computer-generated randomization scheme will be used to randomly assign subjects, 
in blocks of 2, to one of the two lens groups ( Test or Control). The randomization will be 
CR-6470, v 2.0  
 
Page 24 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
stratified by site and type of habitual lens wear  (daily disposable and daily wear reusable). The 
ratio of habitual wearers of daily disposable lense s to habitual wearers of daily wear reusable 
lenses is 7:3 within each study site (7 habitual wearers of daily disposable lenses versus 3 
habitual wearers of daily wear reusable lense s).  See Table 1. The random scheme will be 
generated using the PROC PLAN procedure from  Statistical Analysis System (SAS) Software 
Version 9.4 or higher (SAS Institute, Cary, NC).11
Randomization will be performed at visit 1. T he following must have occurred prior to
randomization:
•Informed consent must have been obtained.
•The subject must have met all eligibility criteria.
•The subject ’sscreening and baseline informati on must have been collected.
When dispensing test articles, the following steps should be followed to maintain 
randomization codes:
1. Investigator or designee (documented on the Delegation Log) will consult the lens
fitting schedule to obtain the test article assign ment for that subject prior to dispensing.
2.Investigator or designee will record the subject’s number on the appropriate line of the 
lens fitting schedule.
3. Investigator or designee will pull the appropriate test articles from the study supply. 
All test articles that are opened, whether dispensed (placed/fit on eye or dispensed 
outside the clinical site) or not, must be recorded on the Test Article Accountability 
Log in the “Dispensed” section .
5.2. Masking 
This is a single-masked trial. The investigators  may be aware of the study lenses based on a
slight difference in lens color (the Test lenses  will be slightly more turquoise in color than the 
Control lens). 
Masking will be used to reduce potential bias. Subjects will be unaware of the identity of the 
investigational product. Investigators and clinical site personnel involved in the data collection 
will not be masked as to the iden tity of the investigational product.
5.3. Procedures for Maintaining and Breaking the Masking 
The identity of the study lenses will be masked to  the subjects by over labeling the blister pack 
of the study lens. The label will contain the st udy number, lot number, sphere power, expiration 
date and the randomization codes. 
The test articles mask shall not be broken unl ess information concerning the lens type is 
necessary for the urgent medical treatment of a subject. The Sponsor must be notified before 
the mask is broken.
CR-6470, v 2.0  
 
Page 25 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Under normal circumstances, the mask should not be broken until all subjects have completed 
the study and the database is fi nalized. Otherwise, the mask shoul d be broken only if specific 
emergency treatment/course of ac tion would be dictated by knowing the treatment status of the 
subject. In such cases, the investigator may, in  an emergency, contact the medical monitor. In 
the event the mask is broken, the sponsor must be informed as soon as possible. The date, time, 
and reason for the unmasking must be documente d in the subject record. The investigator is 
also advised not to reveal the study treatmen t assignment to the clinical site or sponsor 
personnel. 
Subjects who have had their treatment assignment unmasked are expected to return for all 
remaining scheduled evaluati ons. Subjects who are discontinued will be replaced.
6. STUDY INTERVENTION 
6.1. Identity of Test Articles  
The following contact lenses will be used in this study:
Table 3: Test Articles
Control Test
Manufacturer JJVC JJVC
Name AV OASYS 1-DAY TRP-200
Hydration PG PG
Material senofilcon A senofilcon A
Packaging Form Sterile blister pack Sterile blister pack
Nominal Water Content (%) 38 38
Nominal Dk (edge corrected) 103 103
Nominal Modulus 101 101
Inversion Indicator 123 123
Nominal Base Curve/Diameter @ 22°C 
(mm)8.5 / 14.3 8.5 / 14.3
Nominal Center Thickness @ -3.00 D 
(mm)0.085 0.085
Nominal Powers (D)-1.00 to -6.00 in 0.25 
steps-1.00 to -6.00 in 0.25 
steps
New UV/HEV-Filter NA Yes
At least 1080 lenses per SKU per study lens will be made available based on the following 
factors: sample size, bilateral wear, daily replacement, 2-week duration, safety margin of 2X, 
and US distribution model for the range of lenses -1.00 through -6.00 DS.
CR-6470, v 2.0  
 
Page 26 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
6.2. Ancillary Supplies/Products 
The following solutions will be used in this study.  Note that RevitaLens will be used 
primarily to transport potential problematic lenses back to the Sponsor.
Table 4: Ancillary Supplies
Solution
Solution 
Name/DescriptionAcuvueRevitaLens 
Multipurpose SolutionSingle use
Eye-Cept®
Rewetting
DropsLacriPure
SalineSolutionScleralFil
PreservativeFree SalineSolution
ManufacturerJohnson & Johnson 
VisionOptics
LaboratoryMenicon Bausch & 
Lomb
Preservativealexidine 
dihydrochloride 0.00016% and polyquaternium
-1
0.0003%None None None
Lens cases and fluorescein stri ps (either 0.6 mg or 1.0 mg) will be supplied for use as needed.
6.3. Administration of Test Articles 
Test articles will be dispensed to subjects mee ting all eligibility requirements, including any 
dispensing requirements set forth in this clin ical protocol. Subjects will be dispensed an 
adequate supply of test articles to complete th e study. Lost or damaged test articles may be
replaced at the discretion of the investigator and/or the sponsor.
6.4. Packaging and Labeling 
The Test articles will be packaged in blister s as the primary packaging. The Test article will 
be over-labeled to mask the identity of the lens. The Test articles will be in plastic bags as the 
secondary packaging form. The sample study label is shown below:
CR-6470, v 2.0  
 
Page 27 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Primary Packaging Secondary Packaging
6.5. Storage Conditions 
Test articles will be maintained at ambient temper atures at the clinical site. Test articles must 
be kept under secure conditions.
6.6. Collection and Storage of Samples 
No samples will be collected as part of the study procedures.
When possible, any lens or test article associat ed with an Adverse Event and/or a Product 
Quality Complaint must be retained and stored in a glass vial with moderate solution pending 
directions from the sponsor for potential return to JJVC.
6.7. Accountability of Test Articles 
JJVC will provide the Investigator with sufficient  quantities of study articles and supplies to 
complete the investigation. The Investigator is asked to retain all lens shipment documentation 
for the test article accountability records. 
Test articles must be kept in a locked storage  cabinet, accessible only to those assigned by the 
Investigator for dispensing. The Investigator may delegate this activity to authorized study site personnel listed on the Site Delegation Log. All test articles must be accounted. This includes:
1. What was dispensed for the subject for trial fitting, to wear out of the office, or issued 
for the subject to replace appropriately between visits.
2. What was returned to the Investigator unused, including expired or malfunctioning 
product.
3. The number and reason for unplanned replacements.
The Investigator will collect all unused test articles  from the subjects at the end of the subject’s 
participation. Subject returned unused test articles must be separated from the clinical study 
inventory of un-dispensed test articles and must be labeled with the subject number and date 
CR-6470, v 2.0  
 
Page 28 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
of return. Following final reconciliation of test articles by the monitor, the Investigator or 
monitor will return all unused test articles to JJVC .
If there is a discrepancy between the shipment documents and the contents, contact the study 
monitor immediately .
          
7. STUDY EVALUATIONS  
7.1. Time and Event Schedule 
Table 5: Time and Events
Visit InformationVisit 1
Screening, Baseline, 
Treatment 1Visit 2
2-week FU
Treatment 1Visit 2
Final Evaluation
Time Point14 days after Visit 1
(+/- 1 day)14 days after Visit 1
(+/- 1 day)
Estimated Visit Duration 2.0 hours 45 min 15 min
Statement of Informed 
Consentx
Demographics x
Medical 
History/Concomitant 
Medicationsxx
Habitual Contact Lens 
Informationx
Inclusion/Exclusion Criteria x
Study Questionnaires 
Baselinex
Entrance Visual Acuity x x
Slit Lamp Biomicroscopy x x x (if applicable)
Expanded Conjunctival 
Rednessxx x (if applicable)
Expanded Corneal Staining x x x (if applicable)
Keratometry x x
Iris Color x
Subjective Spherocylindrical 
Refractionxx
Lens Selection x
Lens Insertion & Settling x
Visual Acuity and Over 
Refractionx
Lens Power Modification (if 
applicable)x
CR-6470, v 2.0  
 
Page 29 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Visit InformationVisit 1
Screening, Baseline, 
Treatment 1Visit 2
2-week FU
Treatment 1Visit 2
Final Evaluation
Time Point14 days after Visit 1
(+/- 1 day)14 days after Visit 1
(+/- 1 day)
Estimated Visit Duration 2.0 hours 45 min 15 min
Subject Reported Ocular 
Symptomsxx
Lens Fit Assessment x x
Lens Wettability x x
Surface characteristics x
Lens dispensing information 
and criteriax
Patient instructions x
Study Questionnaires FU x
logMAR Acuity x
Exit Acuity x x
Final Evaluation x
7.2. Detailed Study Procedures 
VISIT 1
The subjects must enter the visit wearing their habitual contact lenses.
Visit 1: Screening
Step Procedure Details
1.1 Statement of 
Informed ConsentEach subject must read, understand, and sign 
the Statement of Informed Consent before being enrolled into the study. The Principal Investigator or his/her designee conducting the informed consent discussion must also sign the consent form.
N
ote:The subject must be provided a signed 
copy of this document.
1.2 Demographics Record the subject’s year of birth, age, 
gender, race and ethnicity.
1.3 Medical History and 
Concomitant MedicationsRecord the subject ’s medical history and 
concomitant medications.
1.4 Habitual Lenses Record the subject’s habitual lens type ,
parameters , lens care solution, wear modality
and approximate prescription date.
CR-6470, v 2.0  
 
Page 30 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Visit 1: Screening
Step Procedure Details
1.5 Habitual Wear Time Record the average wearing time and 
comfortable wearing time.
1.6 SCL Rx 
ConfirmationThe investigator confirms:
1.The subject is wearing a SCL Rx that 
has been confirmed current (up-to -
date) within the prior 6 months.
2. The subject has worn the up-to- date 
SCL Rx for at least 2 weeks.
1.7 Eligibility after 
ScreeningAll responses to Screening Inclusion Criteria 
questions must be answered “yes” and all 
responses to Exclusion Criteria must be answered “no” for the subject to be considered eligible. 
If subject is deemed to be ineligible after 
screening, proceed to Final Evaluation and complete Subject Disposition. Refraction and Biomicroscopy forms 
do not need to be 
completed as part of Final Evaluation.
Visit 1: Baseline
Step Procedure Details
1.8 Baseline 
QuestionnaireThe subject will respond to the following 
Baseline Questionnair es based on their 
habitual lenses:
1. CLUE Baseline
1.9 Entrance Visual 
AcuityRecord the distance Snellen visual acuity 
(OD, OS , and OU) to the nearest letter with
their habitual contact lens correction in place.
Subjects must read the smallest line until at least 50% of the letters are read incorrectly.
1.10 Remove Habitual 
LensThe subject’s habitual lenses will be removed 
and stored in their own lens case. If they 
forgot to bring their lens case, one will be 
provided to them.
CR-6470, v 2.0  
 
Page 31 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Visit 1: Baseline
Step Procedure Details
1.11 Slit Lamp 
Biomicroscopy  FDA Slit Lamp Classification Scale will be 
used to grade the findings and determine 
eligibility .
If any of these slit lamp findings are grade 3 
or higher (FDA scale) , the subject may not 
continue at this time, but may return up to 
one additional time to de termine eligibility. If 
discontinued a final examination must be 
completed.
Limbal and Bulbar Conjunctival Hyperemia 
findings ( ) and Corneal Staining 
Assessment ( ) will also be 
collected for internal purposes.
If the clearance of the fluorescein needs to be 
expedited, preservative -free rewetting drops 
or saline may be instilled. 
1.12 Keratometry Record the keratometry readings OD and OS 
in diopters. This can come from any appropriate instrument so long as the same 
instrument is used at the Final Evaluation.
1.13 Iris Color The investigator will record the subject’s iris 
color based on the scale provided.
1.14 Subjective Sphero-
cylindrical RefractionComplete subjective spherocylindrical 
refraction and record the resultant distance visual acuity (OD, OS, and OU) to the nearest letter.
1.15 Eligibility after 
BaselineAll responses to Inclusion Criteria questions 
must be answered “yes” and all responses to Exclusion Criteria questions must be answered “no” for the subject to be considered eligible.
If subject is deemed to be 
ineligible after 
baseline , proceed to Final Evaluation and 
complete Subject Disposition. Refraction and 
Biomicroscopy forms do not need to be completed as part of Final Evaluation.
CR-6470, v 2.0  
 
Page 32 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Visit 1: Treatment 1 Lens Fitting
Step Procedure Details
1.16 Lens Selection Assign the study lens based on the 
randomization scheme provided by the biostatistician.  Select the contact lens power based on thespherical equivalent from the subjective sphero
-cylindrical refraction.
Record the test condition.
1.17 Lens Insertion The Investigator or the subject inserts the 
study lenses. Record the time of lens 
insertion.
Check for lens damage under the slit lamp 
before proceeding with lens settling. Replace damaged lenses if applicable.Ensure the subject is given a Patient Instruction Guide.
1.18 Lens Settling Allow the study lenses to settle for a 
minimum of 5 minutes.
1.19 Subjective Best 
Sphere Over RefractionPerform subjective best sphere refraction 
over the study lenses with a phoropter (adopt the maximum plus to maximum visual acuity (MPMVA) approach and record the best corrected 
distance visual acuity to th e nearest 
letter (OD and OS).
1.20 Lens Power 
Modification (if applicable)Adjust the lens power if the subject’s best 
sphere over -refraction is not plano. 
For each power modification, select the 
adjusted fitting lens power as appropriate and 
repeat steps 1.17 through 1.19.
One power modification is allowed. 
1.21 Subject Reported 
Ocular SymptomsSubjects will respond to a verbal open-ended 
symptoms questionnaire.
CR-6470, v 2.0  
 
Page 33 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Visit 1: Treatment 1 Lens Fitting
Step Procedure Details
1.22 General Lens Fit 
AssessmentEvaluate lens centration, movement on blink, 
and push-up test for each eye.
An unacceptable fit is deemed by one of the 
following criteria: 
xlimbal exposure at primary gaze or 
with extreme eye movement.
xedge lift.
xexcessive movement in primary and 
up gaze.
xinsufficient movement in all three of 
the following conditions: primary 
gaze, up gaze, and push-up test.
Note:if lens fit is unacceptable for either eye, 
thesubject will be discontinued from the 
study.
1.23 White Light Lens Surface Wettability Record the white light lens wettability of both lenses.
1.24 Visual Acuity Record the distance visual acuity with the contact lenses (OD, OS, and OU) to the nearest letter. Smaller lines must be shown 
until the subject incorrectly identifies at least 
50% of the letters.
1.25 Continuance For the subject to continue in the study, they must meet all three of the following criteria:
xVisual acuity is 20/30 or better OD 
and OS.
xThe lens fit is acceptable OD and OS.
xInvestigator approval.
If the Investigator does not approve the dispensing of the first study lens, then the 
study is terminated for that subject.
CR-6470, v 2.0  
 
Page 34 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Visit 1: Treatment 1 Lens Fitting
Step Procedure Details
1.26 Dispense The lenses will be dispensed for 13-15 days
1.The subjects should wear their lenses 
similar to the inclusion criteria: t6 hours 
per day, t5 days per week.
2. The lenses will be worn as daily wear 
daily disposable only.
3.All subjects will be provided a bottle of 
ACUVUE RevitaLens  to return any 
problematic lenses to the investigational 
site.
4.Rewetting drops are permitted if needed.
5.A patient instruction booklet will be 
provided.
Note 1 :Ensure that the subject has enough 
lenses to last them to their next scheduled visit with no extras.  
In the event a lens is lost 
or damaged, and the subject has run out of lenses, 
the subject will return to the 
investigator site for replacement.
Note 2 :The subject’s habitual contact lenses 
cannot be worn at any time during the study.
Note 3 : Remind the subjects to b ring back 
any unworn lenses to the next visit.
Note 4 : Remind the subject to bring a 
habitual form of correction to next visit.
1.27 Schedule next visit Schedule the follow-up visit to occur in 14 ±1 days (counting the day of this visit as day 0, the subject may return on day 13 through 15).
CR-6470, v 2.0  
 
Page 35 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
VISIT 2
The follow-up will occur 13-15 days after Visi t 1. The subjects must enter the visit wearing 
their study contact lenses.
Visit 2: Treatment 1 Follow-Up 1
Step Procedure Details
2.1 Adverse Events and 
Concomitant Medications ReviewReview any changes to the subject’s medical 
history or concomitant medications from the previous study visit. Record any changes, and any adverse events.
2.2 Wearing Time Record the average wearing time and 
comfortable wearing time.
2.3 Compliance Confirm compliance with the prescribed wear 
schedule.
2.4 Return unworn 
lensesCollect any unworn study lenses from the 
subject.
2.5 Subject Reported 
Ocular SymptomsSubjects will respond to a verbal open-ended 
symptoms questionnaire.
2.6 Follow-Up
QuestionnaireSubjects will respond to the following 
questionnaires:
1.CLUE Follow-up
2.GSI Product Performance
3. Lens preference to habitual
2.7 Distance ETDRS 
LogMAR Visual AcuityMeasure monocular distance high luminance 
high contrast (HLHC) visual acuity using ETDRS charts at 4 meters. 
Measure each eye once using the charts shown 
in the table below:
Condition HLHC
Room 
illumination> 400 lux
Chart 
luminance120 - 200 cd/m2
Eye OD OS
Charts HC-1 HC-2
Recorded letter-by-letter results into EDC.
2.8 Visual Acuity Record the distance Snellen visual acuity with 
the contact lenses (OD , OS, and OU ) to the 
nearest letter.  Subjects must read the smallest 
line until at least 50% of the letters are read 
incorrectly.
CR-6470, v 2.0  
 
Page 36 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Visit 2: Treatment 1 Follow-Up 1
Step Procedure Details
2.9 Subjective Lens Fit 
AssessmentEvaluate overall lens fit acceptance 
(acceptable or unacceptable) based on centration, movement and other fitting characteristics.
An unacceptable fit is deemed by one of the 
following criteria: 
xlimbal exposure at primary gaze or 
with extreme eye movement.
xedge lift.
xexcessive movement in primary and 
up gaze.
xinsufficient movement in all three of 
the following conditions: primary 
gaze, up gaze, and push-up test.
Note:if lens fit is unacceptable subject will 
be discontinued from the study.
2.10 Wettability Characteristics Record the white light lens wettability of both lenses.
2.11 Surface Deposits Record any front and back surface lens deposits.
2.12 Lens Removal Both lenses will be removed and discarded.
2.13 Slit Lamp Biomicroscopy FDA Slit Lamp Classification Scale will be used to grade the findings. If no slit lamp finding is noted on the EDC form it is considered as a zero “0” grade for all observations listed. 
Note:
If the subject has Grade 3 or 4 slit 
lamp findings on the FDA scale, then they must be followed as an adverse event.  
Adverse events must be reported to the JJVC 
monitors immediately.
Limbal and Bulbar Conjunctival Hyperemia 
findings ( ) and Corneal Staining 
Assessment ( ) will be emphasized 
using a more detailed scale.
After the slit lamp examination, at the discretion of the Investigator, rinse the 
subject’s eyes thoroughly with rewetting 
drops or saline.
CR-6470, v 2.0  
 
Page 37 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
FINAL EVALUATION
The final evaluation will ordinarily take place immediately following the last scheduled 
follow-up visit per the study protocol. It may also take place at any point the subject 
discontinues the study or is terminated from the study.
Final Evaluation
Step Procedure Details
F.1 Final Exam Form Indicate if the subject completed the study successfully. If subject discontinued from the study, indicate the reason.
F.2 Keratometry Record the keratometry readings OD and OS in diopters. This can come from any 
appropriate instrument so long as the same 
instrument
was used at the Baseline
Evaluation.
F.3 Exit Refraction Perform bare-eye subjective spherocylindrical refraction with a phoropter and record the best
-corrected distance visual acuity (OD ,O S
and OU ) to the nearest letter. 
Note : This step is not necessary if the subject 
was exited due to screen failure.
CR-6470, v 2.0  
 
Page 38 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Final Evaluation
Step Procedure Details
F.4 Exit Slit Lamp 
Biomicroscopy (for subjects that are discontinued early)FDA Slit Lamp Classification Scale will be 
used to grade the findings. If no slit lamp finding is noted on the EDC form it is considered as a zero “0” grade for all observations listed. 
Note: If the subject has Grade 3 or 4 slit 
lamp findings on the FDA scale, then they must be followed as an adverse event.  Adverse events must be reported to the JJVC monitors immediately.
Limbal and Bulbar Conjunctival Hyperemia 
findings  and Corneal Staining 
Assessment  will be emphasized 
using a more detailed scale.
If the clearance of the fluorescein needs to be 
expedited, preservative -free rewetting drops 
or saline may be instilled. This step is not 
necessary if the subject was exited due to screen failure.
Note
: This step is not necessary if the subject 
was exited due to screen failure, or if 
biomicroscopy was performed as part of the 
final follow -up visit procedures (i.e., 
immediately prior to the final evaluation).
7.3. Unscheduled Visits 
If, during the investigation, a subject requires an  unscheduled visit to the clinical site, the 
following information will be collected, as appropriate:
xChief complaint prompting the visit. If the re ason is an adverse event, the applicable 
eCRF for the adverse event must be comp leted and subject record completed as 
appropriate.
xDate and time of the visit and all procedures completed at the unscheduled visit.
xReview of adverse event and concomitant medications.
xDocumentation of any test article dispensed or collected from the subject, if applicable.
xSlit lamp findings (using the Slit Lamp Classification Scale).
If the Investigator withdraws a subject from th e study, the final study visit case report forms 
must be completed indicating the reason(s) w hy the subject was withdrawn. The subject record 
must be completed documenti ng the date and primary reason for  withdrawal and the study 
CRA notified.
CR-6470, v 2.0  
 
Page 39 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Any ocular and non-ocular Adverse Events that are ongoing at the time of the study visit will 
be followed by the Investigator, within licensure , until they have resolved, returned to pre-
treatment status, stabilized, or been satisfactor ily explained. If further treatment i.e., beyond 
licensure is required, the subject will be refe rred to the appropriate health care provider. 
The following information will be collected during an unscheduled visit.
Unscheduled Visit
Step Procedure Details
U.1 Reason for 
unscheduled visitIndicate if the only reason for the visit is that 
the subject requires additional test articles. If 
the reason is other than resupply of 
previously dispensed lenses , specify the 
reason for the visit.
U.2 Chief Complaints (if 
applicable)Record the subject’s chief complaints for 
reasons for the unscheduled visit.
U.3 Adverse Events and 
Concomitant Medications Review(if applicable)Review any changes to the subject’s medical 
history or concomitant medications from the previous study visit. Record any changes, and any adverse events.
U.4 Entrance VA (if 
applicable)Record the entrance distance visual acuity 
(OD, OS) to the nearest letter. 
U.5 Subjective Sphero-
cylindrical Refraction
(if 
applicable)Perform bare-eye subjective spherocylindrical 
refraction with a phoropter (adopt the maximum plus to maximum visual acuity 
(MPMVA) approach and use the duo
-chrome 
test for binocular balancing) and record the 
best corrected distance visual acuity to the 
nearest letter (OD, OS). 
U.6 Slit Lamp 
Biomicroscopy (if applicable)FDA Slit Lamp Classification Scale will be 
used to grade the findings.  If the clearance of the fluorescein needs to be expedited, preservative
-free rewetting drops may be 
instilled.
Limbal and Bulbar Conjunctival Hyperemia 
findings ( ) and Corneal Staining 
Assessment ( ) will be emphasized 
using a more detailed scale.
After the slit lamp examination, at the 
discretion of the Investigator, rinse the subject’s e
yes thoroughly with rewetting 
drops or saline.
CR-6470, v 2.0  
 
Page 40 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Unscheduled Visit
Step Procedure Details
U.7 Dispensing (if 
applicable)If the subject requires additional lenses to 
complete the wear period and is eligible to do so, provide additional lenses per 
the
dispensing instructions given in the detailed 
study procedures.
U.8 Exit Visual Acuity 
(if applicable)Record the subject’s exit distance visual 
acuity (OD, OS) to the nearest letter. 
Note : If the only reason for the unscheduled visit is that the subject requires additional test 
articles, only the dispensing information needs to be recorded.
7.4. Laboratory Procedures  
Not Applicable.
8. SUBJECTS COMPLETION/WITHDRAWAL  
8.1. Completion Criteria 
Subjects are considered to have completed the study if they: 
xprovided informed consent.
xthey are eligible.
xhave not withdrawn/discontinued from the study for any reason described in section 
8.2.
xcompleted all visits through the final visit 3.
xIf all visits were completed but an additi onal visit is considered necessary for subject 
care, follow the requirements for unscheduled visits in section 7.3.
8.2. Withdrawal/Discontinuation from the Study 
A subject will be withdrawn from the study for any of the following reasons:
xSubject withdrawal of consent.
xSubject not compliant to protocol such as study lens wear time or habitual lens wear 
while enrolled in the study.
xSubject lost to follow-up.
xSubject no longer meets eligibility criteria (e.g. the subject becomes pregnant).
xSubject develops significant or serious adverse events necessitating discontinuation of 
study lens wear.
xSubjects who have experienced a Corneal Infiltrative Event (CIE).
xInvestigator’s clinical judgment regarding the subject safety reasons (that it is in the best interest of the subject to stop treatment).
xSubject missed a study visit .
CR-6470, v 2.0  
 
Page 41 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
xSubject not compliant with study lens wear schedule (i.e. wears study lenses less than 
at least 6 hours per day for at least 5 days a week over the 2 week wear period)
xSubject not successfully dispensed due to lack of efficacy and safety including poor 
vision, poor comfort or unacceptable fit.
For discontinued subjects, the Investigator will:
xComplete the current visit (scheduled or unscheduled).
xComplete the Final Evaluation, indicating the reason that the subject was discontinued 
from the study.
xRecord the spherocylindrical refraction with best corrected distance visual acuity.
xCollect used test article(s) (worn or brought to  the visit) from the subject and discard 
them, unless otherwise stated in section 7.2.
xCollect all unused test article(s) from the subject.
xMake arrangements for subject care, if needed, due to their study participation
Additional subjects will be enrolled if a subject  discontinues from the study prematurely. 
In cases where a subject is lost to follow-up, eve ry possible effort must be made to contact the 
subject and determine the reason for discontinuation/withdrawal. The measures taken to follow 
up must be documented including two written attemp ts and a certified letter (or equivalent) as 
the final attempt. 
9. PRE-STUDY AND CONCOMITANT INTERVENTION/MEDICATION 
Concomitant medications will be documented during screening and updated during the study.
xDisallowed medications for this study include: medications that may interfere with 
contact lens wear (see section 9.1).  Habitu al medications used by successful soft 
contact lens wearers are considered acceptable.
xConcomitant therapies that are disallowed include: NA
9.1. Systemic Medications 
Certain systemic medications ar e known to have a higher likeli hood to interfere with contact 
lens wear, chiefly by disrupting the tear film. 
A summary of disallowed systemic medications is  shown in Table 6. Subjects with a history 
of taking these medications will be allowed to enroll only if:
xThe medications have been taken on a cont inual, routine basis for at least 6 months,
and
xThe subject has demonstrated successful contact lens wear during this time.
Or:
CR-6470, v 2.0  
 
Page 42 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
xThe subject was taking the medication on a temporary basis and ceased taking that 
medication at least 2 weeks prior to signing the informed consent (this is considered 
sufficient time for the medication to have left the body prior to enrollment).
Subjects with a history of taking medications listed in Table 6 on a long-term, routine basis for 
less than 6 months will not be allowed to participate in the study.
Table 6: Disallowed systemic medications
Class of Drug Common Indication(s) Common Examples
Estrogens (not
including
contraceptive 
medication)Menopause, osteoporosis, vaginitis Vagifem, Estrace, Climara, 
Vivelle -Dot, Premarin, Minivelle, 
etc.
Anticholinergics Irritable bowel syndrome, 
Parkinson’s disease, peptic ulcer, 
cystitis, nasal congestion, cold symptoms, overactive bladder, COPDBentyl, Spiriva, Atrovent, 
Hyosyne, Levsin, Symax Fastab, Symax SL, Homax SL, Cogentin, Transderm Scop, etc.
Beta-blockers Hypertension, angina, heart attack, 
migraine, artrial fibrillation, andrenal cancer, essential tumor, glaucomaToprol XL, Lopressor, Tenormin, 
Propranolol, Timoptic, Trandate, Inderal LA, etc.
Psychotropics Antipsychotic (schizophrenia, 
mania), antidepression, 
antiobsessive, antianxiety, mood stabilizer, stimulants (ADHD)Zoloft, Celexa, Prozac, Lexapro, 
Effexor, Cymbalta, Ativan, 
Xanax, Desyrel, Wellbutrin, etc.
Vitamin A 
analogsCystic acne Isotretinoin
Examples of disallowed systemic  antihistamines are given in 
Table 7. Subjects with a history of taking system ic antihistamines will be allowed to enroll 
only if:
xThey have taken antihistamines c ontinuously for at least 2 weeks, and 
xThey have demonstrated successful wear while taking the medication
Or:
xThey stopped taking the medication for at least 2 weeks prior to enrollment.
CR-6470, v 2.0  
 
Page 43 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Table 7: Disallowed systemic antihistamines
Class of Drug Common Indication(s) Common Examples
Antihistamines Allergic rhinitis, sedation, hives, 
allergic conjunctivitis, skin allergy, 
itching, motion sicknessHydroxyzine, Promethagan, 
Phenadoz, Vistaril, Claritin, 
Zyrtec, Astepro, Astelin, Optivar, 
Allegra, Benedryl, etc.
10. DEVIATIONS FROM THE PROTOCOL 
Investigator will notify study sponsor upon iden tification of a protocol deviation. Protocol 
deviations must be reported to the sponsor within 24 hours after discovery of the protocol 
deviation. The Investigator will report deviations  per IRB/IEC requirements. All deviations 
will be tracked, and corrective act ions implemented as appropriate. 
If it becomes necessary for the Investigator to implement a deviation in order to eliminate an immediate hazard to the trial subject, th e Investigator may implement the deviation 
immediately without notification to the spons or. Within 24 hours after the implemented 
deviation, the Investigator must notify and provi de the rationale to the Sponsor and, as 
required, the IEC/IRB. 
If the deviation potentially impacts the safety of patient or changes the technical integrity of 
the study, then it must be reported to IEC/IRB. This is a "Major Deviation". Deviations
that contradict the information contained in the Informed Consent/Assent forms will beconsidered Major Deviations.
Minor deviations have no substantive effect on patient safety or technical integrity of the 
study. They are often logistical in nature. Protocol waivers are prohibited.
Table 8 lists examples of deviations that will constitute major and minor protocol deviations
for this study. 
Table 8: Examples of major and minor protocol deviations
CR-6470, v 2.0  
 
Page 44 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Deviation category Major deviation Minor deviation
Out-of-window visit Visit attended 2 days or more 
than out of visit window defined in study proceduresVisit attended 1 day or fewer 
out of visit window defined in study procedures
Unanswered PRO questions For questionnaires where 
data is related to a primary or secondary endpoint, 2 or more PRO questions are unanswered (i.e., left blank).For questionnaires where 
data is related to a primary or secondary endpoint, 1 or fewer PRO questions are unanswered (i.e., left blank).
For questionnaires where 
data where data is not related 
to a primary or secondary endpoint, any PRO questions are unanswered (i.e., left blank).
Insufficient wear of study 
lenses Subject does not wear study 
lenses for at least 6 hours on at least 5 days of a study lens wear period.NA
In the case of a major protocol deviation, the decision of whether or not the subject will be 
excluded from the Per-Protocol analysis popul ation will be made at the time of cohort 
review.
11. STUDY TERMINATION 
If more than 2 subjects in the investigational soft contact lens group develop serious expected 
(e.g., definite or probable MK) or unexpected device  related adverse events, the study will be 
suspended. Upon review and consultation w ith IRB, DMC, and JJVC Safety Management 
Team , the study may be terminated. This poten tial stopping rule is established based on our 
trial involving approximately 200 subjects wearing th e investigational soft contact lens for up 
to 3 years with an assumed MK rate that is be low 0.2% per patient-ye ar. The rate of 0.2% per 
patient year is the established rate for extended wear lenses in adults, which was requested by 
the FDA as a criterion for evaluating a contact lens for pediatric use in an FDA response to a 
pre-IDE submission. To be conservative, 200 inde pendent patient years were used in the 
calculation. The probability of observing 2 cases or more incidents of MK is 0.061, and 3 cases 
or more incidents of MK is 0.007 (given an MK rate of 0.2% per patient year). 
The occurrence of one or more Unanticipate d Serious Adverse Device Effect (USADE), or 
any SAE where the relationship to study agent cannot be ruled out, may result in stopping 
further dispensing of test article. In the event of a USADE or SAE, the Sponsor may unmask 
CR-6470, v 2.0  
 
Page 45 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
the treatment regimen for the subject(s) and w ill discuss this with the Investigator before any 
further subjects are enrolled.
The Sponsor will determine when a study will be stopped. The Principal Investigator always 
has the discretion to initiate stopping the study  based on patient safety or if information 
indicates the study’s results are compromised.JJVC reserves the right to terminate the study at any time for any reason. Additionally, the 
IEC/IRB reserves the right to terminate the study  if an unreasonable risk is determined. The 
study can be terminated by the Principal Invest igator at the individual clinical site due to 
specific clinical observations, if in their opinion, after a discussion with JJVC, it is determined 
that it would be unwise to continue at the clinical site.
JJVC (and the IEC/IRB and DMC, if applicable) w ill evaluate all adverse events. If it is 
determined that an adverse event presents an unre asonable risk, the investigation, or that part 
of the investigation presenting the risk, will be terminated as soon as possible.
Should the study be terminated (either prematu rely or as scheduled), the Investigator will 
notify the IEC/IRB and Regulatory Authority as required by local regulatory requirements.
12. PROCEDURE FOR HANDLING PRODUCT QUALITY COMPLAINTS 
A Product Quality Complaint (PQC) refers to an y written, electronic, or oral communication 
that alleges deficiencies relate d to the identity, quality, dura bility, reliability, safety, 
effectiveness or performance of test articles after th ey have been released for clinical trial use.  
Potential complaints may come from a variety of sources including but not limited to subjects, 
clinical research associates (CRA), clinical operations managers (COM), medical monitors, 
and site personnel, etc. The following are not considered product quality complaints:
xSubject satisfaction inquiries reported via “Subjective Questionna ires” and “Patient 
Reported Outcomes (PRO). ”
xClinical test articles that are stored improp erly or damaged after receipt at the 
investigational site.
xLens replacements that occur due to drops/fall-outs.
xDamage deemed by clinicians or clinical staff to be caused by handling by the user, 
and not indicative of a quality deficiency (i.e. tears, rips, etc.), only in situations where 
there is no deficiency alleged by the subject.
Within 24 hours of site personnel becoming aware that a PQC has occurred, the PQC must be recorded in the EDC system, which will tr igger an automatic email notification to the 
appropriate COM/CRA and Clinical QA representative.  In cases where the EDC system in use 
is not configured to send automatic notificati ons or when an EDC system is not used, the 
COM/CRA is responsible for notifying Clinical QA upon discovery that a PQC has occurred.  
CR-6470, v 2.0  
 
Page 46 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Upon receipt of the EDC notification, the COM/CR A will contact the study site to collect 
additional information which will include: 
xDate the complaint was received/recorded in the EDC System (Date of Sponsor 
Awareness).
xWho received the complaint.
xStudy number.
xClinical site information (contact name, site ID, telephone number).
xLot number(s).
xUnique Subject Identifier(s).
xIndication of who first observed complaint (site personnel or subject).
xOD/OS indication, along with whether the lens was inserted.
xAny related AE number if applicable.
xDetailed complaint description (scheduled/unscheduled visit, wear time, symptoms, 
resolution of symptoms, etc.).
xEye Care Provider objective (sli t lamp) findings if applicable.
xConfirmation of product availability for return (and trac king information, if available), 
or rationale if product is not available for return 
Once a complaint is received, it will be asse ssed by the COM, CRA, or trained site personnel 
to determine if it is an Adverse Event/Seri ous Adverse Event (AE/SAE). If the complaint 
results in an AE/SAE, the COM/CRA, or traine d site personnel will follow section 13 of this 
protocol. If the AE/SAE was potentially the result  of a product quality related deficiency, these 
procedures also applies and will be executed in parallel.  
In some cases, a PQC form may be generated in EDC by the site in error. In this event, the 
PQC forms will be marked “Intentionally Left Bla nk” or “ILB”.  Justification for ILB must be 
documented.
13. ADVERSE EVENTS 
13.1. Definitions and Classifications 
Adverse Event (AE) – An AE is “any untoward medical occurrence, unintended dise ase or 
injury, or untoward clinical signs (including abnormal laboratory findings) in subjects, users 
or other persons, whether or not related to  the investigational medical device. ”
Note : This definition includes events related to  the investigational medical device or the 
comparator, and to the procedures involved. For users or other persons, this definition is 
restricted to events related to investigational medical devices.0
An AE includes any condition (including a pre-existing condition) that:
CR-6470, v 2.0  
 
Page 47 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
1. Was not present prior to the study, but a ppeared or reappeared following initiation of 
the study.
2. Was present prior to the study but worsened  during the study. This would include any 
condition resulting from concomitant illnesse s, reactions to concomitant medications, 
or progression of disease states.
Note : Pregnancy must be documented as an adverse event and must be reported to the clinical 
monitor and to the Sponsor immediately upon learning of the event.
Serious Adverse Event (SAE) –An SAE is any adverse event that led to any of the following:
xDeath
xSerious deterioration in the health of the subj ect that resulted in any of the following:
xLife-threatening illness or injury
xPermanent or persistent impairment of a body structure or a body function
xHospitalization or prolongation of patient hospitalization
xMedical or surgical intervention to prevent life-threatening illness or injury or 
permanent impairment to a body structure or a body function.
xChronic disease
xFoetal distress, foetal death or a congenita l physical or mental impairment of birth 
defect.
Diagnoses and conditions that are considered Oc ular Serious Adverse Events include, but not 
limited to:
xMicrobial Keratitis (MK)
xIritis (including cells in the anterior chamber)
xPermanent decrease in best sp ectacle corrected visual acuity e quivalent to 2 acuity lines 
or greater
xCentral Corneal Opacity
xCentral Corneal Neovascularization
xUveitis
xEndophthalmitis
xHypopyon
xHyphemia
xPenetration of Bowman’s Membrane
xPersistent Epithelial Defect
xLimbal cell Damage leading to Conjunctivalization
Significant Adverse Events –are defined as events that are symptomatic and warrant 
discontinuation (temporary or permanent) of the contact lens wear
Diagnoses and conditions that are considered Oc ular Significant Adverse Events include, but 
not limited to the following:
CR-6470, v 2.0  
 
Page 48 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
xContact Lens Induced Peripheral Ulcer (CLPU)
xSignificant Infiltrative Events (SIE)
xSuperior Epithelial Arcuate Lesions (SEALs)
xAny Temporary Loss of > 2 Lines of BSCVA
xOther grade 3 or higher corneal findings, such as abrasions or edema
xNon-contact lens related corneal events - e.g. Epidemic Keratoconjunctivitis (EKC)
xAsymptomatic Corneal Scar
xAny corneal event which necessitates temporary lens discontinuation > 2 weeks
Non-Significant Adverse Events –are defined as those events that are usually asymptomatic 
and usually do not warrant discontinuation of con tact lens wear but may cause a reduction in 
wear time.  However, the Investigator may choos e to prescribe treatment as a precautionary 
measure.
Diagnoses and conditions that are considered Oc ular Non-Significant Adverse Events include, 
but not limited to the following:
xNon-significant Infiltrative Event (NSIE)
xContact Lens Papillary Conjunctivitis (CLPC)
xSuperficial Punctate Keratitis (SPK)
xConjunctivitis: Bacterial, Viral, Allergic
xBlepharitis
xMeibomianitis
xContact Dermatitis
xLocalized Allergic Reactions
xAny corneal event not explicitly defined as serious or significant adverse event, which 
necessitates temporary lens discontinuation < 2 weeks
Adverse Device Effect (ADE) – An ADE is an “adverse event related to the use of an 
investigational medical device. ”
Note 1: This definition includes adverse events re sulting from insufficient or inadequate 
instructions for use, deployment, implanta tion, installation, or operation, or any malfunction 
of the investigational medical device.
Note 2: This definition includes any event resulting from use error or from intentional misuse 
of the investigational medical device.0
Unanticipated Adverse Device Effect (UADE) –A UADE is any serious adverse effect on 
health or safety or any life-threatening problem or death caused by, or associated with, the test article, if that effect, problem, or death was not  previously identified in nature, severity, or 
degree of i ncidence in the investigational plan, Investigator’s Brochure or protocol, or any 
other unanticipated serious problem  associated with the test artic le that relates to the rights, 
safety and welfare of subjects.
CR-6470, v 2.0  
 
Page 49 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
13.2. Assessing Adverse Events 
In conjunction with the medical monitor, the Invest igator will evaluate adverse events to ensure 
the events are categorized correctly. Elements of categorization will include:
xSeriousness/Classifications (see  definition in section 13.1).
xCausality or Relatedness –i.e. the relationship between the test article, study treatment 
or study procedures and the adverse event (not related, unlikely related, possibly
related, or related - see definition in section 13.2.1).
xAdverse Event Severity –Adverse event severity is used to assess the degree of 
intensity of the adverse event (mild, m oderate, or severe - see definition in 
section 13.2.2).
xOutcome –not recovered or not resolved, rec overing or resolving, recovered or 
resolved with sequelae, recovered or reso lved, death related to adverse event, or
unknown.
xActions Taken –none, temporarily discontinued, permanently discontinued, or other.
13.2.1. Causality Assessment 
Causality Assessment –A determination of the relationship be tween an adverse event and the 
test article. The test article relationship for each  adverse event should be determined by the 
investigator using these explanations:
xNot Related- An adverse event that is not relate d to the use of the test article, study 
treatment or study procedures.
xUnlikely Related –An adverse event for which an alternative explanation is more 
likely, e.g. concomitant treatment, concomi tant disease(s), or the relationship of time 
suggests that a causal relationship is not likely.
xPossibly Related –An adverse event that might be due  to the use of the test article, or 
to the study treatment or study procedures. An  alternative explanation, e.g. concomitant 
treatment, concomitant disease(s), is in conclusive. The relationship in time is 
reasonable. Therefore, the causal relationship cannot be excluded.
xRelated –An adverse event that is listed as a po ssible adverse effect (device) or adverse 
reaction (drug) and cannot be reasonably exp lained by an alternative explanation, e.g. 
concomitant treatment of c oncomitant disease(s). The relationship in time is very 
suggestive, e.g. it is confirmed by de-challenge and re-challenge.
13.2.2. Severity Assessment 
Severity Assessment –A qualitative assessment of the degree of intensity of an adverse event 
as determined by the Investigator or reported to  him/her by the subject. The assessment of 
severity is made irrespective of test article, st udy treatment or study procedure relationship or 
seriousness of the event and should be evaluated according to the following scale:
CR-6470, v 2.0  
 
Page 50 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
xMild –Event is noticeable to the subject but is  easily tolerated and does not interfere 
with the subject’s daily activities .
xModerate –Event is bothersome, possible requiring additional therapy, and may 
interfere with the subject’s daily activities .
xSevere –Event is intolerable, necessitates additi onal therapy or alteration of therapy 
and interferes with the subject’s daily activities .
13.3. Documentation and Follow-Up of Adverse Events 
The recording and documenting of adverse events  (ocular and non-ocular) begin when the 
subjects are exposed to the test article, study treatment or study procedure.  Adverse events 
reported before the use of test article, start of study treatment, or study procedures will be 
recorded as medical history. However, if the c ondition deteriorates at any time during the study 
it will be recorded and reported as an AE. Unto ward medical events reported after the subject’s 
exit from the study will be recorded as adve rse events at the discretion of the Investigator.
Upon finding an adverse event, the Principal In vestigator will document the condition in the 
subject record and in the eCRFs and complete the Adverse Event eCRF.  
Complete descriptions of all adverse events must be available in the subject record. All 
Adverse Events including local and systemic re actions not meeting the criteria for “serious 
adverse events” shall be capture d on the appropriate case report form or electronic data system. 
All adverse events occurring while the subject is enrolled in the study  must be documented 
appropriately regardless of relationship.  
It is the Investigator’s responsibility to maintain  documentation of each reported adverse event. 
All adverse events will be followed in accordan ce with applicable licensing requirements. Such 
documentation will include the following:
xAdverse event (diagnosis not symptom).
xDrawings or photographs (where appropriate) that detail the finding (e.g., size, 
location, and depth, etc.).
xDate the clinical site was notified.
xDate and time of onset.
xDate and time of resolution.
xAdverse event classification, severity, and relationship to test articles, as applicable.
xTreatment regimen instituted (where appropr iate), including concomitant medications 
prescribed, in accordance with a pplicable licensin g requirements.
xAny referral to another health care provider if needed.
xOutcome, ocular damage (if any).
xLikely etiology.
xBest corrected visual acuity at the disc overy of the event and upon conclusion of the 
event, if the AE is related to the visual system.
CR-6470, v 2.0  
 
Page 51 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Upon discovery of an AE that is deemed ‘possibly related ’or ‘related ’to the test article or 
study procedures (whether related to the visual system or not), a nAE review form 
must be completed .Additional dated and initialed entries should be made atfollow -up 
evaluations .Separate forms must be completed for each eye if the AE is bilateral. 
In addition, if an infiltrate(s) is present, he /she will complete the Corneal Infiltrate Assessment 
eCRF. Where necessary, a culture of the corneal les ion will be collected to determine if the 
infection is microbial in nature. If cultures are collected, the date of culture collection and 
laboratory utilized will be recorded. 
Changes in the severity of an AE shall be documented to allow an assessment of the duration 
of the event at each level of in tensity to be performed. Adve rse events characterized as 
intermittent require doc umentation of the onset and duration of each episode. Changes in the 
assessment of relationship to the Test Article shall also be clearly documented.Subjects who present with an adverse event shall be followed by the Investigator, within 
licensure, until all signs and symptoms have returned to pre-treatment status, stabilized, or 
been satisfactorily resolved. If further treatm ent beyond licensure is required, the patient will 
be referred to the appropriate health care provi der. The Investigator will use his/her clinical 
judgment as to whether a subject reporting with an adverse event will continue in the study. If a subject is discontinued from the study, it w ill be the responsibility of the Investigator to 
record the reason for discontinuation. The Invest igator will also document the adverse event 
appropriately and complete the Adverse Even t eCRF. Any subjects with ongoing adverse 
events related to the test article, study treatment or study procedures, as of the final study visit 
date, should be followed to reso lution of the adverse event or until  referral to an appropriate 
health care provider, as recommended by the Investigator. Non-ocular adverse events that are not related to the test article, study treatmen t, or study procedures may be recorded as 
“ongoing” without further follow -up.
13.4. Reporting Adverse Events  
The Investigator will notify the Sponsor of an adverse event by e-mail , facsimile, or telephone 
as soon as possible and no later than 24 hours from discovery for any serious /significant 
adverse events, and 2 days from discovery for an y non-significant adverse event. In addition, 
a written report will be submitted by the Prin cipal Investigator to the IEC/IRB according to 
their requirements (section 13.4.2). The report will comment whether the adverse event was considered to be related to the test article, study treatment or study procedures.
13.4.1. Reporting Adverse Events to Sponsor 
Serious/Significant Adverse Events
The Investigator will inform the sponsor of all serious/significant adverse events occurring 
during the study period as soon as possible by e-mail or telephone, but no later than 24 hours 
following discovery of the event. The Invest igator is obligated to pursue and obtain 
information requested by the Sponsor in addition to that information reported on the eCRF. All 
subjects experiencing a serious/si gnificant adverse event must be  followed up and all outcomes 
must be reported.
CR-6470, v 2.0  
 
Page 52 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
When medically necessary, the Investigator may break the randomization code to determine 
the identity of the treatment that the subject  received. The Sponsor and study monitor should 
be notified prior to unmasking the test articles.
In the event of a serious/significant adverse event, the Investigator must:
xNotify the Sponsor immediately.
xObtain and maintain in the subject’s records all pertinent medical information and 
medical judgment for colleagues who assisted  in the treatment and follow-up of the 
subject.
xProvide the Sponsor with a complete case history which includes a statement as to 
whether the event was or was not related to the use of the test article.
xNotify the IEC/IRB as required by the IEC/IRB reporting procedure according to
national regulations.
Unanticipated (Serious) Adverse Device Effect (UADE)
In the event of an Unanticipated (Serious) Adverse Device Effect (UADE), the Investigator 
will submit a report of the UADE to the Sponsor and IEC/IRB as soon as possible, but no later 
than 24 hours after the Investigator first learns of the effect. This report is in addition to the 
immediate notification mentioned above.
The Sponsor must conduct an evaluation of the UADE and must report the results of the 
evaluation to FDA, the IEC/IRB and participati ng Investigators within 10 working days after 
the Sponsor first receives notification of the effect.
Non-Serious Adverse Events
All non-serious adverse events, including non-seri ous adverse device effects, will be reported 
to the sponsor by the Investigator no later than 2 days from discovery.
13.4.2. Reporting Adverse Events to the Responsible IEC/IRB and Health Authorities 
Adverse events that meet the IEC/IRB requirements for reporting must be reported within the 
IEC/IRB’s written guidelines. Each clinical site will refer to and follow any guidelines set forth 
by their Approving IEC/IRB. Each clinical site will refer to and follow any guidelines set forth by their local governing Health Authorities.
The Sponsor will report applicable Adverse Events  to the local health authorities according the 
written guidelines, incl uding reporting timelines. 
13.5. Event of Special Interest 
None
CR-6470, v 2.0  
 
Page 53 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
13.6. Reporting of Pregnancy 
Subjects reporting pregnancy (by self-report) durin g the study will be discontinued after the 
event is recorded as an Adverse Event. Once  discontinued, pregnant participants and their 
fetuses will not be monitored for study related purposes. Pregnant participants are not 
discontinued from contact lens or solution re lated studies for safety concerns, but due to 
general concerns relating to pregna ncy and contact lens use. Spec ifically, pregnant women are 
discontinued due to fluctuations in  refractive error and/or visual  acuity that occur secondary to 
systemic hormonal changes, and not due to unforeseen health risks to the mother or fetus.
14. STATISTICAL METHODS 
14.1. General Considerations 
Statistical Analysis will be undertaken by the sponsor or under the authority of the sponsor. A 
general description of the statistical methods to be implemented in this clinical trial is outlined below. More details will be included in the s tand-alone Statistical Analysis Plan (SAP). The 
SAP will be developed and finalized prior to database lock.
All data summaries and statistical analyses will be performed using the SAS software Version
9.4 or higher (SAS Institute, Cary, NC).
11Throughout the analysis of data, the results for each 
subject/eye will be used when available for summarization and statistical analysis. 
Unscheduled visits will be summarized separa tely and will be excluded from the efficacy 
analysis.
Summary tables (descriptive statistics and/or freque ncy tables) will be provided for all baseline 
variables, efficacy variables and safety variable s as appropriate. Continuous variables will be 
summarized with descriptive statistics (n, mean, standard deviation (SD), median, minimum 
and maximum). Frequency count an d percentage of subjects or eyes within each category will 
be provided for categorical data.
14.2. Sample Size Justification 
This study is designed and powered to demonstr ate non-inferiority of the Test lens compared 
to the Control lens with respect to the prima ry endpoints: slit lamp findings, fit acceptance, 
distance monocular logMAR VA, and CLUE overa ll quality of vision. Sample size was 
estimated to achieve a minimum statistical power  of 80% for logMAR VA and CLUE vision 
with a 2-sided type I error of 0.05 each, and a minimum statistical power of 80% for slit lamp 
findings and lens fit acceptance with the 95% central posterior credible interval. For 
information purpose, power was estimated for the se condary endpoints usi ng the sample size 
determined by the primary endpoints.
Sample size/power estimati on was based on historical h ard-lock data from  and 
 and the interim read data from . The same type of Test and Control lenses were 
investigate d in  and  with a 2×2 crossover design. Test lenses in 
were made from the pilot line while Test lenses in  and the current study are produced 
from the manufacturing line.  is a 6×6 crossover study with 6 different types of lenses. 
CR-6470, v 2.0  
 
Page 54 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
For sample size estimation, the log MAR VA data for the Theia lens and ACUVUE OASYS 1-
Day lens in  were used to make assumptions for the Test and Control lenses in the 
current study, respectively. Only the first period data from these stud ies were used in the 
sample size estimation. There were n o grade 3 or higher slit lamp findings or unacceptable lens 
fit observed in . No unacceptable lens fit and only one Grade 3 slit lamp findings 
(conjunctival injection) for one subject eye with the Test lens at an unscheduled visit was 
observed in  interim data. Table 9 and Table 10 below present the descriptive statistics 
and adjusted means/proportions of logMAR VA , CLUE scores, and individual situational 
visual performance items for indoors and digital devices observed from these studies.Error! R
eference source not found.
Table 9:Descriptive Summary and Adjusted Means ofLogMAR Visual Acuity and CLUE 
Scores from ,  and  (Interim)
Study Endpoint TimepointTest 
Mean(SD)Control 
Mean(SD)Test 
Adjusted 
MeanControl 
Adjusted 
Mean
LogMAR
VA (High 
Contrast 
Dim)1-Week 
FU-0.01(0.046) 0.023(0.020) -0.02 0.03
(Interim)CLUE 
Vision 2-Week 
FU71.3(20.36) 68.5(20.65) 73.6 69.1
CLUE 
Comfort 2-Week 
FU71.4(22.22) 67.1(23.18) 73.4 69.8
CLUE 
Handling2-Week 
FU70.3 (21.38) 69.5 (21.66) 68.9 70.7
SD = standard deviation, FU = follow-up
Table 10:Descriptive Summary and Adjusted Proportion Estimates for Two Situational 
Visual Performance Items at 2 -week Follow -up from  and  (Interim)
Study Item Lens Number of 
SubjectsProportion of
“Excellent” 
RatingAdjusted 
Proportion of
“Excellent” 
Rating
(Interim)Clarity of 
vision 
indoors in 
bright light Test 146 60% 63%
Control 141 45% 47%
Study  Item Lens Prefer Habitual 
LensNo Preference Prefer Study Lens
Unadjusted Adjusted Unadjusted Adjusted Unadjusted Adjusted
CR-6470, v 2.0  
 
Page 55 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Study Item Lens Number of 
SubjectsProportion of
“Excellent” 
RatingAdjusted 
Proportion of
“Excellent” 
Rating
(Interim)Overall 
preference 
while 
using 
computer 
screens & 
digital 
devicesTest 24
(16%)19
(13%)54
(37%)56
(38%)69
(47%)72
(49%)
Monocular Distance logMAR Visual Acuity
The sample size estimation for monocular dist ance logMAR visual acuity was calculated using 
a linear mixed model-based power analysis method.12The model included lens as a fixed 
effect. An unstructured (UN) covariance matrix was used to model the residual errors between 
measurements with in the same subject across eyes. It was assumed there was no difference 
between the Test and Control lenses since the two lenses have not been evaluated for logMAR 
VA performance in the same study previously. Sample size estimation was carried out using 
anapproximation of the power of an F -test derived from the non -centrality parameter 
calculated from the observed F statistic of the linear mixed model. Below is the variance -
covariance matrix used in the sample si ze calculation based on historical data from
Period 1 for monocular logMAR visual acuity. 
The UN covariance matrix: ቂ0.002492 0.000689
0.000689 0.000736ቃ
CLUE Overall Quality of Vision
Sample size for CLUE overall quality of vision was calculated us ing a two independent sample 
ttest in PROC Power assuming the Test lens is 2 points higher than the Control lens and a 
common standard deviation of 21. A non-inferiority margin of -5 points was used since this is 
considered to be no more than a 10% shift in the population distribution of CLUE scores.
Lens Fit Acceptance
Unacceptable lens fitting is a binary response as ܻ=1 if a subject eye has an unacceptable 
fitting and ܻ=0otherwise. From the historical data ther e was no unacceptable lens fitting for 
both study lenses. Assuming no difference betw een study lenses and a correlation of 0.70
between left and right eyes within the same subject, a total of 2000 replicating trials were 
simulated with an unacceptable fitting rate of 5% (worse-case scenario). Given the rare event 
binary outcome of fit acceptance, each replica ted sample was analyzed using a Bayesian beta-
binomial model with correlated binary data.13Sample size was estimated to achieve a minimal 
statistical power of 80% with a non -inferiority margin of 10% (Test –Control) based on the 
simulated data. For each simulated trial, the lo wer bound of the 95% central posterior credible 
interval constructed for the percentage difference was compared to the 10% margin. With the 
proposed sample size, there was at least 80% of the estimated 95% credible intervals with 
upper bound being below 10%. 
CR-6470, v 2.0  
 
Page 56 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Biomicroscopy (Slit Lamp Findings)
Slit lamp findings (SLF) are converted to a binary response as ܻ=1 if a subject eye has a
clinically significant SLF and ܻ=0otherwise for analysis purpose. From the historical data 
there was no or extremely low rate for clinically significant SLF for the study lenses. Assuming 
no difference between study lenses and a correlati on of 0.70 between left and right eyes within 
the same subject, a total of 2000 replicating trials  were simulated with clinically significant 
SLF rate of 2% (worse-case scenario). Given the rare event binary outcome of slit lamp findings, each replicated sample was analyzed using a Bayesian beta-binomial model with 
correlated binary data (Diniza et al; 2010). Sa mple size was estimated to achieve a minimal 
statistical power of 80% with a non -inferiority margin of 5% (Test –Control) based on the 
simulated data. For each simulated trial, the lo wer bound of the 95% central posterior credible 
interval constructed for the percentage differen ce was compared to the 5% margin. With the 
proposed sample size, there was at least 80% of the estimated 95% credible intervals with 
upper bound being below 5%. 
CLUE Overall Comfort 
Power for CLUE overall comfort was es timated using a two independent sample ttest in PROC 
Power assuming the Test lens is 2 points higher than the Control lens and a common standard 
deviation of 23. A non-inferiority margin of -5 points  was used since this is considered to be 
no more than a 10% shift in the population distribution of CLUE scores.
CLUE Overall Handling
Power for CLUE overall handling was estimate d using PROC Power for a two independent 
sample ttest assuming the Test lens is 2 points lowe r than the Control lens and a common 
standard deviation of 21. A non-infe riority margin of -5 points was used since this is considered 
to be no more than a 10% shift in the population distribution of CLUE scores.Clarity of Vision Indoors in Bright Light
Clarity of vision indoors in bright light will be evaluated at 2 -week follow -upusing a 5-point 
Likert scale (1: Excellent, 2: Very Good, 3: Good, 4: Fair and 5: Poor) with a “Not Applicable” 
response option .Response s to clarity of vision indoors in bright  light will be converted into a 
binary variable for the purpose of analysis (Excel lent = 1 and others = 0) and “Not Applicable” 
will not be included in the analysis. Based on historical data from  and 
(Interim), it was assumed the percentage of subj ects with an “Excellent” rating was 60% and 
50% for the Test and Control len ses, respectively. Power was calculated using PROC POWER 
for Pearson chi -square test for two proportions. The non -inferiority odds r atio margin of 0.67 
was used, which corresponds to no more than a 10% diff erence between the Test and Control 
lenses.
Overall Preference While Using Com puter Screens & Digital Devices
Responses to overall preference while using computer screens & digital devices in the Test 
lens group will be collapsed into three categorie s for the purpose of analysis (Prefer Test Lens, 
No Preference, and Prefer Habitual  Lens). Based on historical data from  and 
CR-6470, v 2.0  
 
Page 57 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
(Interim) for period 1, it was assumed that th e percentage of subjects preferring Test lens 
was 0.4, the percentage of subjects preferring Ha bitual lens was 0.2, and the percentage of 
subjects with no preference was 0.4. A total of 2000 replicating trials were simulated. To 
estimate statistical power, the simulated multinomial data were analyzed using a generalized 
linear regression model with a generalize d logit link function and tested for statistical 
superiority (preference ratio of preferring Test to Habitual). 
Table 11 below summarizes the required number of completed subjects to achieve a minimum 
of 80% statistical power for the primary endpoints.  Table 12 shows the statistical power for 
the secondary endpoints based on the sample size determine d by the primary endpoints. 
Table 11: Sample Size Estimation for the Primary Endpoints
EndpointHypothesis 
TestingSample Size Power
Monocular Distance LogMAR VA Non-inferiority 16 84%
CLUE Vision Non-inferiority 286 80%
Lens Fit Acceptance Non-inferiority 140 83%
Slit Lamp Findings Non-inferiority 240 83%
Table 12: Power Estimation for the Secondary Endpoints
EndpointHypothesis 
TestingSample Size Power
CLUE Comfort Non-inferiority 286 73%
CLUE Handling Non-inferiority 286 23%
Situational Visual Performance –
Indoor ( Clarity of Vision Indoors in 
Bright Light)Non- inferiority 286 93%
Situational Visual Performance –
Digital Devices (Overall Preference 
While Using Computer Screens & Digital Devices)Superiority143 for Test 
Lens Group88%
As indicated in Table 11 above, the sample size chosen for this study was primarily driven by 
the primary endpoint of CLUE overall quality of vision in order to achieve a statistical power 
of at least 80% for all primary endpoints. The plan is to enroll approximately 320 eligible 
subjects with a target of 286 to complete the study (143 per arm).
14.3. Analysis Populations 
Safety Population:
All subjects who are administered any test ar ticle excluding subjects who drop out prior to 
administering any test article. At lea st one observation should be recorded.
CR-6470, v 2.0  
 
Page 58 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Per-Protocol Population: 
All subjects who successfully complete all visi ts and do not substantially deviate from the 
protocol as determined by the trial cohort revi ew committee prior to database hard lock. 
Justification for the exclusion of subjects with  protocol deviations from the per-protocol 
population set will be documented in a memo to file.
Intent-to-Treat (ITT) Population:
All randomized subjects regardless of actual treatment and subsequent withdrawal from the study or deviation from the protocol. At least one observation should be recorded.
14.4. Level of Statistical Significance 
All planned analysis for this study will be cond ucted with an overall type I error rate of 5%. 
14.5. Primary Analyses  
Primary Efficacy Analyses:Primary efficacy analyses will be conducted on the Per-Protocol (PP) population. Sensitivity 
analysis may be considered on the Intent-to-Treat (ITT) population with no missing data imputation.
CLUE Overall Quality of Vision
CLUE vision scores will be analyzed using a linear mixed model to compare the Test and 
Control lenses at the 2-week follow-up evalu ation. The model will include baseline CLUE 
vision score and lens type as fixed effects and cl inical site as a random effect (G-side). Other 
subject characteristics such as age, gender, iris  category (dark iris and light iris), and habitual
lens type (habitual daily disposable and habitual  daily wear reusable) will be included when 
appropriate. The Kenward and Roger method will be used for  the denominator degree of 
freedom.14
Hypothesis Testing
The null and alternative hypotheses for testing non-i nferiority of the Test lens relative to the 
Control lens with respect to CLUE vision scores are as follows: 
ܪ଴:ߤ்− ߤ஼≤− 5
ܪ஺:ߤ்− ߤ஼ >−5
Where, ߤ்represents the mean CLUE vision score for the Test lens and ߤ௖represents the mean 
CLUE vision score for the Control lens. Non-infe riority will be declared if the lower bound of 
the 2-sided 95% confidence interval of the difference (Test –Control) is greater than -5. If
non-inferiority of the Test lens over Control lens is  met, then superiority will be assessed. If 
the lower bound is greater than 0, then superiorit y of the Test lens over the Control lens will 
be established.
Monocular Distance logMAR Visual Acuity
CR-6470, v 2.0  
 
Page 59 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Monocular distance logMAR VA under bright HLHC will be analyzed using a linear mixed 
model. The model will include lens type as a fixe d effect. Other subject characteristics such as 
age, gender, iris category, and habitual lens t ype will be included when appropriate. Site will 
be included in the model as a random effect (G-side). The covariance of residuals between measurements within the same subject across ey es (R-side random effect) will be modeled 
using Unstructured (UN) covariance structure. If the model does not converge, then compound Symmetry (CS) covariance structure will be c onsidered. The Kenward and Roger method will 
be used for the denominator degree of freedom.
14
Hypothesis TestingThe null and alternative hypotheses for testing non-i nferiority of the Test lens relative to the 
Control lens with respect to logMAR visual acuity are as follows: 
ܪ
଴:ߤ்− ߤ஼≥0.05
ܪ஺:ߤ்− ߤ஼ <0 . 0 5
Where, ߤ்represents the mean logMAR VA score for the Test lens and ߤ௖represents the mean 
logMAR VA score for the Control lens. Non-i nferiority will be declared if the upper bound of 
the 2-sided 95% confidence interval of the difference (Test –Control) is less than 0.05. If non-
inferiority of the Test le ns over Control lens is met, then s uperiority will be assessed. If the 
upper bound is less than 0, then superiority of the Test lens over the Control lens will be 
established.
Primary Safety Analyses:
Primary safety analysis will be conducted on the safety population based on treatments actually 
received by subjects.
Lens Fit Acceptance
Lens fit acceptance will be analyzed using a Bayesian beta-binomial model with correlated 
binary data.13
The Model:
Let ܻଵand ܻଶdenote the binary outcomes of lens fit acceptance (Yes/No) in left and right eyes, 
respectively, across dispensing and follow-up vi sits when wearing a study lens. Considering 
the correlation,  ߩ ,between ܻଵand ܻଶ, the distribution of the sum ܻ = ܻଵ + ܻଶis obtained by 
the mixture of two variables. One of them follow a binomial distribution ݊݅ܤ(2,݌)with mixing 
probability (1− ߩ)and the other one follows a modified Bernoulli distribution, ݊ݎ݁ܤܯ( ݌),
taking value 0 and 2 rather than conventional 0 and 1, with mixing probability ߩ:
ܲ(ܻ = ݕ| ݌,ߩ( = ) 1− ߩ)݊݅ܤ(2,݌)ܫ஺ଵ +  ݊ݎ݁ܤܯߩ( ݌)ܫ஺ଶ ,
where ܫ஺ଵ = { 0 ,1 ,2 } ,ܫ஺ଶ= { 0 ,2 } and ݌is the probability of success (i.e., acceptable lens 
fitting).
CR-6470, v 2.0  
 
Page 60 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
To overcome the complexity of the mixture likelihood a latent variable ܼ௜, i = 1, 2 is introduced 
in the model to indicate in which component of the model the observation ݕ௜, i=1, 2, belongs 
to, that is,
ܼ௜=൜1, if the observation belong to the MBern(p),
0, if the observation belong to the Bin(2, p)  
The joint distribution of the augmented data (ܻ௜,ܼ௜),݅=1 ,2 , is given by
P(Y=y୧,Z =z୧| p,ρ)
=  ρ୸౟p୷౟୸౟/ଶ(1−p)(ଶି୷౟)୸౟/ଶ(1−ρ)ଵି୸౟൬2
y୧൰p୷౟(ଵି୸౟)(1−p)(ଶି୷౟)(ଵି୸౟)
The probability p links to the regression variables through a logit transformation as follow:
logit (p)=  β଴+ βଵlens
It is assumed that β଴,βଵ and ߩto be independent with a non-informative prior N(0, 1000) for
β଴ andβଵ,and beta(0.5, 0.5) for ߩ. The Metropolis sampler algorithm as implemented in the 
SAS/STAT MCMC Procedure11will be used to estimate the posterior distributions of the 
parameters ( β଴,βଵ,ߩ.) Inferences will be made based on a posterior credible interval for the 
relevant parameters.
Bayesian Estimation and Statistical Evaluation of Hypothesis:
Non-inferiority of the Test lens relative to the Co ntrol lens with respect to lens fit acceptance 
will be evaluated using Bayesian statistics. The null and alternative hypotheses for evaluating 
non-inferiority of the Test lens relative to the Cont rol lens with respect to les fit acceptance are 
as follows: 
ܪ଴: ݌୘− ݌େ≥0.1
ܪ஺: ݌୘− ݌େ<0 . 1 ,
where ݌୘and ݌େare the probability of event (i.e., unacceptable lens fitting) for Test lens and 
Control lens, respectively. Based on Bayesian  posterior probability distribution of the 
proportion difference ( ݌்− ݌஼), non-inferiority is interpreted as 95% probability of Test 
being no worse than Control by 10% (i.e., ݌୘− ݌େ<0 . 1 ) with respect to unacceptable lens 
fitting rate. If the upper bound of the 95% central pos terior credible interval is below 0.1, it 
can be concluded that there is 95% probability that the Test lens is non-inferior to the Control lens based on the observed sample. 
In the case of all eyes have an acceptable lens  fit (i.e., zero unacceptable lens fit), a Bayesian 
hierarchical model accounting for zero event problem will be considered.
15Details of this 
model will be provided in the stand-along SAP.Biomicroscopy (Slit Lamp Findings) 
Biomicroscopy will be analyzed using the same Bayesian beta-binomia l model as described 
for lens fit acceptance. The proportion of eyes with clinically significant slit lamp findings (i.e., 
Grade 3 or higher, or significant corneal inf iltrates) across study visits will be modeled.
CR-6470, v 2.0  
 
Page 61 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Bayesian Estimation and Statistical Evaluation of Hypothesis:
Non-inferiority of the Test lens relative to the Control lens with respect to slit lamp findings
will be evaluated using Bayesian statistics. The null and alternative hypotheses for evaluating 
non-inferiority of the Test lens relative  to the Control lens are as follows: 
ܪ଴: ݌୘− ݌େ≥0.05
ܪ஺: ݌୘− ݌େ<0 . 0 5 ,
where ݌୘and ݌େare the probability of clinically signifi cant slit lamp findings across study 
visits for Test and Control, respectively. Based on Bayesian posterior probability distribution 
of the proportion difference ( ݌்− ݌஼), non-inferiority is interpreted as 95% probability of 
Test being no worse than Control by 5% (i.e., ݌୘− ݌େ<0 . 0 5 ). If the upper bound of the 95% 
central posterior credible interval is below 0.05, it can be concl uded that there is 95% 
probability that the Test lens is non-inferior to  the Control lens based on the observed sample. 
In the case of zero clinically significant SLF,  a Bayesian hierarchical model accounting for
zero event problem will be considered.15
14.6. Secondary Analyses  
Secondary Efficacy Analyses:Secondary efficacy analyses will be c onducted on the Per-Protocol (PP) population.
CLUE Overall Comfort and Overall Handling
CLUE overall comfort and handling will be analyzed using the same statistical method 
described for CLUE overall quality of vision. 
Situational Visual Performance –Indoors
Situation visual performance –indoors will be assessed using the individual item “ Clarity of 
vision indoors in bright light ”() .Item responses will be converted into a binary 
variable for the purpose of analysis (Excellent  = 1 and others = 0) and “Not applicable” 
response will not be considered in the analysis. The dichotomized item responses will be 
analyzed using a generalized linear mixed model with a binomial distribution and the logit as 
the link function. The model will include lens type as a fixed effect and site as a (G-side) 
random effect. Other subject characteristics such as age, gender, iris category , habitual lens 
type will be included when appropriate.
Hypothesis Testing
The null and alternative hypotheses for testing non-i nferiority of the Test lens relative to the 
Control lens with respect to clarity of vision indoors at bright light are as follows: 
ܪ଴:ܴܱ ≤ 0.67
ܪ஺:ܴܱ>0 . 6 7
Where OR represents the odds ratio of having “Excellent” rating for the Test lens compared to 
the Control at the 2-week follow-up. Non-inferi ority will be declared if the lower bound of the 
CR-6470, v 2.0  
 
Page 62 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
2-sided 95% confidence interval is above 0.67. If non-inferiorit y of the Test lens over Control 
lens is met, then superiority will be assessed. If the lower bound is above 1.0, then superiority 
of the Test lens over the Control lens can be concluded.
Situational Visual Performance –Digital Devices
Situation visual performance –digital devices will be assessed using the preference item 
“Overall preference while using computer screens & digital devices ” among the 
Test lens group. Item responses will be collapsed into three categories for the purpose of 
analysis (Prefer Test Lens, No Preference, a nd Prefer Habitual Lens). The collapsed item 
responses will be analyzed using a generalized linear mixed model with a multinomial 
distribution and the generalized l ogit as the link function. The analysis model will include site 
as a random effect (G -sided), and gender, habitual lens type, and iris category will be included 
as fixed covariates when appr opriate.
Hypothesis Testing
The null and alternative hypotheses for testing s uperiority of the Test lens relative to the 
Control lens are as follows: 
ܪ଴:ܴܲ ≤ 1.0
ܪ஺:ܴܲ>1 . 0
Where PR represents the preference ratio of Test lens to Habitual lens (proportion of subjects preferring Test to proportion of subjects preferr ing Habitual lens) at the 2-week follow-up.
Superiority will be declared if the lower bound of the 2-sided 95% confidence interval is above 
1.0.
14.7. Other Exploratory Analysis  
Not applicable
14.8. Interim Analysis  
Not applicable
14.9. Procedure for Handling Missing Data and Drop-Outs 
Missing or spurious values will not be imputed. The count of missing values will be included 
in the summary tables and listings. 
Subject dropout is expected to be one of the main reasons of missing data in this clinical trial. 
Past clinical trials don’t provide the evidence that subjec t dropout is systematic or not-at-
random. To evaluate the impact of missing data on the primary efficacy analyses, sensitivity 
analysis may be conducted on the ITT population using multiple imputation methods if the 
proportion of subject dropout is greater than the 15%. The SAS/STAT procedures PROC MI 
and PROC MIANALYZE will be utilized with  a parametric regression method used to make 
at least 20 imputations.
CR-6470, v 2.0  
 
Page 63 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
14.10. Procedure for Reporting Deviations from Statistical Plan 
The analysis will be conducted according to th at specified in above sections. There are no 
known reasons for which it is planned to deviate from these analysis methods. If for any reason 
a change is made, the change will be documented in the study report along with a justification 
for the change.
15. DATA HANDLING AND RECORD KEEPING/ARCHIVING 
15.1. Electronic Case Report Form/Data Collection 
The data for this study will be captured on electronic case report forms (eCRFs) using the 
BioClinica EDC system. An authorized data origi nator will enter study data into the eCRFs 
using the EDC system. Data collected on equi pment that is not captured in EDC will be
formatted to the specification of the JJVC database manager and sent to JJVC for analysis. 
External data sources for this study include: Not Applicable .
The clinical data will be recorded on dedicated eCRFs specifically designed to match the study 
procedures for each visit. Only specifically  delegated staff can enter data on a CRF.  Once 
completed, the eCRFs will be reviewed for accuracy and completeness and signed by the 
Investigator. The sponsor or sponsor’s repr esentatives will be authorized to gai n access to the 
subject recordation for the purposes of monitoring and auditing the study. 
Edit checks, electronic queries, and audit trails ar e built into the system to ensure accurate and 
complete data collection. Data will be transmitte d from the clinical site to a secure central 
database as forms are completed or updated, ensuring information accuracy, security, and 
confidentiality. After the final database lock, the Investigator will be provided with Individual 
Patient Profiles (IPP) including the full audit trail on electronic media in PDF format for all of 
the study data. The IPP must be retained in the study files as a certified copy of the source data 
for the study. 
The content and structure of the eCRFs are compliant with ISO14155:2020.1
15.2. Subject Record 
At a minimum, subject record should be available for the following: 
xsubject identification
xeligibility
xstudy identification
xstudy discussion
xprovision of and date of informed consent
xvisit dates
xresults of safety and efficacy parameters as required by the protocol
xa record of all adverse events
CR-6470, v 2.0  
 
Page 64 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
xfollow-up of adverse events
xmedical history and concomitant medication
xtest article receipt/dispensing/return records
xdate of study completion
xreason for early discontinuation of test article or withdrawal from the study, if 
applicable
The subject record is the eCRF or an external record. The author of an entry in the subject 
record must be identifiable. The first point of entry is considered to be the source record.
Adverse event notes must be reviewed and initialed by the Investigator.
15.3. Trial Registration on ClinicalTrials.gov  
This study will be registered on ClinicalTrials.gov by the Sponsor.
16. DATA MANAGEMENT 
16.1. Access to Source Data/Document 
The Investigator/Institution will permit trial- related monitoring, audits, IEC/IRB review and 
regulatory inspection(s) by providing direct access to source data/documents. Should the 
clinical site be contacted for an audit by an  IEC/IRB or regulatory authority, JJVC must be 
contacted and notified in writing within 24 hours.
16.2. Confidentiality of Information 
Information concerning the investigational product and patent application processes, scientific 
data or other pertinent information is confide ntial and remains the property of JJVC. The 
Investigator may use this information for the purpo ses of the study only. It is understood by 
the Investigator that JJVC will use information deve loped in this clinical study in connection 
with the development of the investigational product  and therefore may disclose it as required 
to other clinical investigators and to regulatory agencies. In order to allow the use of the information derived from this clinical study, the Investigator understands that he/she has an 
obligation to provide complete test results and all data developed during this study to the 
Sponsor.
16.3. Data Quality Assurance 
Steps will be taken to ensure the accuracy a nd reliability of data, include the selection of 
qualified investigators and appropriate clinical sites and review of protocol procedures with the Principal Investigator. The Principal Investigator, in turn, must ensure that all Sub-Investigators and clinical site personnel are fami liar with the protocol and all study-specific 
procedures and have appropriate knowledge of the study article.
Training on case report form completion will be provided to clinical site personnel before the 
start of the study. The Sponsor will review case report forms for accuracy and completeness 
CR-6470, v 2.0  
 
Page 65 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
remotely during the conduct of the study, during monitoring visits, and after transmission to 
data management. Any data discrepancies will be  resolved with the Investigator or designee, 
as appropriate.
Quality Assurance representatives from JJVC may visit clinical sites to review data produced 
during the study and to access compliance with applicable regulations pe rtaining to the conduct 
of clinical trials. The clinical sites will provi de direct access to study-related source 
data/documents and reports for the purpose of monitoring and auditing by JJVC and for 
inspection by local and regulatory authorities.
16.4. Data Monitoring Committee (DMC) 
Not applicable
17. CLINICAL MONITORING 
The study monitors will maintain close contact with the Principal Investigator and the 
Investigator’s designated clinical site personnel. The monitor’s responsibilities will include:
xEnsuring that the investigation is bei ng conducted according to the protocol, any 
subsequent versions, and regulatory requirements are maintained.
xEnsuring the rights and wellbeing of subjects are protected.
xEnsuring adequate resources, including facilities, laboratories, equipment, and qualified clinical site personnel.
xEnsuring that protocol deviations are documen ted with corrective action plans, as 
applicable.
xEnsuring that the clinical site has sufficient test article and supplies.
xClarifying questions regarding the study.
xResolving study issues or problems that may arise.
xReviewing of study records and source documentation veri fication in accordance with 
the monitoring plan.
18. ETHICAL AND REGULATORY ASPECTS 
18.1. Study-Specific Design Considerations 
Potential subjects will be fully informed of the risks and requirements of the study and, during 
the study, subjects will be given any new informati on that may affect their decision to continue 
participation. Subjects will be to ld that their consent to particip ate in the study is voluntary and 
may be withdrawn at any time with no reason give n and without penalty or loss of benefits to 
which they would otherwise be entitled. Subjects  will only be enrolled if the subject is fully 
able to understand the risks, benefits, and po tential adverse events of the study and provide
their consent voluntarily .
CR-6470, v 2.0  
 
Page 66 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
18.2. Investigator Responsibility 
The Principal Investigator is responsible for ensuring that the clinical study is performed in 
accordance with the signed agreement, the i nvestigational plan, section 4 of the ICH E6(R2)
guidelines on Good Clinical Practice (GCP),2and applicable regulatory requirements. GCP is 
an international ethical and scientific quality  standard for designing, conducting, recording, 
and reporting studies that involve the particip ation of human subjects. Compliance with this 
standard provides public assurance that the rights, safety, and well-being of study subjects are 
protected, consistent with the principles of the Declaration of Helsinki 64th WMA General 
Assembly 20133 and that the clinical study data are credible. The Investigator must maintain 
clinical study files in accordance with section 8 of the ICH E6(R2) guidelines on Good Clinical 
Practice (GCP),2and applicable regulatory requirements.
18.3. Independent Ethics Committee or In stitutional Review Board (IEC/IRB) 
Before the start of the study, the Investigator (o r Sponsor when applicable) will provide the 
IEC/IRB with current and complete copies of  the following documents (where applicable):
xFinal protocol.
xSponsor-approved informed consent form (and  any other written materials to be 
provided to the subjects)
xInvestigator’s Brochure (or equivalent information) .
xSponsor-approved subject recruitment materials.
xInformation on compensation for study-related injuries or payment to subjects for participation in the study.
xInvestigator’s curriculum vitae, clinical licenses, or equivalent information (unless not 
required, as documented by IEC/IRB).
xInformation regarding funding, name of the S ponsor, institutional affiliations, other 
potential conflicts of interest, and incentives for subjects.
xAny other documents that the IEC/IRB requests to fulfill its obligation.
This study will be undertaken only after IEC/ IRB has given full approval of the final protocol,
the informed consent form, applicable rec ruiting materials, and subject compensation 
programs, and the Sponsor has received a copy of  this approval. This approval letter must be 
dated and must clearly identify the documents being approved.
During the study, the Investigator (or Sponsor when applicable) will send the following 
documents to the IEC/IRB for their review and approval, where appropriate:
xProtocol revisions
xRevision(s) to informed consen t form and any other written materials to be provided to 
subjects
xIf applicable, new or revised subject re cruitment materials approved by the Sponsor
xRevisions to compensation for study-relate d injuries or payment to subjects for 
participation in the study
xInvestigator’s Brochure revisions
CR-6470, v 2.0  
 
Page 67 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
xSummaries of the status of the study (at lea st annually or at intervals stipulated in
guidelines of the IEC/IRB)
xReports of adverse events that are serious, unanticipated, and asso ciated with the test 
articles, according to the IRB’s requirements
xNew information that may adversely affect th e safety of the subj ects or the conduct of 
the study
xMajor protocol deviations as required by the IEC/IRB
xReport of deaths of subjects under the Investigator's care
xNotification if a new Investigator is res ponsible for the study at the clinical site
xAny other requirements of the IEC/IRB
For protocol revisions that increase subject ris k, the revisions and applicable informed consent 
form revisions must be submitted promptly to  the IEC/IRB for review and approval before 
implementation of the change(s).
At least once a year, the IEC/IRB will review and reapprove this clinical study. This request 
should be documented in writing.
At the end of the study, the Investigator (or Sponsor where required) will notify the IEC/IRB 
about the study completion. Documentation of this not ification must be retained at the clinical 
site and a copy provided to the CRO or Sponsor as applicable.
18.4. Informed Consent 
Each subject or their representative, must give  written consent according to local requirements 
after the nature of the study has been fully e xplained. The consent form must be signed before 
performance of any study-related activity. The consent form that is used must be approved by both the Sponsor and by the reviewing IEC/IRB. The informed consent is in accordance with 
principles that originated in the Declaration of Helsinki,
3current ICH GCP2and ISO 
14155:20201guidelines, applicable regulatory requirements, and Sponsor Policy.
Before entry into the study, the Investigator or an authorized member of the clinical site personnel must explain to potential subject the aims, methods, reasonably anticipated benefits, 
and potential hazards of the study, and any discom fort it may entail. Subjects will be informed 
that their participation is voluntary and that th ey may withdraw consent to participate at any 
time. 
The subject will be given sufficient time to re ad the informed consent form and the opportunity 
to ask questions. After this explanation and be fore entry into the study, consent should be 
appropriately recorded by means of the subject 's dated signature. After having obtained the 
consent, a copy of the informed consent form must be given to the subject.
18.5. Privacy of Personal Data 
The collection, processing and disclosure of pe rsonal data and medical information related to 
the Study Subject, and personal data related to  Principal Investigator and any clinical site 
personnel (e.g., name, clinic address and phone number, curriculum vitae) is subject to 
CR-6470, v 2.0  
 
Page 68 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
compliance with the Health Information Portab ility and Accountability Act (HIPAA) and other
applicable personal data protection a nd security laws and regulations.16,17Appropriate 
measures will be employed to safeguard thes e data, to maintain the confidentiality of the 
person’s related health and medical information, to properly inform the concerned persons 
about the collection and processing of their pers onal data, to grant them reasonable access to 
their personal data and to prevent access by unauthorized persons.
All information obtained during the course of the invest igation will be regarded as confidential. 
All personal data gathered in th is trial will be treated in strictest confidence by Investigators, 
monitors, Sponsor’s personnel and IEC/IRB. No data will be disclosed to any third party 
without the express permission of the subjec t concerned, with the exception of Sponsor 
personnel (monitor, auditor), IEC/IRB and regulatory organizations in the context of their 
investigation related activities that, as part of the investigation will have access to the CRFs 
and subject records.
The collection and processing of pers onal data from subjects enrolled in this study will be 
limited to those data that are necessary to invest igate the efficacy, safety, quality, and utility of 
the investigational product(s) used in this study.These data must be collected and processed with adequate precautions to ensure confidentiality 
and compliance with applicable data privacy protection laws and regulations.
The Sponsor ensures that the personal data will be:
xprocessed fairly and lawfully.
xcollected for specified, explicit, and legitimate purposes and not further processed in a 
way incompatible with these purposes.
xadequate, relevant, and not excessive in relation to said purposes.
xaccurate and, where necessary, kept current.
Explicit consent for the processing of personal data will be obtained from the participating 
subject before collection of data. Such consent should also addre ss the transfer of the data to 
other entities and to other countries.
The subject has the right to request through the In vestigator access to his personal data and the 
right to request rectificati on of any data that are not correc t or complete. Reasonable steps 
should be taken to respond to such a request, taking into consideration the nature of the request, 
the conditions of the study, and the applicable laws and regulations.
Appropriate technical and organizational meas ures to protect the personal data against 
unauthorized disclosures or access, accidental or  unlawful destruction, or accidental loss or 
alteration must be put in place. Sponsor pers onnel whose responsibilities require access to 
personal data agree to keep the identity of study subjects confidential.
CR-6470, v 2.0  
 
Page 69 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
19. STUDY RECORD RETENTION 
In compliance with the ICH GCP guidelines,2the Investigator/Institution will maintain all 
CRFs and all subject records that support the data co llected from each subject, as well as all 
study documents as specified in ICH GCP2and all study documents as specified by the 
applicable regulatory requirement(s). The Investigator/Institution will take measures to prevent 
accidental or premature destruction of these documents.
Essential documents must be retained until at  least two (2) years after the last approval of a 
marketing application in an ICH region and until there are no pending or contemplated 
marketing applications in an ICH region or until at least two (2) years have elapsed since the 
formal discontinuation of clinical developmen t of the investigational product. These 
documents will be retained for a longer period if required by the applicable regulatory 
requirements or instructed by the Sponsor. It is the responsibility of the Sponsor to inform the 
Investigator/Institution as to when these documents no longer need to be retained.
If the responsible Investigator retires, relocates, or for other reasons withdraws from the 
responsibility of keeping the study records, custo dy must be transferred to a person who will 
accept the responsibility. The Sponsor must be not ified in writing of th e name and address of 
the new custodian. Under no circumstance shall the Investigator relocate or dispose of any study documents before having obtained written approval from the Sponsor.
If it becomes necessary for the Sponsor or the appropriate regulatory authority to review any 
documentation relating to this study, the Investigator must permit access to such reports.
If the Investigator has a question regarding re tention of study records, he/she should contact 
JJVC.
20. FINANCIAL CONSIDERATIONS 
Remuneration for study services and expenses will be set forth in detail in the Clinical Research 
Agreement. The Research Agree ment will be signed by the Principal Investigator and a JJVC 
management representative prior to study initiation.
JJVC reserves the right to withhold remuneration for costs associated with protocol violations 
such as:
xContinuing an ineligible subject in the study.
xScheduling a study visit outside the subject’s acceptable visit range .
JJVC reserves the right to withhold final remuneration until all study related activities have 
been completed, such as:
xQuery resolution.
xCase Report Form signature.
xCompletion of any follow-up action items.
CR-6470, v 2.0  
 
Page 70 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
21. PUBLICATION 
This is a multicenter study. The participating inst itution and Principal Investigations for this 
study agree that, should this study results be published, the first publication of the results of 
this study shall be made in conjunction with th e presentation of a joint, multicenter publication 
of the study results with the investigators an d the institutions from all appropriate sites 
contributing data, analyses and comments.
22. REFERENCES 
1. ISO 14155:2020: Clinical Investigation of Medical Devices for Human Subjects —
Good Clinical Practice. Available at https://www.iso.org/standard/45557.html
2. International Conference on Harmonization Good Clinical Practice E6 (ICH-GCP). 
Available at http://www.ich.org/products /guidelines/efficacy/article/efficacy-
guidelines.html
3. Declaration of Helsinki - Ethical princip les for Medical Research Involving Human 
Subjects. Available at https://www.wma .net/policies-post/wma-declaration-of-
helsinki-ethical-principles-for-medic al-research-involving-human-subjects/
4. United States (US) Code of Federal Regulations (CFR). . Available at 
https://www.gpo.gov/fdsys/browse/collectionC fr.action?collectionCode=CFR
5. Gallas J, Eisner M. Eye protection from sunlight damage. In. Comprehensive Series 
in Photosciences : Elsevier; 2001:437-455.
6. Kim H, Kim H-S, Jung C-H, Yoon I. Monitor Calibration Approach to Reducing 
HighEnergy Visible Light from White Light-Emitting Diode. 2015/04/15, 2015.
7. Rai V, Dayan N, Michniak-Kohn B. A comparative evaluation of photo-toxic effect 
of fractionated melanin and chlorpromazine hydrochloride on human (dermal 
fibroblasts and epidermal keratinocytes) and mouse cell line/s (fibroblast Balb/c 3T3). 
Toxicology in Vitro. 2011;25(2):538-544.
8. Smick K, et al. Blue light hazard: New knowledge, new approaches to maintaining 
ocular health. : Report of a roundtable sponsored by Essilor of America;2013.
9. Panda S. Illumination of th e Melanopsin Signaling Pathway. Science. 
2005;307(5709):600-604.
10. Wirth RJ, Edwards MC, Henderson M, Henderson T, Olivares G, Houts CR. 
Development of the Contact Lens User Experience: CLUE Scales. Optometry and 
vision science : official publication of the American Academy of Optometry. 2016;93(8):801-808.
11. SAS Institute Inc. 2016 SAS/STAT
®14.3 User’s Guide. Cary, NC: SAS Institute 
Inc.
12. Stroup W, ed Mixed model procedures to assess power, precision, and sample size in 
the design of experiments. Baltimore, MD: Proc Biophar maceutical Section Am Stat 
Assoc; 1999.
13. Diniz CAR, Tutia MH, Leite JG. Bayesian analysis of a correlated binomial model. 
Brazilian Journal of Probability and Statistics. 2010;24(1).
14. Kenward MG, Roger JH. Small Sample Infe rence for Fixed Effects from Restricted 
Maximum Likelihood. Biometrics. 1997;53(3):983.
CR-6470, v 2.0  
 
Page 71 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
15. Chen Z, McGee M. A Bayesian Approach to Zero-Numerator Problems Using 
Hierarchical Models. Journal of Data Science. 2021;6(2):261-268.
16. Health Information Portability and Ac countability Act (HIPAA). Available at 
https://www.hhs.gov/hipaa/for-professionals/privacy/index.html
17. Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 
2017 on medical devices. Available at http://data.europa.eu/eli/reg/2017/745/2017-
05-05
CR-6470, v 2.0  
 
Page 72 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
APPENDIX A: PATIENT REPORTED OUTCOMES (STUDY QUESTIONNAIRES) 
 
CR-6470, v 2.0  
 
Page 73 of 192JJVC CONFIDENTIAL
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 1
CR-6470, v 2.0  
 
Page 74 of 192JJVC CONFIDENTIAL
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 2
CR-6470, v 2.0  
 
Page 75 of 192JJVC CONFIDENTIAL
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 3
CR-6470, v 2.0  
 
Page 76 of 192JJVC CONFIDENTIAL
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 4
CR-6470, v 2.0  
 
Page 77 of 192JJVC CONFIDENTIAL
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 5
CR-6470, v 2.0  
 
Page 78 of 192JJVC CONFIDENTIAL
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 6
CR-6470, v 2.0  
 
Page 79 of 192JJVC CONFIDENTIAL
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 7
CR-6470, v 2.0  
 
Page 80 of 192JJVC CONFIDENTIAL
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 8
CR-6470, v 2.0  
 
Page 81 of 192JJVC CONFIDENTIAL
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 9
CR-6470, v 2.0  
 
Page 82 of 192JJVC CONFIDENTIAL
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 10
CR-6470, v 2.0  
 
Page 83 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
APPENDIX B: PATIENT INSTRUCTION GUIDE   
The Patient Instruction Guide (PIG ) will be provided separately.
CR-6470, v 2.0  
 
Page 84 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
APPENDIX C: PACKAGE INSERT (APPROVED PRODUCT) 
1-Day ACUVUE OASYS®with HydraLuxe™
CR-6470, v 2.0  
 
Page 85 of 192JJVC CONFIDENTIAL
IMPORTANT:  Please read carefully and keep this 
information for future use.
This Package Insert and Fitting Guide is intended for the 
Eye Care Professional, but should be made available to 
patients upon request. 
The Eye Care Professional should provide the patient 
with the appropriate instructions that pertain to the 
patient’s prescribed lenses. Copies are available for 
download at www.acuvue.com.
senoﬁ  lcon A Soft (hydrophilic) Contact Lenses
Visibility Tinted with UV Blocker
for Daily Disposable Wear
CAUTION: U.S. Federal law restricts this device to 
sale by or on the order of a licensed practitioner.ACUVUE OASYS® Brand Contact Lenses 1-Day 
with HydraLuxeTM Technology
ACUVUE OASYS® Brand Contact Lenses 1-Day 
with HydraLuxeTM Technology for ASTIGMATISM
CR-6470, v 2.0 VCT-0007 (13)
 
Page 86 of 192JJVC CONFIDENTIAL
SYMBOLS KEY
The following symbols may appear on the label or carton:
Date of ManufactureManufactured by or inConsult Instructions for Use
CAUTION: U.S. Federal law restricts this device 
to sale by or on the order of a licensed practitionerUse By Date (expiration date)
Diameter DIA
Base Curve BC
Diopter (lens power) DBatch Code LOT
Sterile Using Steam or Dry Heat STERILE
UV-Blocking
Fee Paid for Waste ManagementQuality System Certification Symbol
123Lens Orientation Correct
123Lens Orientation Incorrect (Lens Inside Out) CYL
AXISCylinder
AxisSingle-Use
CR-6470, v 2.0  
 
Page 87 of 192JJVC CONFIDENTIAL
DESCRIPTION
ACUVUE OASYS® Brand Contact Lenses 1-Day and ACUVUE OASYS® 
Brand Contact Lenses 1-Day for ASTIGMATISM are soft (hydrophilic) 
contact lenses made with HydraLuxe™ Technology. They are available as spherical or toric lenses respectively. 
These lenses are made of a silicone hydrogel material containing an internal 
wetting agent, visibility tint, and UV absorbing monomer and are tinted blue using Reactive Blue Dye #4 to make the lenses more visible for handling.
A benzotriazole UV absorbing monomer is used to block UV radiation. The 
transmittance characteristics for these lenses are less than 1% in the UVB range of 280 nm to 315 nm and less than 10% in the UVA range of 316 nm to 380 nm 
for the entire power range.
Lens Properties:
The physical/optical properties of the lens are:
• Speciﬁ  c Gravity (calculated): 0.98 - 1.12
• Refractive Index: 1.42
• Light Transmission: 85% minimum• Surface Character: Hydrophilic• Water Content: 38%
• Oxygen Permeability:
VALUE METHOD
122 x 10
-11 (cm2/sec) 
(ml O2/ml x mm Hg) at 35°CFatt (boundary corrected, non-
edge corrected)
103 x 10-11 (cm2/sec) 
(ml O2/ml x mm Hg) at 35°CFatt (boundary corrected, edge corrected)
Lens Parameters:
• Diameter Range: 12.0 mm to 15.0 mm
• Center Thickness: varies with power
• Base Curve Range: 7.85 mm to 10.00 mm
• Spherical Power Range: -20.00D to +20.00D
• Cylinder Power Range: -0.25D to -10.00D
• Axis Range: .5° to 180°CR-6470, v 2.0  
 
Page 88 of 192JJVC CONFIDENTIAL
AVAILABLE LENS PARAMETERS
ACUVUE OASYS® Brand 1-Day with HydraLuxe™ Technology are 
hemispherical shells of the following dimensions:
Diameter: 14.3 mm
Center Thickness: 0.085 mm to 0.221 mm (varies with power)
Base Curve: 8.5 mm, 9.0 mm
Powers: -0.50D to -6.00D (in 0.25D increments)
-6.50D to -12.00D (in 0.50D increments)+0.50D to +6.00D (in 0.25D increments)+6.50D to +8.00D (in 0.50D increments)
ACUVUE OASYS® Brand 1-Day with HydraLuxe™ Technology for 
ASTIGMATISM  are hemitoric shells of the following dimensions:
Diameter: 14.3 mm
Center Thickness: 0.075 mm to 0.172 mm (varies with power)
Base Curve: 8.5 mm
Powers: +0.00D to -6.00D (in 0.25D increments)
Cylinders: -0.75D, -1.25D, -1.75D, -2.25D*Axis: 10° to 180° in 10° increments
*-2.25D cylinder is availble in 10°, 20°, 70°, 80°, 90°, 100°, 110°, 
160°, 170°, 180° axes only.
+0.25D to +4.00D (in 0.25D increments)
-6.50D to -9.00D (in 0.50D increments)Cylinders: -0.75D, -1.25D, -1.75DAxis: 10°, 20°, 70°, 80°, 90°, 100°, 110°, 160°, 
170°, 180°
CR-6470, v 2.0  
 
Page 89 of 192JJVC CONFIDENTIAL
TRANSMITTANCE CURVES
ACUVUE OASYS® 1-Day with HydraLuxe™ Technology  (senoﬁ  lcon A) 
Visibility Tinted with UV Blocker vs. 24 yr. old human cornea and 25 yr. old 
human crystalline lens. 
……. ACUVUE OASYS®  
1-Day with HydraLuxe™ Technology (senoﬁ  lcon A)*
_____ 24 YR. OLD HUMAN CORNEA
1
- - - - - 25 YR. OLD HUMAN CRYSTALLINE LENS
2
* The data was obtained from measurements taken through the central 3-5 mm portion for 
the thinnest marketed lens (-9.00D lens, 0.075 mm center thickness).
1Lerman, S., Radiant Energy and the Eye, MacMillan, New York, 1980, p. 58, ﬁ  gure 2-21
2Waxler, M., Hitchins, V.M., Optical Radiation and Visual Health, CRC Press, Boca Raton, Florida, 
1986, p. 19, ﬁ  gure 5 
WARNING: UV absorbing contact lenses are NOT substitutes for 
protective UV absorbing eyewear, such as UV absorbing goggles or sunglasses because they do not completely cover the eye and surrounding area. The patient should continue to use UV absorbing eyewear as directed.
ACTIONS
In its hydrated state, the contact lens, when placed on the cornea, acts as a refracting medium to focus light rays onto the retina.
The transmittance characteristics for these lenses are less than 1% in the 
UVB range of 280 nm to 315 nm and less than 10% in the UVA range of 316 nm to 380 nm for the entire nge.
CR-6470, v 2.0 ) 
Page 90 of 192JJVC CONFIDENTIAL
NOTE:  Long-term exposure to UV radiation is one of the risk 
factors associated with cataracts.  Exposure is based on a number of factors such as environmental conditions (altitude, geography, cloud cover) and personal factors (extent and nature of outdoor activities).  UV-Blocking contact lenses help provide protection against harmful UV radiation. However, clinical studies have not been done to demonstrate that wearing UV-Blocking contact lenses reduces the risk of developing cataracts or other eye disorders. The Eye Care Professional should be consulted for more information.
INDICATIONS (USES)
ACUVUE OASYS® Brand Contact Lenses 1-Day with HydraLuxe™ 
Technology are indicated for daily disposable wear for the optical correction of refractive ametropia (myopia and hyperopia) in phakic or aphakic persons with non-diseased eyes who may have 1.00D or less of astigmatism.
ACUVUE OASYS® Brand Contact Lenses 1-Day with HydraLuxe™ Tech-
nology for ASTIGMATISM are indicated for daily disposable wear for the 
optical correction of refractive ametropia (myopia and hyperopia) in phakic 
or aphakic persons with non-diseased eyes who may have 0.50D to 3.00D of astigmatism.
These lenses contain a UV Blocker to help protect against transmission of 
harmful UV radiation to the cornea and into the eye.
CONTRAINDICATIONS (REASONS NOT TO USE) 
DO NOT USE these contact lenses when any of the following conditions exist:
• Acute or subacute inﬂ  ammation or infection of the anterior chamber 
of the eye.
• Any eye disease, injury or abnormality that affects the cornea, 
conjunctiva, or eyelids.
• Severe insufﬁ  ciency of lacrimal secretion (dry eye).
CR-6470, v 2.0  
 
Page 91 of 192JJVC CONFIDENTIAL
• Corneal hypoesthesia (reduced corneal sensitivity).
• Any systemic disease that may affect the eye or be exaggerated by 
wearing contact lenses.
• Allergic reactions of ocular surfaces or adnexa that may be induced 
or exaggerated by wearing contact lenses or use of contact lens 
solutions.
• Ocular irritation due to allergic reactions which may be caused by 
use of contact lens solutions (i.e., rewetting drops) that contain chemicals or preservatives (such as mercury, Thimerosal, etc.) to which some people may develop an allergic response.
• Any active corneal infection (bacterial, fungal, protozoal, or viral).
• If eyes become red or irritated.
WARNINGS
Patients should be advised of the following warnings pertaining to 
contact lens wear:
EYE PROBLEMS, INCLUDING CORNEAL ULCERS, CAN DEVELOP 
RAPIDLY AND LEAD TO LOSS OF VISION; IF THE PATIENT EXPE-RIENCES:
• Eye Discomfort,
• Excessive Tearing,• Vision Changes,• Loss of Vision,• Eye Redness,• Or Other Eye Problems, 
THE PATIENT SHOULD BE INSTRUCTED TO IMMEDIATELY RE-
MOVE THE LENSES AND PROMPTLY CONTACT THE EYE CARE PROFESSIONAL.
• When prescribed for daily wear, patients should be instructed not 
to wear lenses while sleeping. Clinical studies have shown that 
the risk of serious adverse reactions is increased when lenses are worn overnight, and that t  ulcerative keratitis is greater for 
CR-6470, v 2.0  
 
Page 92 of 192JJVC CONFIDENTIAL
extended wear contact lens users than for daily wear users.3
• Studies have shown that contact lens wearers who are smokers 
have a higher incidence of adverse reactions than nonsmokers.
• Problems with contact lenses or lens care products could result in 
serious injury to the eye. Patients should be cautioned that proper 
use and care of contact lenses and lens care products are essential for the safe use of these products.
• The overall risk of ulcerative keratitis may be reduced by carefully 
following directions for lens care.
3 New England Journal of Medicine, September 21, 1989; 321 (12), pp. 773-783
Speciﬁ  c Instructions for Use and Warnings:
• Water Activity
Instructions for Use
Do not expose contact lenses to water while wearing them.WARNING:
Water can harbor microorganisms that can lead to severe infection, vision loss or blindness. If lenses have been submersed in water when participating in water sports or swimming in pools, hot tubs, lakes, or oceans, the patient should be instructed to discard them and replace them with a new pair. The Eye Care Professional should be consulted for recommendations regarding wearing lenses during any activity involving water.
PRECAUTIONS
Special Precautions for Eye Care Professionals:
• Due to the small number of patients enrolled in clinical investiga-
tion of lenses, all refractive powers, design conﬁ  gurations, or lens parameters available in the lens material are not evaluated in signif-icant numbers. Consequently, when selecting an appropriate lens design and parameters, the Eye Care Professional should consider all characteristics of the lens that can affect lens performance and ocular health, including oxygen permeability, wettability, central and peripheral thickness, and optic zone diameter.
CR-6470, v 2.0  
 
Page 93 of 192JJVC CONFIDENTIAL
• The potential impact of these factors on the patient’s ocular health 
should be carefully weighed against the patient’s need for refractive 
correction; therefore, the continuing ocular health of the patient and lens performance on the eye should be carefully monitored by the prescribing Eye Care Professional.
• Patients who wear these lenses to correct presbyopia using mono-
vision may not achieve the best corrected visual acuity for either far or near vision. Visual requirements vary with the individual and should be considered when selecting the most appropriate type of lens for each patient.
• Fluorescein, a yellow dye, should not be used while the lenses are 
on the eyes. The lenses absorb this dye and become discolored. Whenever ﬂ  uorescein is used in eyes, the eyes should be ﬂ  ushed with a sterile saline solution that is recommended for in-eye use.
• Eye Care Professionals should instruct the patient to remove the 
lenses immediately if the eyes become red or irritated. 
Eye Care Professionals should carefully instruct patients about the following care regimen and safety precautions.
Handling Precautions:
• Before leaving the Eye Care Professional’s ofﬁ  ce, the patient should 
be able to promptly remove the lenses or should have someone 
else available who can remove the lenses for him or her. 
• DO NOT use if the sterile blister package is opened or damaged. 
• Always wash and rinse hands before handling lenses. Do not get 
cosmetics, lotions, soaps, creams, deodorants, or sprays in the 
eyes or on the lenses. It is best to put on lenses before putting on makeup. Water-based cosmetics are less likely to damage lenses than oil-based products. 
• DO NOT touch contact lenses with the ﬁ  ngers or hands if the 
hands are not free of foreign materials, as microscopic scratches of the lenses may occur, causing distorted vision and/or injury to the eye.
• Carefully follow the handlin on, removal, and wearing 
instructions in the “Patient n Guide” for the prescribed 
CR-6470, v 2.0  
 
Page 94 of 192JJVC CONFIDENTIAL
wearing schedule and those prescribed by the Eye Care 
Professional.
• Always handle lenses carefully and avoid dropping them.
• Never use tweezers or other tools to remove lenses from the lens 
container unless speciﬁ  cally indicated for that use. Slide the lens up 
the side of the bowl until it is free of the container. 
• Do not touch the lens with ﬁ  ngernails. 
Lens Wearing Precautions:
• If the lens sticks (stops moving) on the eye, follow the recom-
mended directions in “Care for a Sticking (Non-Moving) Lens." The lens should move freely on the eye for the continued health of the eye. If non-movement of the lens continues, the patient should be instructed to immediately consult his or her Eye Care Professional.
• Never wear lenses beyond the period recommended by the Eye 
Care Professional.
• The patient should be advised to never allow anyone else to wear 
their lenses. They have been prescribed to ﬁ  t their eyes and to correct their vision to the degree necessary. Sharing lenses greatly increases the chance of eye infections.
• If aerosol products, such as hair spray, are used while wearing 
lenses, exercise caution and keep eyes closed until the spray has settled.
• Avoid all harmful or irritating vapors and fumes while wearing 
lenses. 
• Always discard lenses worn as prescribed by the Eye Care 
Professional. 
Lens Care Precautions:  
• The patient should be informed that no cleaning or disinfection is 
needed when lenses are worn for daily disposable wear.  Patients should always dispose of lenses when removed and have spare lenses or spectacles available.
CR-6470, v 2.0  
 
Page 95 of 192JJVC CONFIDENTIAL
Other Topics to Discuss with Patients:
• Always contact the Eye Care Professional before using any medi-
cine in the eyes. 
• Certain medications, such as antihistamines, decongestants, 
diuretics, muscle relaxants, tranquilizers, and those for motion 
sickness may cause dryness of the eye, increased lens awareness, or blurred vision. Should such conditions exist, proper remedial measures should be prescribed. Depending on the severity, this could include the use of lubricating drops that are indicated for use with soft contact lenses or the temporary discontinuance of contact lens wear while such medication is being used. 
• Oral contraceptive users could develop visual changes or changes 
in lens tolerance when using contact lenses. Patients should be cautioned accordingly. 
• As with any contact lens, follow-up visits are necessary to assure 
the continuing health of the patient’s eyes. The patient should be instructed as to a recommended follow-up schedule. 
Who Should Know That the Patient is Wearing Contact Lenses?
• Patients should inform all doctors (Health Care Professionals) about 
being a contact lens wearer. 
• Patients should always inform their employer of being a contact 
lens wearer. Some jobs may require use of eye protection equip-ment or may require that the patient not wear contact lenses. 
ADVERSE REACTIONS
The patient should be informed that the following problems may occur when wearing contact lenses:
• The eye may burn, sting, and/or itch.
• There may be less comfort than when the lens was ﬁ  rst placed on 
the eye.
• There may be a feeling of something in the eye (foreign body, 
scratched area).
• There may be the potentia e temporary impairment due to CR-6470, v 2.0  
 
Page 96 of 192JJVC CONFIDENTIAL
peripheral inﬁ  ltrates, peripheral corneal ulcers, or corneal erosion. 
There may be the potential for other physiological observations, such as local or generalized edema, corneal neovascularization, corneal staining, injection, tarsal abnormalities, iritis, and conjuncti-vitis; some of which are clinically acceptable in low amounts.
• There may be excessive watering, unusual eye secretions, or 
redness of the eye.
• Poor visual acuity, blurred vision, rainbows, or halos around 
objects, photophobia, or dry eyes may also occur if the lenses are worn continuously or for too long a time.
The patient should be instructed to conduct a simple 3-part self-examina-tion at least once a day. They should ask themselves:
• How do the lenses feel on my eyes?
• How do my eyes look?• Have I noticed a change in my vision? 
If the patient reports any problems, he or she should be instructed to 
IMMEDIATELY REMOVE THE LENS. If the problem or discomfort stops, the patient should discard the lens and place a new fresh lens on the eye.
If after inserting the new lens, the problem continues, the patient should be 
directed to IMMEDIATELY REMOVE THE LENS AND CONTACT HIS OR HER EYE CARE PROFESSIONAL.
The patient should be instructed NOT to use a new lens as self-treatment 
for the problem.
The patient should be advised that when any of the above symptoms oc-
cur, a serious condition such as infection, corneal ulcer, neovascularization, or iritis may be present. He or she should be instructed to seek immediate professional identiﬁ  cation of the problem and prompt treatment to avoid serious eye damage.
CR-6470, v 2.0  
 
Page 97 of 192JJVC CONFIDENTIAL
GENERAL FITTING GUIDELINES
A. Patient Selection
Patients selected to wear these lenses should be chosen based on: 
• Motivation to wear lenses 
• Ability to follow instructions regarding lens wear care
• General health 
• Ability to adequately handle and care for the lenses 
• Ability to understand the risk and beneﬁ  ts of lens wear
Patients who do not meet the above criteria should not be provided with 
contact lenses. 
B. Pre-ﬁ  tting Examination
Initial evaluation of the patient should begin with a thorough case history 
to determine if there are any contraindications to contact lens wear. During 
the case history, the patient’s visual needs and expectations should be 
determined as well as an assessment of their overall ocular, physical, and 
mental health. 
Preceding the initial selection of trial contact lenses, a comprehensive 
ocular evaluation should be performed that includes, but is not limited to, 
the measurement of distance and near visual acuity, distance and near 
refractive prescription (including determining the preferred reading distance 
for presbyopes), keratometry, and biomicroscopic evaluation. 
Based on this evaluation, if it is determined that the patient is eligible to 
wear these lenses, the Eye Care Professional should proceed to the lens 
ﬁ  tting instructions as outlined below. 
C. Initial Power Determination
A spectacle refraction should be performed to establish the patient’s 
baseline refractive status and to guide in the selection of the appropriate 
lens power. Remember to compensate for vertex distance if the refraction 
is greater than ±4.00D.
D. Base Curve Selection (Trial Lens Fitting)
The following trial lenses should be selected for patients regardless of kera-
tometry readings. However, corneal curvature measurements should be 
performed to establish the patient’s baseline ocular status. CR-6470, v 2.0 VCT-0007 (13)
 
Page 98 of 192JJVC CONFIDENTIAL
• ACUVUE OASYS® 1-Day: 8.5 mm/14.3 mm
• ACUVUE OASYS® 1-Day for ASTIGMATISM: 8.5 mm/14.3 mm
The trial lens should be placed on each of the patient's eyes and evaluated 
after the patient has adjusted to the lenses.  
1. Criteria of a Properly Fit Lens 
A properly ﬁ  t lens will center and completely cover the cornea (i.e., no limbal exposure), have sufﬁ  cient movement to provide tear exchange under the contact lens with the blink, and be comfortable. The lens should move freely when manipulated digitally with the lower lid, and then return to its properly centered position when released.
2. Criteria of a Flat Fitting Lens 
A ﬂ  at ﬁ  tting lens may exhibit one or more of the following characteris-tics: decentration, incomplete corneal coverage (i.e., limbal exposure), excessive movement with the blink, and/or edge standoff. If the lens is judged to be ﬂ  at ﬁ  tting, it should not be dispensed to the patient.
3. Criteria of a Steep Fitting Lens 
A steep ﬁ  tting lens may exhibit one or more of the following charac-teristics: insufﬁ  cient movement with the blink, conjunctival indentation, and resistance when pushing the lens up digitally with the lower lid. If the lens is judged to be steep ﬁ  tting, it should not be dispensed to the patient.
If the initial trial base curve is judged to be ﬂ  at or steep ﬁ  tting, the alternate base curve, if available, should be trial ﬁ  t and evaluated after the patient has adjusted to the lens. The lens should move freely when manipulated digitally with the lower lid, and then return to a properly centered position when released. If resistance is encountered when pushing the lens up, the lens is ﬁ  tting tightly and should not be dispensed to the patient.
E. Final Lens Power (Spherical)
A spherical over-refraction should be performed to determine the ﬁ  nal lens power after the lens ﬁ  t is judged acceptable. The spherical over-refraction should be combined with the trial lens power to determine the ﬁ  nal lens prescription. The patient should e e good visual acuity with the correct lens power unless there is ve residual astigmatism.
CR-6470, v 2.0  
 
Page 99 of 192JJVC CONFIDENTIAL
Example 1
Diagnostic lens: -2.00DSpherical over-refraction: -0.25D
Final lens power: -2.25D
Example 2
Diagnostic lens: -2.00DSpherical over-refraction: +0.25D
Final lens power: -1.75D
If vision is acceptable, perform a slit lamp examination to assess adequate 
ﬁ  t (centration and movement). If the ﬁ  t is acceptable, dispense the lenses and instruct the patient to return in one week for reassessment (see dispensing and follow up information in PATIENT MANAGEMENT).
All patients should be supplied with a copy of the PATIENT 
INSTRUCTION GUIDE for these lenses. Copies are available for download at www.acuvue.com.
TORIC FITTING GUIDELINES
Although most aspects of the ﬁ  tting procedure are identical for all types 
of soft contact lenses, including toric lenses, there are some additional steps and/or rules to follow to assure the proper ﬁ  t of toric lenses.
The only new steps you must follow in prescribing ACUVUE
 OASYS® 
1-Day for ASTIGMATISM are that you must determine the stability, 
repeatability, and drift angle of the lens axis so that you can prescribe the correct lens axis for the patient.
A. How to Determine Lens Cylinder and Axis Orientation 
1. Locate the Orientation Marks
To help determine the proper orientation of the toric lens, you’ll 
ﬁ  nd two primary marks approximately 1 mm from the lens edge representing the vertical position on opposite ends of the lens at 6 and 12 o’clock (Fig. 1). Because of the lens’ ballasting system, either mark can represent the vertical position – there is no “top” and “bottom” as in a prism-ballasted lens. You don’t need to view both marks to assess orientation; simply look for the 6 o’clock mark as you would with a prism-ballasted lens.
CR-6470, v 2.0  
 
Page 100 of 192JJVC CONFIDENTIAL
Figure 1
You’ll need a slit lamp biomicroscope with a 1 to 2 mm 
parallelepiped beam to highlight the marks when the lens is ﬁ  tted to the eye. There are a number of techniques you can use to improve the visibility of the 6 o’clock mark. Using a parallelepiped beam and medium magniﬁ  cation (10x or 15x), slowly pan down the lens, looking just below the direct illumination at the retroilluminated area. Backlighting the mark this way should make it more visible. Sometimes manipulating the lower lid may be necessary to uncover the mark.
2. Observe Lens Rotation and Stability
Observe the position and stability of the “bottom” mark. It usually stabilizes at the 6 o’clock position. If it does, calculation of the lens power will be straightforward. The 6 o’clock position is not a “must”; however, the absolute requirement is that the axis position be stable and repeatable.
The mark may stabilize somewhat left or right (drift) of the vertical 
meridian and still enable you to ﬁ  t a toric lens for that eye, as long as the lens always returns to the same “drift axis” position after settling. The deviation can be compensated for in the ﬁ  nal prescription. Your objective is to ensure that whatever position the initial lens assumes near 6 o’clock, this position must be stable and repeatable. With full eye movement or heavy blink, you may see the marks swing away, but they must return quickly to the original stable position. If the lens does not return quickly, you may need to select a different lens.
3. Assessing Rotation
Imagine the eye as a clock dial and every hour represents a 30° interval. If the orientation mark of the initial lens stabilizes somewhat left or right of the vertical position, the ﬁ  nal lens will orient on the eye with the same deviation. You can use an axis reticule in the slit lamp or use a line-scribed lens in a spectacle trial frame to measure or estimate the “drift angle” of the cylinder axis.
To compensate for this “drift”, measure or estimate the “drift”, then 
add or subtract it from the refractive axis to determine the correct cylinder axis. Use the LARS (Left Add, Right Subtract) method to determine which direction to compensate.
CR-6470, v 2.0  
 
Page 101 of 192JJVC CONFIDENTIAL
B. Final Lens Power 
When the diagnostic lens has its axis aligned in the same meridian 
as the patient’s refractive axis, a spherocylindrical over-refraction may be performed and visual acuity determined. However, in the case of crossed axes, such as when the diagnostic lens axis is different from the spectacle cylinder axis, it is not advisable to perform a full spherocylindrical over-refraction because of the difﬁ  culty in computing the resultant power. A spherical over-refraction without cylinder refraction may be performed. 
If the required cylinder correction falls between two available cylinder 
powers, it is recommended to prescribe the lower cylinder power lens. See below for instructions on how to determine the ﬁ  nal lens power.
1. For the Sphere
If sphere alone or combined sphere and cylinder Rx > ±4.00D, 
compensate for vertex distance. If sphere alone or combined sphere and cylinder Rx ≤ ±4.00D, vertex compensation is not necessary.
2. For the Cylinder
Adjust the axis by the drift angle using the LARS method. Choose a cylinder that is ≤ 0.50D from the refractive cylinder.
3. Case Examples
Example 1
Manifest (spectacle) refraction:
O.D. -2.50D / -1.25D x 180° 20/20O.S. -2.00D / -1.00D x 180° 20/20
Choose a diagnostic lens for each eye with axis 180°. Place 
the lens on each eye and allow a minimum of 3 minutes for it to equilibrate, based on the patient’s initial response to the lens. If the lens has not yet stabilized, recheck until stable.
Check the orientation of the axis mark. If the bottom axis mark 
is in the 6 o’clock position on both eyes, choose the appropriate cylinder as listed previously. If the lens has not yet stabilized, recheck until stable.
Here is the Rx Prescribed:
O.D. -2.50D / -1.25D x 180°O.S. -2.00D / -0.75D x 180°
CR-6470, v 2.0  
 
Page 102 of 192JJVC CONFIDENTIAL
Example 2
Manifest (spectacle) refraction:O.D. -3.00D / -1.00D x 90° 20/20O.S. -4.75D / -2.00D x 90° 20/20
Choose diagnostic lenses of -3.00D / -0.75D x 90° for the right 
eye and -4.50D / -1.75D x 90° for the left eye, the nearest lenses available to the spherical power, cylinder power, and axis needed. For the left eye, since the manifest refraction called for -4.75D, compensating for vertex distance the sphere is reduced by 0.25D to -4.50D. The cylinder power will be -1.75D. Place the lens on each eye and allow a minimum of 3 minutes for it to equilibrate, based on the patient's initial response to the lens. If the lens has not yet stabilized, recheck until stable. 
Right Eye
The orientation mark on the right lens rotates left from the 6 
o’clock position by 10° and remains stable in this position. Compensation for this rotation should be done as follows: 
Compensate the 10° axis drift by adding it to the manifest 
refraction axis.
Here is the Rx Prescribed:
O.D. -3.00D / -0.75D x 100°
Left Eye
The orientation mark on the left lens rotates right from the 6 
o’clock position by 10° and remains stable in this position. 
Compensate for the 10° axis drift by subtracting it from the 
manifest refraction axis. 
Here is the Rx Prescribed: 
O.S. -4.50D / -1.75D x 80°
If vision is acceptable, perform a slit lamp examination to assess 
adequate ﬁ  t (centration and movement). If ﬁ  t is acceptable, dispense the lenses instructing the patient to return in one week for reassessment (see dispensing and follow-up information in PATIENT MANAGEMENT).
All patients should be supplied with a copy of the PATIENT INSTRUCTION GUIDE for these lenses. Copies are available for download at www.acuvue.com.
CR-6470, v 2.0  
 
Page 103 of 192JJVC CONFIDENTIAL
MONOVISION FITTING GUIDELINES
A. Patient Selection
1. Monovision Needs Assessment
For a good prognosis, the patient should have adequately 
corrected distance and near visual acuity in each eye. The amblyopic patient or the patient with signiﬁ  cant astigmatism (greater than 1.00D) in one eye may not be a good candidate for monovision correction with these lenses.
Occupational and environmental visual demands should be 
considered. If the patient requires critical vision (visual acuity and stereopsis), it should be determined by trial whether this patient can function adequately with monovision correction. Monovision contact lens wear may not be optimal for activities such as:
• visually demanding situations such as operating potentially 
dangerous machinery or performing other potentially hazardous 
activities; and
• driving automobiles (e.g., driving at night). Patients who cannot 
meet state driver's licensing requirements with monovision correction should be advised to not drive with this correction, OR may require that additional over-correction be prescribed.
2. Patient Education
All patients do not function equally well with monovision correc-tion. Patients may not perform as well for certain tasks with this correction as they have with spectacles (multifocal, bifocal, trifocal, readers, progressives). Each patient should understand that monovision, as well as other presbyopic alternatives, can create a vision compromise that may reduce visual acuity and depth perception for distance and near tasks. Therefore, caution should be exercised when the patient is wearing the correction for the ﬁ  rst time until they are familiar with the vision provided in visually chal-lenging environments (e.g., reading a menu in a dim restaurant, driving at night in rainy/foggy conditions, etc.). During the ﬁ  tting process, it is necessary for the patient to realize the disadvantages as well as the advantages of clear near vision and straight ahead and upward gaze that monovision contact lenses provide.
CR-6470, v 2.0  
 
Page 104 of 192JJVC CONFIDENTIAL
B. Eye Selection
1. Ocular Preference Determination Methods
Generally, the non-dominant eye is corrected for near vision. The 
following two methods for eye dominance can be used.
Method 1:  Determine which eye is the “sighting eye.” Have the 
patient point to an object at the far end of the room. 
Cover one eye. If the patient is still pointing directly at the object, the eye being used is the dominant (sighting) eye.
Method 2:  Determine which eye will accept the added power with 
the least reduction in vision. Place a hand-held trial lens equal to the spectacle near ADD in front of one eye and then the other while the distance refractive error correction is in place for both eyes. Determine whether the patient functions best with the near ADD lens over the right or left eye.
2. Other Eye Selection Methods
Other methods include the "Refractive Error Method" and the "Visual Demands Method."
Refractive Error MethodFor anisometropic correction, it is generally best to ﬁ  t the more 
hyperopic (less myopic) eye for distance and the more myopic (less hyperopic) eye for near.
Visual Demands Method
Consider the patient’s occupation during the eye selection process 
to determine the critical vision requirements. If a patient’s gaze for near tasks is usually in one direction, correct the eye on that side for near.
Example: A secretary who places copy to the left side of the desk 
will function best with the near lens on the left eye.
C. Special Fitting Characteristics
1. Unilateral Vision Correction
There are circumstances where only one contact lens is required. As an example, an emmetropic patient would only require a near lens, whereas a bilateral uld require corrective lenses on 
CR-6470, v 2.0
Page 105 of 192JJVC CONFIDENTIAL
both eyes.
Examples: A presbyopic emmetropic patient who requires a +1.75D ADD 
would have a +1.75D lens on the near eye and the other eye left without correction. 
A presbyopic patient requiring a +1.50D ADD who is -2.50D 
myopic in the right eye and -1.50D myopic in the left eye may have the right eye corrected for distance and the left uncorrected for near.
2. Near ADD Determination
Always prescribe the lens power for the near eye that provides optimal near acuity at the midpoint of the patient’s habitual reading distance. However, when more than one power provides optimal reading performance, prescribe the least plus (most minus) of the powers.
3. Trial Lens Fitting
A trial ﬁ  tting is performed in the ofﬁ  ce to allow the patient to experience monovision correction. Lenses are ﬁ  t according to the GENERAL FITTING GUIDELINES for base curve selection described in this Package Insert.
Case history and standard clinical evaluation procedure should 
be used to determine the prognosis. Determine the distance correction and the near correction. Next determine the near ADD. With trial lenses of the proper power in place, observe the reaction to this mode of correction.
Allow the lenses to settle for about 20 minutes with the correct 
power lenses in place. Walk across the room and have the patient look at you. Assess the patient’s reaction to distance vision under these circumstances. Then have the patient look at familiar near objects such as a watch face or ﬁ  ngernails. Again assess the reaction. As the patient continues to look around the room at both near and distance objects, observe the reactions. Only after these vision tests are completed should the patient be asked to read print. Evaluate the patient’s reaction to large print (e.g., typewritten copy) at ﬁ  rst and then graduate to newsprint and ﬁ  nally smaller type sizes.
After the patient’s performance under the above conditions 
is completed, tests of vis and reading ability under 
CR-6470, v 2.0
 
Page 106 of 192JJVC CONFIDENTIAL
conditions of moderately dim illumination should be attempted.
An initial unfavorable response in the ofﬁ  ce, while indicative of 
a guarded prognosis, should not immediately rule out a more extensive trial under the usual conditions in which a patient functions.
4. Adaptation
Visually demanding situations should be avoided during the initial wearing period. A patient may at ﬁ  rst experience some mild blurred vision, dizziness, headaches, and a feeling of slight imbalance. You should explain the adaptational symptoms to the patient. These symptoms may last for a brief minute or for several weeks. The longer these symptoms persist, the poorer the prognosis for successful adaptation.
To help in the adaptation process, the patient can be advised to 
ﬁ  rst use the lenses in a comfortable familiar environment such as in the home.
Some patients feel that automobile driving performance may not 
be optimal during the adaptation process. This is particularly true when driving at night. Before driving a motor vehicle, it may be recommended that the patient be a passenger ﬁ  rst to make sure that their vision is satisfactory for operating an automobile. During the ﬁ  rst several weeks of wear (when adaptation is occurring), it may be advisable for the patient to only drive during optimal driving conditions. After adaptation and success with these activities, the patient should be able to drive under other conditions with caution.
D. Other Suggestions
The success of the monovision technique may be further improved by having the patient follow the suggestions below:
• Have a third contact lens (distance power) to use when critical 
distance viewing is needed.
• Have a third contact lens (near power) to use when critical near 
viewing is needed.
• Having supplemental spectacles to wear over the monovision 
contact lenses for speciﬁ  c visual tasks may improve the success of monovision correction. This is particularly applicable for those patients who cannot meet state driver's licensing requirements with monovision correction.
• Make use of proper illu  when carrying out visual tasks.
CR-6470, v 2.0  
 
Page 107 of 192JJVC CONFIDENTIAL
Monovision ﬁ  tting success can be improved by the following 
suggestions:
• Reverse the distance and near eyes if a patient is having trouble 
adapting.
• Reﬁ  ne the lens powers if there is trouble with adaptation. 
Accurate lens power is critical for presbyopic patients.
• Emphasize the beneﬁ  ts of clear near vision and straight ahead 
and upward gaze with monovision.
The decision to ﬁ  t a patient with monovision correction is most appropriately left to the Eye Care Professional in conjunction with the patient after carefully considering the patient’s needs.
All patients should be supplied with a copy of the PATIENT 
INSTRUCTION GUIDE for these lenses. Copies are available for download at www.acuvue.com.
PATIENT MANAGEMENT
Dispensing Visit
Each sterile lens is supplied in a foil-sealed plastic package containing 
buffered saline solution with methyl ether cellulose. To remove the lens from the container, peel back the foil seal, place a ﬁ  nger on the lens, and slide the lens up the side of the bowl of the lens package until it is free of the container.
• Evaluate the physical ﬁ  t and visual acuity of the lens on each eye.
• Teach the patient how to apply and remove his or her lenses.
• Explain daily disposable lens wear and schedule a follow-up examination.
• Provide the patient with a copy of the PATIENT 
INSTRUCTION GUIDE for these lenses. Copies are available for download at www.acuvue.com.
REVIEW THESE INSTRUCTIONS WITH THE PATIENT SO THAT HE 
OR SHE CLEARLY UNDERSTANDS THE PRESCRIBED WEARING AND REPLACEMENT SCHEDULES.
Follow-Up Examinations
Follow-up care (necessary to ensure continued successful contact lens wear) should include routine periodic progress examinations, management of speciﬁ  c problems, if any, and a ith the patient of the wear schedule, daily disposable modalit oper lens handling procedures. 
CR-6470, v 2.0  
 
Page 108 of 192JJVC CONFIDENTIAL
Recommended Follow-up Examination Schedule (complications 
and speciﬁ  c problems should be managed on an individual patient 
basis):
1. One week from the initial lens dispensing to patient
2. One month post-dispensing
3. Every three to six months thereafter 
NOTE: Preferably, at the follow-up visits, lenses should be worn for at least 
six hours.
Recommended Procedures for Follow-up Visits:
1. Solicit and record patient’s symptoms, if any.
2. Measure visual acuity monocularly and binocularly at distance and 
near with the contact lenses.
3. Perform an over-refraction at distance and near to check for residual 
refractive error.
4. With the biomicroscope, judge the lens ﬁ  tting characteristics (as 
described in the GENERAL FITTING GUIDELINES) and evaluate 
the lens surface for deposits and damage.
5. Following lens removal, examine the cornea and conjunctiva with 
the biomicroscope and ﬂ  uorescein (unless contraindicated).
• The presence of vertical corneal striae in the posterior central 
cornea and/or corneal neovascularization is indicative of 
excessive corneal edema.
• The presence of corneal staining and/or limbal-conjunctival 
hyperemia can be indicative of an unclean lens, a reaction to solution preservatives, excessive lens wear and/or a poorly ﬁ  tting lens.
• Papillary conjunctival changes may be indicative of an unclean 
and/or damaged lens.
6. Periodically perform keratometry and spectacle refractions. The 
values should be recorded and compared to the baseline meas-
urements.
If any observations are abnormal, use professional judgment to 
alleviate the problem and restore the eye to optimal conditions. If CR-6470, v 2.0 VCT-0007 (13) 
 
Page 109 of 192JJVC CONFIDENTIAL
the criteria for successful ﬁ  t are not satisﬁ  ed during any follow-up 
examinations, repeat the patient’s trial ﬁ  tting procedure and reﬁ  t 
the patient.
WEARING SCHEDULE
The wearing schedule should be determined by the Eye Care Professional.   
Regular checkups, as determined by the Eye Care Professional, are also extremely important.
Patients tend to overwear the lenses initially. The Eye Care Professional 
should emphasize the importance of adhering to the initial maximum wear-ing schedule.  Maximum wearing time should be determined by the Eye Care Professional based upon the patient’s physiological eye condition, because individual response to contact lenses varies.
The maximum suggested wearing time for these lenses is:
Day Hours
1 6-8
2 8-10
3 10-12
4 12-14
5 and after all waking hours
REPLACEMENT SCHEDULE
These lenses are indicated for daily disposable wear and should be 
discarded upon removal.
LENS CARE DIRECTIONS
When lenses are prescribed for daily disposable wear, the Eye Care Professional should provide the patient with appropriate and adequate warnings and instructions for daily disposable lens wear at the time they are dispensed. 
CR-6470, v 2.0  
 
Page 110 of 192JJVC CONFIDENTIAL
The Eye Care Professional should review with patients that no cleaning 
or disinfection is needed with daily disposable lenses. Patients should always dispose of lenses when they are removed and have spare lenses or spectacles available.
Basic Instructions
• Always wash, rinse, and dry hands before handling contact lenses.
• Do not use saliva or anything other than the recommended solutions 
for lubricating or rewetting lenses. Do not put lenses in the mouth.
• Eye Care Professionals may recommend a lubricating/rewetting solution which can be used to wet (lubricate) lenses while they are being worn to make them more comfortable. 
Care for a Sticking (Non-Moving) Lens
If the lens sticks (stops moving), the patient should be instructed to apply 
a few drops of the recommended lubricating or rewetting solution directly to the eye and wait until the lens begins to move freely on the eye before removing it. If non-movement of the lens continues after a few minutes, the patient should immediately consult the Eye Care Professional.
EMERGENCIES
The patient should be informed that if chemicals of any kind (household products, gardening solutions, laboratory chemicals, etc.) are splashed into the eyes, the patient should: FLUSH EYES IMMEDIATELY WITH TAP WATER AND IMMEDIATELY CONTACT THE EYE CARE PROFESSIONAL OR VISIT A HOSPITAL EMERGENCY ROOM WITHOUT DELAY. 
HOW SUPPLIED
Each UV-blocking sterile lens is supplied in a foil-sealed plastic package containing buffered saline solution with methyl ether cellulose. The plastic package is marked with the following: 
• ACUVUE OASYS
® 1-Day: base curve, power, diameter, lot number, 
and expiration date
• ACUVUE OASYS® 1-Day for ASTIGMATISM: base curve, power, 
diameter, cylinder, axis, lot  and expiration dateCR-6470, v 2.0 ) 
 
Page 111 of 192JJVC CONFIDENTIAL
REPORTING OF ADVERSE REACTIONS
All serious adverse experiences and adverse reactions observed in 
patients wearing these lenses or experienced with these lenses should be reported to:
Johnson & Johnson Vision Care, Inc.
7500 Centurion Parkway
Jacksonville, FL 32256
USA
Tel: 1-800-843-2020
www.acuvue.com
CR-6470, v 2.0  
 
Page 112 of 192JJVC CONFIDENTIAL
Johnson & Johnson Vision Care, Inc.
7500 Centurion Parkway
Jacksonville, FL 32256
USA
Tel: 1-800-843-2020
www.acuvue.com
©Johnson & Johnson Vision Care Companies 2016
In Canada: Johnson & Johnson Vision Care, division of Johnson & Johnson, Inc. 
In USA: Johnson & Johnson Vision Care, Inc.
Printed in USA.
Revision date: 09/16
Revision number: AO-03-16-13
ACUVUE OASYS® and HydraLuxe ™ are Trademarks of 
the Johnson & Joh n Care Companies20401080
CR-6470, v 2.0 - 
 
Page 113 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
APPENDIX D:   
Limbal & Conjunctival (Bulbar) Redness
Expanded Sodium Fluorescein Corneal Staining
 Lens Fitting Characteristics
 Subject Reported Ocular Symptoms/Problems
Front and Back Surface Lens Deposit Grading Procedure
 Determination of Distance Spherocylindrical Refracti ve Error 
 Biomicroscopy Scale
Keratometry Procedure
 Distance and Ne ar Snellen Visual Acuity Evaluation
Distance LogMAR Visual Acuity Measurement Procedure
 Patient Reported Outcomes 
White Light Lens Surface Wettability
Visual Acuity Chart Luminance and Room Illumination Testing
 
CR-6470, v 2.0  
 
Page 114 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
 LIMBAL & CONJUNCTIVAL (BULBAR) REDNESS  
CR-6470, v 2.0  
 
Page 115 of 192JJVC CONFIDENTIAL
Title:                          Limbal & Conjunctival (Bulbar) Redness
Document Type:  
Document Number: Revision Number:  5 
CR-6470, v 2.0  
 
Page 116 of 192JJVC CONFIDENTIAL
Title:                          Limbal & Conjunctival (Bulbar) Redness
Document Type:  
Document Number: Revision Number:  5 
CR-6470, v 2.0  
 
Page 117 of 192JJVC CONFIDENTIAL
Title:                          Limbal & Conjunctival (Bulbar) Redness
Document Type:  
Document Number: Revision Number:  5 
CR-6470, v 2.0  
 
Page 118 of 192JJVC CONFIDENTIAL
Title:                          Limbal & Conjunctival (Bulbar) Redness
Document Type:  
Document Number: Revision Number:  5 
CR-6470, v 2.0  
 
Page 119 of 192JJVC CONFIDENTIAL
Title:                          Limbal & Conjunctival (Bulbar) Redness
Document Type:  
Document Number: Revision Number:  5 
  
CR-6470, v 2.0  
 
Page 120 of 192JJVC CONFIDENTIAL
Title:                          Limbal & Conjunctival (Bulbar) Redness
Document Type:  
Document Number: Revision Number:  5 
CR-6470, v 2.0  
 
Page 121 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
 EXPANDED SODIUM FLUORESCEIN CORNEAL STAINING   
CR-6470, v 2.0  
 
Page 122 of 192JJVC CONFIDENTIAL
Title:                          Expanded Sodium Fluorescein Corneal Staining
Document Type:  
Document Number: Revision Number:  5 
  
          
  
CR-6470, v 2.0  
 
Page 123 of 192JJVC CONFIDENTIAL
Title:                          Expanded Sodium Fluorescein Corneal Staining
Document Type:  
Document Number: Revision Number:  5 
CR-6470, v 2.0  
 
Page 124 of 192JJVC CONFIDENTIAL
Title:                          Expanded Sodium Fluorescein Corneal Staining
Document Type:  
Document Number: Revision Number:  5 
CR-6470, v 2.0  
 
Page 125 of 192JJVC CONFIDENTIAL
Title:                          Expanded Sodium Fluorescein Corneal Staining
Document Type:  
Document Number: Revision Number:  5 
CR-6470, v 2.0  
 
Page 126 of 192JJVC CONFIDENTIAL
Title:                          Expanded Sodium Fluorescein Corneal Staining
Document Type:  
Document Number: Revision Number:  5 
     
CR-6470, v 2.0  
 
Page 127 of 192JJVC CONFIDENTIAL
Title:                          Expanded Sodium Fluorescein Corneal Staining
Document Type:  
Document Number: Revision Number:  5 
CR-6470, v 2.0  
 
Page 128 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
 LENS FITTING CHARACTERISTICS  
CR-6470, v 2.0  
 
Page 129 of 192JJVC CONFIDENTIAL
Title:                          Lens Fitting Characteristics
Document Type:  
Document Number :  Revi sion Number:  5
Page 1of 5CR-6470, v 2.0  
 
Page 130 of 192JJVC CONFIDENTIAL
Title:                          Lens Fitting Characteristics
Document Type:  
Document Number :  Revi sion Number:  5
Page 2of 5        
       
CR-6470, v 2.0  
 
Page 131 of 192JJVC CONFIDENTIAL
Title:                          Lens Fitting Characteristics
Document Type:  
Document Number :  Revi sion Number:  5
Page 3of 5CR-6470, v 2.0  
 
Page 132 of 192JJVC CONFIDENTIAL
Title:                          Lens Fitting Characteristics
Document Type:  
Document Number :  Revi sion Number:  5
Page 4of 5CR-6470, v 2.0  
 
Page 133 of 192JJVC CONFIDENTIAL
Title:                          Lens Fitting Characteristics
Document Type:  
Document Number :  Revi sion Number:  5
Page 5of 5CR-6470, v 2.0  
 
Page 134 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
 SUBJECT REPORTED OCULAR SYMPTOMS/PROBLEMS   
CR-6470, v 2.0  
 
Page 135 of 192JJVC CONFIDENTIAL
Title:                         Subject Reported Ocular Symptoms/Problems
Document Type:  
Document Number :  Revi sion Number:  3
Page 1of 1  
  
            
CR-6470, v 2.0  
 
Page 136 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
 FRONT AND BACK SURFACE LENS DEPOSIT GRADING PROCEDURE   
CR-6470, v 2.0  
 
Page 137 of 192JJVC CONFIDENTIAL
Title:                        Front and Back Surface Lens Deposit Grading Procedure
Document Type:  
Document Number :  Revi sion Number:  4
Page 1of 4CR-6470, v 2.0  
 
Page 138 of 192JJVC CONFIDENTIAL
Title:                        Front and Back Surface Lens Deposit Grading Procedure
Document Type:  
Document Number :  Revi sion Number:  4
Page 2of 4CR-6470, v 2.0  
 
Page 139 of 192JJVC CONFIDENTIAL
Title:                        Front and Back Surface Lens Deposit Grading Procedure
Document Type:  
Document Number :  Revi sion Number:  4
Page 3of 4  
CR-6470, v 2.0  
 
Page 140 of 192JJVC CONFIDENTIAL
Title:                        Front and Back Surface Lens Deposit Grading Procedure
Document Type:  
Document Number :  Revi sion Number:  4
Page 4of 4CR-6470, v 2.0  
 
Page 141 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
 DETERMINATION OF DISTANCE SPHEROCYLINDRICAL 
REFRACTI VE ERROR  
CR-6470, v 2.0  
 
Page 142 of 192JJVC CONFIDENTIAL
Title:                       Determination of Dist ance Spherocylindrical Refractive Error
Document Type:  
Document Number : Revi sion Number:  5
Page 1of5       
  
       
       
       
        
CR-6470, v 2.0  
 
Page 143 of 192JJVC CONFIDENTIAL
Title:                       Determination of Dist ance Spherocylindrical Refractive Error
Document Type:  
Document Number : Revi sion Number:  5
Page 2of5CR-6470, v 2.0  
 
Page 144 of 192JJVC CONFIDENTIAL
Title:                       Determination of Dist ance Spherocylindrical Refractive Error
Document Type:  
Document Number : Revi sion Number:  5
Page 3of5CR-6470, v 2.0  
 
Page 145 of 192JJVC CONFIDENTIAL
Title:                       Determination of Dist ance Spherocylindrical Refractive Error
Document Type:  
Document Number : Revi sion Number:  5
Page 4of5       
       
       
       
       
CR-6470, v 2.0  
 
Page 146 of 192JJVC CONFIDENTIAL
Title:                       Determination of Dist ance Spherocylindrical Refractive Error
Document Type:  
Document Number : Revi sion Number:  5
Page 5of5CR-6470, v 2.0  
 
Page 147 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
 BIOMICROSCOPY SCALE   
CR-6470, v 2.0  
 
Page 148 of 192JJVC CONFIDENTIAL
Title:     Biomicroscopy Scale
Document Type:
Document Number:       Revision Number:  9 
Page 1 of 5  
  
  
CR-6470, v 2.0  
 
Page 149 of 192JJVC CONFIDENTIAL
Title:     Biomicroscopy Scale
Document Type:
Document Number:       Revision Number:  9 
Page 2 of 5   
  
   
  
CR-6470, v 2.0  
 
Page 150 of 192JJVC CONFIDENTIAL
Title:     Biomicroscopy Scale
Document Type:
Document Number:       Revision Number:  9 
Page 3 of 5  
   
CR-6470, v 2.0  
 
Page 151 of 192JJVC CONFIDENTIAL
Title:     Biomicroscopy Scale
Document Type:
Document Number:       Revision Number:  9 
Page 4 of 5  
   
                 
CR-6470, v 2.0  
 
Page 152 of 192JJVC CONFIDENTIAL
Title:     Biomicroscopy Scale
Document Type:
Document Number:       Revision Number:  9 
Page 5 of 5   
  
   
     
  
   
CR-6470, v 2.0  
 
Page 153 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
 KERATOMETRY PROCEDURE   
CR-6470, v 2.0  
 
Page 154 of 192JJVC CONFIDENTIAL
Page 1 of 1 Keratometry Procedure
   
    
   
    
    
      
  
CR-6470, v 2.0  
 
Page 155 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
 DISTANCE AND NEAR SNELLEN VISUAL ACUITY EVALUATION   
CR-6470, v 2.0  
 
Page 156 of 192JJVC CONFIDENTIAL
Title:                        Distance and Near Snellen Visual Acuity Evaluation
Document Type:  
Document Number :  Revi sion Number:  4
Page 1of 4  
CR-6470, v 2.0  
 
Page 157 of 192JJVC CONFIDENTIAL
Title:                        Distance and Near Snellen Visual Acuity Evaluation
Document Type:  
Document Number :  Revi sion Number:  4
Page 2of 4CR-6470, v 2.0  
 
Page 158 of 192JJVC CONFIDENTIAL
Title:                        Distance and Near Snellen Visual Acuity Evaluation
Document Type:  
Document Number :  Revi sion Number:  4
Page 3of 4CR-6470, v 2.0  
 
Page 159 of 192JJVC CONFIDENTIAL
Title:                        Distance and Near Snellen Visual Acuity Evaluation
Document Type:  
Document Number :  Revi sion Number:  4
Page 4of 4CR-6470, v 2.0  
 
Page 160 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
 DISTANCE LOGMAR VISUAL ACUITY MEASUREMENT PROCEDURE   
CR-6470, v 2.0  
 
Page 161 of 192JJVC CONFIDENTIAL
Title: Distance LogMAR Visual Acuity Measurement Procedure 
Document Type:  
Document Number:   Revision Number: 4 
 
Page 1 of 3 
   
CR-6470, v 2.0  
 
Page 162 of 192JJVC CONFIDENTIAL
Title: Distance LogMAR Visual Acuity Measurement Procedure 
Document Type:  
Document Number:   Revision Number: 4 
 
Page 2 of 3 
  
CR-6470, v 2.0  
 
Page 163 of 192JJVC CONFIDENTIAL
Title: Distance LogMAR Visual Acuity Measurement Procedure 
Document Type:  
Document Number:   Revision Number: 4 
 
Page 3 of 3 
  
CR-6470, v 2.0  
 
Page 164 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
PATIENT REPORTED OUTCOMES  
CR-6470, v 2.0  
 
Page 165 of 192JJVC CONFIDENTIAL
Title: Patient Reported Outcomes
Document Type:
Document Number: Revision Number: 2
Page 1 of 1  
                       
CR-6470, v 2.0  
 
Page 166 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
 WHITE LIGHT LENS SURFACE WETTABILITY   
CR-6470, v 2.0  
 
Page 167 of 192JJVC CONFIDENTIAL
 
Page 1 of 1  
  White Light Lens Surface Wettability   
  
   
 
 
   
   
   
 
 
   
   
     
 
        
      
  
  
 
      
 
CR-6470, v 2.0  
 
Page 168 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
 VISUAL ACUITY CHART LUMINANC E AND ROOM ILLUMINATION 
TESTING   
CR-6470, v 2.0  
 
Page 169 of 192JJVC CONFIDENTIAL
Title:                          Visual Acuity Chart Luminance and Room Illumination Testing 
Document Type:  
Document Number: Revision Number:  4 
CR-6470, v 2.0  
 
Page 170 of 192JJVC CONFIDENTIAL
Title:                          Visual Acuity Chart Luminance and Room Illumination Testing 
Document Type:  
Document Number: Revision Number:  4 
CR-6470, v 2.0  
 
Page 171 of 192JJVC CONFIDENTIAL
Title:                          Visual Acuity Chart Luminance and Room Illumination Testing 
Document Type:  
Document Number: Revision Number:  4 
CR-6470, v 2.0  
 
Page 172 of 192JJVC CONFIDENTIAL
Title:                          Visual Acuity Chart Luminance and Room Illumination Testing 
Document Type:  
Document Number: Revision Number:  4 
CR-6470, v 2.0  
 
Page 173 of 192JJVC CONFIDENTIAL
Title:                          Visual Acuity Chart Luminance and Room Illumination Testing 
Document Type:  
Document Number: Revision Number:  4 
CR-6470, v 2.0  
 
Page 174 of 192JJVC CONFIDENTIAL
Title:                          Visual Acuity Chart Luminance and Room Illumination Testing 
Document Type:  
Document Number: Revision Number:  4 
CR-6470, v 2.0  
 
Page 175 of 192JJVC CONFIDENTIAL
Title:                          Visual Acuity Chart Luminance and Room Illumination Testing 
Document Type:  
Document Number: Revision Number:  4 
CR-6470, v 2.0  
 
Page 176 of 192JJVC CONFIDENTIAL
Title:                          Visual Acuity Chart Luminance and Room Illumination Testing 
Document Type:  
Document Number: Revision Number:  4 
CR-6470, v 2.0  
 
Page 177 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
 
 
CR-6470, v 2.0  
 
Page 178 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
APPENDIX F: STARTING LENS POWER GUIDANCE  
CR-6470, v 2.0  
 
Page 179 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
APPENDIX G: GUIDELINES FOR COVID-19 RISK MITIGATION 
 
CR-6470, v 2.0  
 
Page 180 of 192JJVC CONFIDENTIAL
7LWOH *XLGHOLQHVIRU&29,'5LVN0LWLJDWLRQ
'RFXPHQW7\SH 
'RFXPHQW1XPEHU  5HYLVLRQ1XPEHU

385326(
7KHSXUSRVHRIWKLVGRFXPHQWLVWRSURYLGHJXLGHOLQHVIRUWKHU HRSHQLQJRULQLWLDWLRQRIFOLQLFDOVWXG\VLWHV
SDUWLFLSDWLQJLQ-RKQVRQ	-RKQVR Q9LVLRQ&DUH,QF--9&,FO LQLFDOVWXGLHVGXULQJWKH&29,'
SDQGHPLF
6&23(
7KLVGRFXPHQWSURYLGHVJXLGHOLQHVIRU-RKQVRQ	-RKQVRQ9LVLRQ &DUH--9&,WRDGGUHVVWKHSRWHQWLDOULVNV
IURP&29,'WRVWXG\VXEMHFWV LQYHVWLJDWRUVVWXG\VLWHVWDI IDQGPRQLWRUVDWVWXG\VLWHV7KHJXLGDQFH
SURYLGHGLQWKLVGRFXPHQWLVLQHIIHFWIURPWKHGDWHRIDSSURYD OWKURXJKWKHGDWHRIUHWLUHPHQWRIWKLV:RUN
,QVWUXFWLRQ$WDPLQLPXPWKLV :RUN,QVWUXFWLRQZLOOEHUHYLHZ HGDQGXSGDWHGRQDTXDUWHUO\EDVLVDV
DSSURSULDWH
127(5HRSHQLQJRIVLWHVRXWVLGHRIWKH86ZLOOEHHYDOXDWHG RQDFRXQWU\E\FRXQWU\EDVLVVXEMHFW
WRORFDOKHDOWKDXWKRULW\JXLGDQFH
'(),1,7,216

$PHULFDQ$FDGHP\RI2SWRPHWU\$$2 7KH$PHULFDQ$FDGHP\RI2SWRPHWU\LVDQRUJDQL]DWLRQRI
RSWRPHWULVWVEDVHGLQ2UODQGR )ORULGD,WVJRDOLVWRPDLQWDLQ DQGHQKDQFHH[FHOOHQFHLQRSWRPHWULF
SUDFWLFHE\ERWKSURPRWLQJUHV HDUFKDQGWKHGLVVHPLQDWLRQRIN QRZOHGJH7KH$$2 KROGVDQDQQXDO
PHHWLQJSXEOLVKHVDPRQWKO\VFLH QWLILFMRXUQDOJLYHVFUHGHQWL DOVWRRSWRPHWULVWV WKURXJKWKHIHOORZVKLS
SURFHVVDQGSXEOLVKHVSRVLWLRQVWDWHPHQWV

$PHULFDQ2SWRPHWULF$VVRFLDWLRQ$2$ 7KH$PHULFDQ2SWRPHWULF $VVRFLDWLRQIRXQGHGLQLV
WKHOHDGLQJDXWKRULW\RQTXD OLW\FDUHDQGDQDGYRFDWHIRURXUQ DWLRQ
VKHDOWKUHSUHV HQWLQJPRUHWKDQ
'RFWRUVRI2SWRPHWU\2'RSWR PHWULFSURIHVVLRQDOVDQGRSWRPHWU\VWXGHQWV'RFWR URI2SWRPHWU\WDNH
DOHDGLQJUROHLQSDWLHQWFDUHZLWKUHVSHFWWRH\HDQGYLVLRQF DUHDVZHOODVJHQHUDOKHDOWKDQGZHOOEHLQJ
$VSULPDU\KHDOWKFDUHSURYLGHUV 'RFWRURI2SWRPHWU\KDYHH[WH QVLYHRQJRLQJWUDLQLQJWRH[DPLQH
GLDJQRVHWUHDWDQGPDQDJHRFXODUGLVRUGHUVGLVHDVHVDQGLQMXU LHVDQGV\VWHPLFGLVHDVHVWKDWPDQLIHVWLQWKH
H\H7KH$PHULFDQ2SWRPHWULF$VVRFLDWLRQLVDIHGHUDWLRQRIVWD WHVWXGHQWDQGDUPHGIRUFHVRSWRPHWULF
DVVRFLDWLRQV7KURXJKWKHVHD IILOLDWLRQVWKH$2$VHUYHVPHPEHU VFRQVLVWLQJRIRSWRPHWULVWVVWXGHQWVRI
RSWRPHWU\SDUDRSWRPHWULFDVVLVWDQWVDQGWHFKQLFLDQV7KH$2$D QGLWVDIILOLDWHVZRUNWRSURYLGHWKHSXEOLF
ZLWKTXDOLW\YLVLRQDQGH\HFDUH
&HQWHUVIRU'LVHDVH&RQWURODQG3UHYHQWLRQ&'& 7KH&HQWHUVIRU'LVHDVH&RQWURODQG3UHYHQWLRQLVD
QDWLRQDOSXEOLFKHDOWKLQVWLWXWHL QWKH8QLWHG6WDWHV,WLVD 8QLWHG6WDWHVIHGHUDODJHQF\XQGHUWKH
'HSDUWPHQWRI+HDOWK DQG+XPDQ6HUYLFHVDQGLVKHDGTXDUWHUHGL Q$WODQWD*HRUJLD 
&29,' &XUUHQWRXWEUHDNRIUHVSLUDWRU\GLVHDVHFDXVHGE\DQRYHOFRURQ DYLUXV7KHYLUXVKDVEHHQ
QDPHG³6$56&R9´DQGWKHGLVHDVHLWFDXVHVKDVEHHQQDPHG³&R URQDYLUXV'LVHDVH´&29,'

&OLQLFDO6WXG\ 9ROXQWDU\UHVHDUFKVWXGLHVFRQGXFWHGLQSHRSOHDQGGHVLJQHGWR DQVZHUVSHFLILFTXHVWLRQV
DERXWWKHVDIHW\RUHIIHFWLYHQHVVRIGUXJVYDFFLQHVRWKHUWKH UDSLHVRUQHZZD\VRIXVLQJH[LVWLQJ
WUHDWPHQWV0D\DOVREHFDOOHGFOLQLFDOWULDOVVWXGLHVUHVHDU FKWULDOVRUSURWRFROV 
&OLQLFDO6WXG\6LWH /RFDWLRQZKHUHDFOLQLFDOVWXG\LVF RQGXFWHGVXFKDVDGRFWRU¶ VRIILFHXQLYHUVLW\RU
ODERUDWRU\&OLQLFDOVWXGLHVDUH FRQGXFWHGE\,QYHVWLJDWRUVZKR DUHLQGLYLGXDOVUHVSRQVLEOHIRUWKH
FRQGXFWRIWKHFOLQLFDOVWXG\DWDVWXG\VLWH,IDVWXG\LVFR QGXFWHGE\DWHDPRILQGLYLGXDOVWKH
,QYHVWLJDWRULVWKHUHVSRQVLEOHOHDGHURIWKHWHDPDQGPD\EHF DOOHGWKH3ULQFLSDO,QYHVWLJDWRU 
&OLQLFDO2SHUDWLRQV0DQDJHU&20 7KH-RKQVRQ	-RKQVRQ9LVLRQ&DUH--9&,LQGLYLGXDO
UHVSRQVLEOHIRUWKHRYHUD OOPDQDJHPHQWRIDFOLQLFDOWULDO 
CR-6470, v 2.0  
 
Page 181 of 192JJVC CONFIDENTIAL
7LWOH *XLGHOLQHVIRU&29,'5LVN0LWLJDWLRQ
'RFXPHQW7\SH 
'RFXPHQW1XPEHU  5HYLVLRQ1XPEHU

0RQLWRU$QLQGLYLGXDOGHVLJQDWHGWRRYHUVHH WKHSURJUHVVRIDFOLQLFDOVWX G\DQGHQVXUHWKDWLWLV
FRQGXFWHGUHFRUGHGDQGUHSRUWHGLQDFFRUGDQFHZLWKWKHSURWRF RO6WDQGDUG2SHUDWLQJ3URFHGXUHV623V
*RRG&OLQLFDO3UDFWLFH*&3DQGDSSOLFDEOHUHJXODWRU\UHTXLUH PHQWV

0HGLFDO6DIHW\2IILFHU062 3K\VLFLDQZKRKDVSULPDU\DFFRXQWDELOLW\LQWKHLUSURGXFWSRUW IROLRIRU
SURGXFWKHDOWKDQGVDIHW\DQGZKRVHUYHVDVDQLQGHSHQGHQWPHG LFDOYRLFHIRUSDWLHQWVDIHW\

6DIHW\0DQDJHPHQW7HDP607 $FURVVIXQFWLRQDOFROODERUDWLY HWHDPUHVSRQVLEOHIRUUHYLHZ
DVVHVVPHQWDQGHYDOXDWLRQRIPHGLFDOVDIHW\GDWDDULVLQJIURPD Q\VRXUFHWKURXJKRXWWKHSURGXFWOLIHF\FOH
*8,'$1&()25678'<'2&80(176
,QDOLJQPHQWZLWKUHFHQWKHDOWKDXW KRULW\JXLGDQFH--9&,LVSU RYLGLQJUHFRPPHQGDWLRQVIRUVWXG\UHODWHG
PDQDJHPHQWLQWKHHYHQWRIGLVUXSWLRQWRWKHFRQGXFWRIWKHFOL QLFDOVWXG\7KLVJXLGDQFHGRHVQRWVXSHUVHGH
DQ\ORFDORUJRYHUQPHQWUHTXLUHPHQWVRUWKHFOLQLFDOMXGJHPHQW RIWKHLQYHVWLJDWRUWRSUR WHFWWKHKHDOWKVDIHW\
DQGZHOOEHLQJRISDUWLFLSDQWV DQGVLWHVWDII,IDWDQ\WLPH DSDUWLFLSDQW¶VVDIHW\LVFRQVLGHUHGWREHDWULVN
VWXG\LQWHUYHQWLRQZLOOEHGLVF RQWLQXHGDQGV WXG\IROORZXSZL OOEHFRQGXFWHGDVRXWOLQ HGLQWKHSURWRFRO
'XULQJWKH&29,'SDQGHPLFW KHDGGLWLRQDOULVNVOLVWHGEHORZ QHHGWREHFRQVLGHUHGIRUVWXG\SDUWLFLSDQWV
DQGVWXG\SHUVRQQHO
$GGLWLRQDO5LVNV5HODWHGWRWKH&29,'3DQGHPLF
x7KHSRVVLEOHWUDQVPLVVLRQRIWKH&RURQDYLUXVLQIHFWLRQDQGFRQV HTXHQWFRPSOLFDWLRQVEH\RQGWKH
ULVNRIDGYHUVHHYHQWVGXHWRWKH LQYHVWLJDWLRQDOGHYLFHDQGRU SURFHGXUHV
x7KHULVNPD\EHKLJKHULQDQRSWRPHWULFFOLQLFDOVWXG\EHFDXVH RIWKHFORVHFRQWDFWWKHVXEMHFWZLOO
KDYHZLWKKHDOWKFDUHSURIHVVLRQDOVGXULQJWKHSURFHGXUHVDQGD VVHVVPHQWVVLQFHWKHLQYHVWLJDWRU
PXVWPDNHWKHPHDVXUHPHQWVFORVHWRWKHVXEMHFW¶VIDFHDQGLQ DGGLWLRQWKHQHHGIRUPXOWLSOH
IROORZXS YLVLWVH[DPV ZKLFK PD\ H [SRVH WKH VXEMHFW WR RWKHU SD WLHQWV DQGRU KHDOWKFDUH
SURIHVVLRQDOVZKRPLJKWEHWUDQ VPLWWLQJWKHYLUXVHYHQLIWKH\ GRQRWKDYHV\PSWRPV
x3RWHQWLDOGLVUXSWLRQVWRWKHVWXG\PD\EHQHFHVVDU\GXHWRFXUU HQWRUIXWXUHSDQGHPLFUHODWHG
HPHUJHQF\UHVWULFWLRQVZKLFKPD\OHDGWRGHOD\VLQVFKHGXOHGI ROORZXSYLVLWV
x6XEMHFWVH[SHULHQFLQJDQDGYHUVHHYHQWUHODWHGWRFRQWDFWOHQV ZHDUPD\UHFHLYHGHOD\HGWUHDWPHQW
GXHWR&29,'UHVWULFWLRQV,QWKLVHYHQWDOODVVHVVPHQWVWK DWFDQEHFRQGXFWHGYLUWXDOO\ZLOOEH
FRPSOHWHGE\WKHLQYHVWLJDWRUWR GHWHUPLQHWKHEHVWFRXUVHRIW UHDWPHQWIRUWKHVXEMHFWLQFOXGLQJ
DQXQVFKHGXOHGYLVLWXSWRGL VFRQWLQXDWLRQIURPWKHVWXG\DV DSSURSULDWH
,IDVWXG\VXEMHFWLVIRXQGWRKDYHFRQWUDFWHG&29,'GXULQJ SDUWLFLSDWLRQLQDVWXG\KHVKHZLOOEH
GLVFRQWLQXHGIURPWKHVWXG\DQGIROORZHGXQWLO&29,'$GYHUVH (YHQW$(UHVROXWLRQ
7RKHOSPLQLPL]HWKHDERYHSRWHQWLDOULVNV--9&,UHFRPPHQGUHY LHZLQJFRPSO\LQJZLWKORFDOVWDWH
DQGJRYHUQPHQWDOJXLGDQFHIRU&29,'ULVNV
--9&,ZLOOSURYLGHWKHIROORZLQJVWXG\VSHFLILFGRFXPHQWVZLWK ODQJXDJHSHUWDLQLQJWR&29,'ULVNV
,QIRUPHG&RQVHQW 
:LOOLQFOXGHLQIRUPDWLRQFRQFHUQLQJ WKHVWXG\DVVRFLDWHGULVNV UHODWHGWRWKH&29,'SDQGHPLF
LQEROGIRQWDQGRUER [HGRQWKHILUVWSDJHRIWKH,QIRUPHG&RQ VHQWGRFXPHQW

CR-6470, v 2.0  
 
Page 182 of 192JJVC CONFIDENTIAL
7LWOH *XLGHOLQHVIRU&29,'5LVN0LWLJDWLRQ
'RFXPHQW7\SH 
'RFXPHQW1XPEHU  5HYLVLRQ1XPEHU

678'<$662&,$7('5,6.65(/$7('72 &29,'&2521$9,5863$1'(0 ,&

,WLVLPSRUWDQWWRQRWHWKDWWKL VVWXG\ZLOOEHFRQGXFWHGDWOHDVWLQSDUWGXULQJWKH&29,'SDQGHPLF$VVXFK
DGGLWLRQDOULVNVDVVRFLDWHGZLWK WKHLQIHFWLRQZLWK&29,'H[ LVWIRU\RX7KLVLVSDUWLFXODUO\LPSRUWDQWIRUWKLV
VWXG\GXHLQSDUWWRWKHFORVHQ HVVRIWKHGRFWRUGXULQJWKHV WXG\H[DPLQDWLRQV

7KHSRWHQWLDOHIIHFWVRIWKHGL VHDVHDUHQRWIXOO\NQRZQDWWK LVWLPHDQGPD\LQFOXGHORQJWHUPVHULRXVKHDOWK
FRQVHTXHQFHV,QVHYHUHFDVHVWKLVPD\UHVXOWLQKRVSLWDOL]DWL RQDQGRUGHDWK%DVHGRQFXUUHQWNQRZOHGJHIURPWKH
&HQWHUVIRU'LVHDVH&RQWURODQG3UHYHQWLRQ&'&WKRVHDWKLJK ULVNIRUVHYHUHLOOQHVVIURP&29,'LQFOXGH
ROGHUDGXOWVDQGSHRSOHZLWKXQG HUO\LQJPHGLFDOFRQGLWLRQV
'XULQJWKLVVWXG\DOODSSURSULDWHPHDVXUHVZLOOEHWDNHQWRPL QLPL]HULVNVLQFOXGLQJWKHX VHRISHUVRQDOSURWHFWLYH
HTXLSPHQWVXFKDVPDVNVDQGJORYHVDVZHOODVSURSHUVDQLWL]DW LRQ7KLVLVLQFRQIRUPDQFHWRJXLGDQFHIURPWKH
&'&ORFDOKHDOWKGHSDUWPHQWVDQGWKHVWDWHDQGFRXQW\LQZKLFKWKHVWXG\GRFWRU¶VRIIL FHLVORFDWHG+RZHYHU
WKHVHPHDVXUHVPD\QRWFRPSOHWHO\HOLPLQDWHWKHULVNVDVVRFLDWH GZLWKFRQWUDFWLQJ&29,'

,I\RXDUHIRXQGWRKDYHFRQWU DFWHG&29,'RUIHHOLOOZLWKI OXOLNHV\PSWRPVGXULQJSDUWLFLSDWLRQLQWKHVWXG\
\RXZLOOQRWEHSHUPLWWHGWRFRQWLQXHLQRIILFHVWXG\IROORZXS YLVLWVEXW\RXZLOOUHFHLYHLQVWUXFWLRQVDQG\RXU
FRQGLWLRQZLOOEHPRQLWR UHGE\WKHGRFWRUDQGRUVWXG\VWDII 
&29,'5LVN&RQWURO&KHFNOLVW$WWDFKPHQW%
:LOOLQFOXGH&29,'ULVNFRQWUR OPHWKRGVWKDWDUHUHTXLUHGE\DVLWHWRFRQGXFW--9&,FOLQLFDO
VWXGLHV 7KH ULVN FRQWUROV DUH FRQVLVWHQW ZLWK &'& $2$ $$2 *X LGDQFH 7KH 3ULQFLSDO
,QYHVWLJDWRUZLOOUHYLHZVLJQWKHVWXG\VSHFLILFFKHFNOLVWSULR UWRWKH6LWH,QLWLDWLRQ0HHWLQJ

3URWRFRO&RPSOLDQFH,QYHVW LJDWRUV6LJQDWXUH3DJH
:LOOLQFOXGHDVWDWHPHQWLQGLFDWLQJWKDWWKH3ULQFLSDO,QYHVWLJ DWRU3,DJUHHVWRFRQGXFWWKHVWXG\
LQFRPSOLDQFHZLWK DOOORFDOVWDWHDQGJRYHUQPHQWDOJXLGDQFH¶ VIRU&29,'ULVNPLWLJDWLRQ
,KDYHUHDGWKHVXJJHVWHGJXLGDQFHSURYLGHGE\--9&,SHUWDLQLQJ WRWKH&29,'ULVNPLWLJDWLRQ
&29,':RUN,QVWUXFWLRQLQWKH$SSHQGL[RIWKLVSURWRFRO, DJUHHWRFRQGXFWWKLVVWXG\LQ
FRPSOLDQFHZLWKORFDOVWDWHJRYHUQPHQWDOJXLGDQFHIRU&29,' ULVNV
6WXG\6LWH,QLWLDWLRQ7UDLQLQJ6OLGHV
:LOOLQFOXGHVXJJHVWLRQVWRKHOS PLWLJDWHSRWHQWLDOWUDQVPLVVLR QRI&29,'6XJJHVWLRQVPD\
LQFOXGHPDLQWDLQLQJVRFLDOGLVWDQ FLQJLQWKHFOLQLFDOVLWHE\V WDJJHUHGVFKHGXOLQJRIVWXG\SDWLHQWV
ZHDULQJSURSHU33(VIUHTXHQWGLVLQIHFWLRQDQGLQVWDOOLQJVKLHOGVRQWKHVOLWODPSDQGRWKHU
DSSOLFDEOHHTXLSPHQW
*8,'$1&()255(027(68%-(&79,6,76
3RWHQWLDOGLVUXSWLRQVWRWKHVWXG\PD\EHQHFHVVDU\GXHWRFXUU HQWRUIXWXUHSDQGHPLFUHODWHGHPHUJHQF\
UHVWULFWLRQV3RVVLEOHGLVUXSWL RQRIWKHVWXG\DVDUHVXOWRI &29,'FRQWUROPHDVXUHVPD\OHDGWRGHOD\V
LQVFKHGXOHGIR OORZXSYLVLWV
6XEMHFWVPD\EHGHOD\HGLQEHLQJVHHQIRUVWXG\IROORZXSYLVLW VIRUH[DPSOHGXHWR&29,'FRQWURO
PHDVXUHVRUGXHWRWKHVXEMHFW¶V FRQFHUQVRUIHDUVDERXW&29,'ULVN:KHQDSSURSULDWHWKHUH PRWH
DVVHVVPHQWZLOOEHFRQGXFWHGWRWK HH[WHQWSRVVLEOH'LVFXVVLR QVZLWKWKHVXEMHFWGXULQJUHPRWHDVVHVVPHQWV
PD\LQFOXGH
CR-6470, v 2.0  
 
Page 183 of 192JJVC CONFIDENTIAL
7LWOH *XLGHOLQHVIRU&29,'5LVN0LWLJDWLRQ
'RFXPHQW7\SH 
'RFXPHQW1XPEHU  5HYLVLRQ1XPEHU


3URFHGXUH 'HWDLOV
6XEMHFW5HSRUWHG2FXODU
6\PSWRPV6XEMHFWVZLOOUHVSRQGWRDYHUEDO RSHQHQGHGV\PSWRPVTXHVWLRQQ DLUH
UHJDUGLQJWKHWHVWDUWLFOHZKHQDSSOLFDEOHDQGIHDVLEOH
&KDQJHRI0HGLFDO+LVWRU\$GYHUVH(YHQWVDQG&RQFRPLWDQW0HGLFDWLRQV
7KHUDSLHV5HYLHZ5HFRUGDQ\DGYHUVHH YHQWVRUPHGLFDOKLVW RU\FKDQJHVIURPWKH
SUHYLRXVVWXG\YLVLWZLWKWKHVXEMHFWSDUHQWV
5HYLHZWKHVXEMHFW ¶VFRQFRPLWDQWPHGLFDWLRQVWKHUDSLHVDQGUHFR UG
DQ\FKDQJHVIURPWKHSUHYLRXVVWXG\YLVLW
:HDULQJ7LPHDQG
&RPSOLDQFH5HFRUGWKHDYHUDJHZHDULQJWLPHLQFOXGLQJQXPEHURIKRXUVSHU GD\
GXULQJZHHNGD\VDQGZHHNHQGVDQGQXPEHURIGD\VSHUZHHN
&RQILUPFRPSOLDQFHZLWKWKHS UHVFULEHGZHDUVFKHGXOH
x5HFRUGDQGGLVFXVVWKHOHQVZHDUFRPSOLDQFHEDVHGRQWKH
VXEMHFW¶VVHOIUHSRUW)RUH[DPSOHWKHVXEMHFWVZLOOEHDVNHG WKH
WLPHRIWKHGD\WKHVXEMHFWW\SLFDOO\SXWVRQWKHVWXG\OHQVHV LQWKH
PRUQLQJDQGWDNHVRIILQWKHHYHQLQJWKHQXPEHURIGD\VSHUZH HN
OHQVHVZHUHZRUQDQGWKHQXPEHURIFRQVHFXWLYHGD\VWKHVXEMHF W
GLGQ¶WZHDUWKHVWXG\OHQVHVHWF
7KHGLVFXVVLRQZLWKWKHVXEMHFWZLOOEHGRFXPHQWHGLQ('&XQGHU 7HOH9LVLWDQGDPLQRUSURWRFROGHYLDWLRQ
ZLOOEHQRWHG,IGXULQJWKHWHOHS KRQHFRQVXOWDWLRQDVXEMHFW VWDWHVKHVKHZLVKHVWRGLVFRQWLQXHSDUWLFLSDWLQJ
LQWKHVWXG\LQVWUXFWWKHVXEMHFWWRVWRSZHDULQJWKHVWXG\OH QVHVDQGVFKHGXOHWKHVXEMHFWWRUHWXUQWRWKH
FOLQLFIRUD)LQDO(YDOXDWLRQDWWKHDWHDUOLHVWSRVVLEOHWLPH 6XEMHFWVVKRXOGUHWXUQDOOXQXVHGOHQVHVWRWKH
FOLQLFDWWKHODVWYLVLW
&KDQJHVLQVWXG\YLVLWVFKHGXOHV PLVVHGYLVLWVRUSDUWLFLSDQWGLVFRQWLQXDWLRQVPD\OHDGWRPLVVLQJGDWD
LQFOXGLQJ GDWD UHODWHG WR SURWRFROVSHFLILHG SURFHGXUHV &DVH UHSRUW IRUPV VKRXOG FDSWXUH VSHFLILF
LQIRUPDWLRQUHJDUGLQJWKHEDVLVRI PLVVLQJGDWDLQFOXGLQJWKH UHODWLRQVKLSWRWKH& 29,'SDQGHPLF
678'<&21'8&7'85,1*3$1'(0,&
,WLVUHFRJQL]HGWKDWWKH&RURQDYLUXV'LVHDVH&29,'S DQGHPLFPD\KDYHDQLPSDFWRQWKHFRQGXFW
RIWKLVFOLQLFDOVWXG\GXHWRIRUH[DPSOHVHOILVRODWLRQTXDU DQWLQHE\SDUWLFLSDQWVDQGVWXG\VLWHSHUVRQQHO
WUDYHOUHVWULFWLRQVOLPLWHGDFFHVVWRSXEOLFSODFHVLQFOXGLQJ 2SWRPHWU\&OLQLFVDQGFKDQJHVLQFOLQLF
SURFHGXUHVUHTXLUHGWRDGGUHV VWKH&29,'FKDOOHQJH
(YHU\HIIRUWVKRXOGEHPDGHWRDGKHUHWRSURWRFROVSHFLILHGDVV HVVPHQWVIRUVWXG\SDUW LFLSDQWVLQFOXGLQJ
IROORZXS+RZHYHULIVFKHGXOHG YLVLWVFDQQRWEHFRQGXFWHGLQ SHUVRQDWWKHVWXG\VLWHLWLVVXJJHVWHGWKDW
DVVHVVPHQWVEHSHUIRUPHGWRWKHH[WHQWSRVVLEOHUHPRWHO\YLUWXD OO\RUGHOD\HGXQWLOVXFKWLPHWKDWRQVLWH
YLVLWVFDQEHUHVXPHGLQRUGHU WRFRQWLQXHSDU WLFLSDQWPRQLWRUL QJLQDFFRUGDQFHZLWKWKHSURWRFROZKHUH
SRVVLEOH$WHDFKFRQWDFWSDUWLFLS DQWVZLOOEHLQWHUYLHZHGWR FROOHFWVDIHW\GDWD.H\HIILFDF\HQGSRLQW
DVVHVVPHQWVVKRXOGEHSHUIRU PHGLIUHTXLUHGDQGDVIHDVLEOH
0RGLILFDWLRQVWRSURWRFROUHTXLUH GDVVHVVPHQWVPD\EHSHUPLWWHG YLD&29,'$SSHQGL[DIWHUFRQVXOWDWLRQ
ZLWKWKHSDUWLFLSDQWLQYHVWLJDWRUDQGWKHVSRQVRU0LVVHGDVV HVVPHQWVYLVLWVZLOOEHFDSWXUHGLQWKHFOLQLFDO
WULDOPDQDJHPHQWV\VWHPIRUSURWRFROGHYLDWLRQV,QWHUUXSWLRQV RIWHVWDUWLFOHZHDURUGLVFRQWLQXDWLRQVRI
VWXG\LQWHUYHQWLRQVDQGZLWKGUDZDOIURPWKHVWXG\VKRXOGEHGRF XPHQWHGZLWKWKHSUHIL[³&29,'
UHODWHG´LQWKHFDVHUHSRUWIRUP&5)
CR-6470, v 2.0  
 
Page 184 of 192JJVC CONFIDENTIAL
7LWOH *XLGHOLQHVIRU&29,'5LVN0LWLJDWLRQ
'RFXPHQW7\SH 
'RFXPHQW1XPEHU  5HYLVLRQ1XPEHU

7KHVSRQVRUZLOOFRQWLQXHWRPRQLWRUWKHFRQGXFWDQGSURJUHVVR IWKHFOLQLFDOVWXG\DQGDQ\FKDQJHVZLOOEH
FRPPXQLFDWHGWRWKHVLWHVDQG WRWKHKHDOWKDXWKRULWLHVDFFRUGL QJWRORFDOJXLGDQFH

,IDSDUWLFLSDQWKDVWHVWHGSRVLWL YHIRU&29,'WKHLQYHVWLJ DWRUVKRXOGFRQWDFWWKHV SRQVRU¶VUHVSRQVLEOH
PHGLFDOPRQLWRUWRGLVFXVVLQLWLDOSODQVIRUVWXG\ LQWHUYHQWLRQ DQGIROORZXS7KH PHGLFDOPRQLWRUZLOO
QRWLI\WKH6DIHW\0DQDJHPHQW7HDPRIDQ\VXEMHFWVWKDWKDYHU HSRUWHG³&29,'´³$V\PSWRPDWLF
&29,'´RU³6XVSHFWHG&29,'´D GYHUVHHYHQWVZLWKLQKRX UVRIWKHQRWLILFDWLRQ
0RGLILFDWLRQVPDGHWRWKHVWXG\FRQGXFWDVDUHVXOWRIWKH&29, 'SDQGHPLFZLOOEHVXPPDUL]HGLQWKH
FOLQLFDOVWXG\UHSRUW
&29,'VFUHHQLQJSURFHGXUHVWKDWPD\EHPDQGDWHGE\ORFDOKHD OWKFDUHV\VWHPVGRQRWQHHGWREH
UHSRUWHGDVDQDPHQGPHQWWRWKHS URWRFROHYHQLIGRQHGXULQJFO LQLFDOVWXG\YLVLWV
0RQLWRULQJ9LVLWV
:KHQRQVLWHPRQLWRULQJE\WKHVSRQVRULVQRWIHDVLEOHWKHVSR QVRU¶VVLWHPRQLWRUZLOOFRQWDFWWKHVWXG\
VLWHWRVFKHGXOHUHPRWHYLVLWV,QVXFKFDVHVRQVLWHPRQLWRUL QJYLVLWVZLOOUHVXPHZKHQIHDVLEOHZLWK
LQFUHDVHGIUHTXHQF\WRDGGUHVVWKHVRXUFHGDWDYHULILFDWLRQEDF NORJ
(YHQZLWKVWDIILQJOLPLWDWLRQVGXULQJ WKLV&29,'SDQGHPLFDOOURXWLQHRSHUDWLRQVUHODWHGWRFOLQLFDO
WULDOVVKRXOGEHZHOOGRFXPHQWHGDQGDUFKLYHGDVSDUWRIVWDQGD UGSURFHVV:KHQFRQGLWLRQVSHUPLWDOO
SDUWLHVLQYROYHGLQWKLVFOLQLF DOWULDOVKRXOGFRPPXQLFDWHUHOH YDQWLQIRUPDWLRQLQDWLPHO\PDQQHUVRWKDW
DOOUHOHYDQWSDUWLHVUHPDL QVXIILFLHQWO\LQIRUPHG
6WXG\6LWH,QLWLDWLRQ'XULQJWKHSHULRGWKDWWKLV:RUN ,QVWUXFWLRQLVLQHIIHFW6LWH ,QLWLDWLRQ0HHWLQJVDQGWUDLQLQJRI
VWXG\VLWHVWDIIZLOOEHFRQGXFWHGUHPRWHO\7KH--9&,VWXG\WH DPZLOOFRQGXFWWUDLQLQJYLD6N\SH
=RRP0LFURVRIW7HDPVRUVLPLODUVRIWZDUHDVZHOODVXWLOL]HRQ OLQHWUDLQLQJPDWHULDOVDVDSSOLFDEOH
6WXG\VLWHWUDLQLQJZLOOEHGRFXPHQWHGXWLOL]LQJ6LWH,QLWLDWLR Q5HSRUW
SHU6WXG\6LWH,QLWLDWLRQ 
2QVLWHYLVLWVPD\EHFRQVLGHUHGZ KHQIRUH[DPSOHKDQGVRQWU DLQLQJRUHYDOXDWLRQRIVLWHIDFLOLWLHV
LVUHTXLUHG:KLOHRQVLWHWKH&OLQLFDO5HVHDUFK$VVRFLDWH&5 $ZLOOIROORZDOOORFDOVWDWHDQG
JRYHUQPHQWDOSROLFLHVIRU&29,' 5LVN0LWLJDWLRQLQFOXGLQJV RFLDOGLVWDQFLQJZHDULQJRI33(
HWFDVDSSOLFDEOHIRUWKHORFDWLRQRIWKHVWXG\VLWH
,QWHULP0RQLWRULQJ9 LVLWVLIDSSOLFDEOH
'XULQJWKHSHULRGWKDWWKLV:RUN ,QVWUXFWLRQLVLQHIIHFW,QWH ULP0RQLWRULQJ2QVLWHYLVLWVZLOOEH
NHSWWRDPLQLPXPDQGLQFOXGHRQO\WKRVHWDVNVWKDWWKH&5$FDQ QRWSHUIRUPUHPRWHO\HJVRXUFH
GRFXPHQWYHULILFDWLRQWHV WDUWLFOHUHFRQFLOLDWLRQHWF
7RHQVXUHGDWDLQWHJULW\GXULQJWKHFRQGXFWRIDOO--9&VWXGLHV FOLQLFDOVWXG\WHDPVZLOOIROORZWKH
VWXG\VSHFLILF&OLQLFDO0RQLWRULQJ3ODQ 
:KLOHRQVLWHWKH&5$ZLOOIROORZDOOORFDOVWDWHDQGJRYHUQ PHQWDOSROLFLHVIRU&29,'5LVN
0LWLJDWLRQLQFOXGLQJVRFLDOGLVWDQ FLQJZHDULQJRI33(HWFD VDSSOLFDEOHIRUWKHORFDWLRQRIWKH
VWXG\VLWH
CR-6470, v 2.0  
 
Page 185 of 192JJVC CONFIDENTIAL
7LWOH *XLGHOLQHVIRU&29,'5LVN0LWLJDWLRQ
'RFXPHQW7\SH 
'RFXPHQW1XPEHU  5HYLVLRQ1XPEHU

6WXG\6LWH&ORVXUH
'XULQJWKHSHULRGWKDWWKLV:RUN ,QVWUXFWLRQLVLQHIIHFWWKH GXUDWLRQRIWKH6WXG\6LWH&ORVXUH9LVLW
ZLOOEHOLPLWHGWRWDVNVWKDWWKH&5$FDQQRWSHUIRUPUHPRWHO\ HJVRXUFHGRFXPHQWYHULILFDWLRQ
WHVWDUWLFOHILQDOUHFRQFLOLDWLRQDQGUHWXUQHWF


CR-6470, v 2.0  
 
Page 186 of 192JJVC CONFIDENTIAL
7LWOH *XLGHOLQHVIRU&29,'5LVN0LWLJDWLRQ
'RFXPHQW7\SH 
'RFXPHQW1XPEHU  5HYLVLRQ1XPEHU

$WWDFKPHQW$6WXG\6LWH&RUUHVSRQGHQFH

;;;;;;


5H&29,'0LWLJDWLRQ3ODQ&5[[[[SURWRFROWLWOH!!

'HDU3ULQFLSDO,QYHVWLJDWRU!!DQG6WXG\7HDP

&RURQDYLUXV&29,'KDVLPSDFWHGVHYHUDOFRPPXQLWLHVDQGEXV LQHVVDFWLYLWLHVRYHUWKHSDVWVHYHUDOPRQWKV
:KLOHZHZRUNWRZDUGWKHVXFFHVVIXOFRQGXFWRIFOLQLFDOVWXGLHV RXUFRPPLWPHQWFRQWLQXHVWREHWKHVDIHW\RI
SDWLHQWVKHDOWKFDUHSURIHVVLRQDOVDQGWRRXUFRPPXQLWLHV7KHUHIRUHZHZRXOGOLNHWRVKDUHWKHIROORZLQJUHYLVLRQVDGGLW LRQVUHODWHGWRWKHDERYHUHIHUHQFHG-RKQVRQ	
-RKQVRQ9LVLRQ&DUHFRPSDQ\V SRQVRUHGFOLQLFDOWULDOV\RXDUHFXUUHQWO\ZRUNLQJRQRUF RQVLGHULQJSDUWLFLSDWLRQ
ZLWKLQ
3URWRFRO
x*XLGHOLQHVIRU&29,'5LVN0LWLJDWLRQSURYLGHGLQWKH$SSHQGL [VHFWLRQ
3URWRFRO6LJQDWXUH3DJH

x:LOOLQFOXGHDVWDWHPHQWLQGLFDWLQJ WKH3ULQFLSDO,QYHVWLJDWRU DJUHHVWRFRQGXFWWKHVWXG\LQFRPSOLDQFH
ZLWKDOOORFDOVWDWHDQGJRYHUQP HQWDOJXLGHOLQHVIRU&29,' ULVNPLWLJDWLRQ

,QIRUPHG&RQVHQW

x:LOOLQFOXGHLQIRUPDWLRQFRQFHUQLQJWKHVWXG\DVVRFLDWHGULVNV UHODWHGWRWKH&29,'SDQGHPLFLQEROG
IRQWDQGRUER[HGRQWKHILUVWSDJH RIWKH,QIRUPHGFRQVHQWGRF XPHQW
&29,'5LVN&RQWURO&K HFNOLVWIRU&OLQLFDO6WXGLHV
x:LOOLQFOXGH&29,'ULVNFRQWUROPHDVXUHVWKDWDUHUHTXLUHGW RHQVXUHWKHVDIHW\DQGKHDOWKRIVXEMHFWV
VLWHVWDIIDQGPRQLWRUVGXULQJWKHSDQGHPLF

:HZDQWWRHQFRXUDJHWKHQHHGIRURSHQOLQHVRIFRPPXQLFDWLRQD ERXWSRWHQWLDOFKDOOHQJHV\RXPD\IRUHVHHDVWKH
UHVXOWRIWKHFXUUHQW&29,'VLWXDWLRQ7KHUHIRUHZHHQFRXUD JH\RXWRUHJXODUO\FRQQHFWZLWK\RXUUHVSHFWLYH
-RKQVRQ	-RKQVRQFOLQLFDOVWX G\WHDP&OLQLFDO5HVHDUFK$VVRFL DWH&5$/HDG&5$RU6W XG\0DQDJ HUV
7KDQN\RXIRU\RXUFRQWLQXHGHQ JDJHPHQWFROODERUDWLRQDQGGHG LFDWLRQWR\RXUVWXG\VXEMHFWVGXULQJWKLV
FKDOOHQJLQJWLPH

3OHDVHILOHWKLVOHWWHULQ\RXUVLWHILOHVWXG\FRUUHVSRQGHQFH 




CR-6470, v 2.0  
 
Page 187 of 192JJVC CONFIDENTIAL
7LWOH *XLGHOLQHVIRU&29,'5LVN0LWLJDWLRQ
'RFXPHQW7\SH 
'RFXPHQW1XPEHU  5HYLVLRQ1XPEHU


&29,'5LVN&RQWURO &KHFNOLVW$WWDFKPHQW%


6WXG\1XPEHU
6LWH1XPEH U
3ULQFLSDO,QYHVWL JDWRU3,1DPH 

7KHIROORZLQJ&29,'ULVNFRQWUROPHWKRGVDUHUHTXLUHGWRFRQ GXFW-RKQVRQ	-RKQVRQ9LVRQ&DUHFOLQLFDO
VWXGLHV3OHDVHUHYLHZWKHIROORZLQJUHTXLUHPHQWVDQG,QLWLDOHDFKUHTXLUHPHQW
3,,QLWLDOV *HQHUDO6LWH6DIHW \3ODQQLQJ0HDVXUHV
6 LJQDJHZLWKLQVLWHGHVFULELQ J5LVN&RQWUROPHWKRGV
 6RFLDO'LVWDQFLQ JSUDFWLFHVWKURX JKRXWVLWHZDLWLQ JURRPVOREE \H[DPURRPVHWF
 1RQFRQWDFWWKHUPRPHWHUDYDLODEOHWRDVVHVVWHPSHUDWXUHVRIVWDI IDQGSDWLHQWV
 7UDLQLQJRQSDWLHQWIORZDQGSK \VLFDOGLVWDQFLQ JLQZDLWLQJURRP
 (VWDEOLVKORQ JHUWLPHIUDPHEHWZHHQSDWLHQWDSSRLQWPHQWVWRUHGXFHSHUVRQVLQ WKHVLWH
 6WDIIVKRXOGUHFHLYHMREVSHFLILFWUDLQLQJRQ33(DQGGHPRQVWU DWHFRPSHWHQF\ZLWKVHOHFWLRQDQG
SURSHUXVHRI33(D QGZHDUDWDOOWLPHVGXULQJLQWHUDFWLRQVZLW KVXEMHFWVHJSXWWLQJRQDQG
UHPRYLQJZLWKRXWVHOIFRQWDPLQDWLRQ

3,,QLWLDOV 6LWH6WDII'DLO \6DIHW\0HDVXUHV
 $VSDUWRIURXWLQHSUDFWLFHVLWHVWDIIVKRXOGUHJXODUO\PRQLW RUWKHPVHOYHVIRUIHYHUDQGV\PSWRPV
RI&29,'LQFOXGLQ JWHPSHUDWXUHFKHFNV
 $Q\VWDIIPHPEHULQFOXGLQJQRQ VWXG\FOLQLFVWDIIDQG,QYHVWL JDWRUVVKRZLQJVLJQVRIEHLQJVLFN
RUWHVWLQJSRVLWLYHIRU&29,' PXVWQRWEHSHUPLWWHGWRZRUN RQDFWLYLW\WKDWPD\H[SRVHVWXG\
UHODWHGVWDIIDQGVXEMHFWDQGWKH6SRQVRUVKDOOEHLQIRUPHG
127(,QIRUP--9&LQKRXUVRI DQ\&29,'FDVHVDQGDOOSRW HQWLDOH[SRVXUHGXULQJ
WKHFOLQLFDOVWXG\
 (QVXUHWKDWDOOVWDIIZHDUDPDVN*ORYHVVKRXOGEHUHTXLUHGZKHQZRUNLQ
JGLUHFWO\ZLWKSDWLHQWVDQGFKDQ JHGEHWZHHQHDFKSDWLHQ W
 +DYHVWDIIWKRURXJKO\ZDVKKDQG VIRUDWOHDVWVHFRQGVRUXV HDQDOFRKROEDVHGKDQGVDQLWL]HU
ZKHQWKH\DUULYHEHIRUHDQGDIWHUHDFKSDWLHQWEHIRUHHDWLQ JDQGDIWHUXVLQ JWKHEDWKURRP
 &OHDQLQJDQGGLVLQIHFWLRQSUR FHGXUHVIRUH[DPURRPVDQGLQVWUXPHQWVRUHTXLSPHQWEHWZHHQ
SDWLHQWVZLWK JORYHV
 &OHDQLQJDQGGLVLQI HFWLRQSURFHGXUHVIRUFRPPRQO\WRXFKHGVXUI DFHVGRRUVFKDLUVFRPSXWHUV
SKRQHVHWFZLWK JORYHV

3,,QLWLDOV %HIRUHD3DWLHQWRU6WXG \9LVLW
 3DWLHQWVVKRXOGEHDVNHGSULRUWRHQWHULQJWKHVLWHDERXWIHYH UDQGUHVSLUDWRU\LOOQ HVVDQGZKHWKHU
WKH\RUDIDPLO\PHPEHUKDYHKDGFRQWDFWZLWKDQRWKHUSHUVRQZL WKFRQILUPHG&29,'LQWKH
SDVWGD\V3DWLHQWV H[KLELWLQJVLJQVRIE HLQJVLFNVKRXOGEH UHVFKHGXOHGZKHQWKHLUV\PSWRPV
UHVROYH
 ,QVWUXFWSDWLHQWVWKDWFRPSDQL RQVVKRXOGUHPDLQRXWVLGHRIWKH IDFLOLW\DQGQRWDFFRPSDQ\WKH
SDWLHQWLQWRWKHIDFLOLW\XQOHVVWKH \DUHDSDUHQWJXDUGLDQRIWKHSDWLHQWRULIWKH\DUHDWUXH
FDUHJLYHUDQGQHHGWRDVVLVWWKHSDWLHQ W
 5HTXHVWWKHSDWLHQWWRFDOORUWH[WWKHRIILFHXSRQDUULYDOVR HQWUDQFHWRDQGPRYHPHQWWKURXJK
IDFLOLW\FDQEHFRRUGLQDWHGE \VLWHVWDII


CR-6470, v 2.0  
 
Page 188 of 192JJVC CONFIDENTIAL
7LWOH *XLGHOLQHVIRU&29,'5LVN0LWLJDWLRQ
'RFXPHQW7\SH 
'RFXPHQW1XPEHU  5HYLVLRQ1XPEHU

3,,QLWLDOV 3DWLHQWV(QWHULQ JWKHVLWH
 7HPSHUDWXUHFKHFNVXWLOL]LQJDQRQFRQWDFWWKHUPRPHWHUIRUDOO SDWLHQWVDQGFRPSDQLRQVHQWHULQJ
WKHVLWH
 $OOSDWLHQWVDQGFRPSDQLRQVPXVWZHDUFORWKRUGLVSRVDEOHPDVNDWDO OWLPHVLQWKHVLWH
 0DLQWDLQVRFLDOGLVWDQFLQJ:DLWLQJURRPVRUOREELHVVKRXOGEH DVHPSW\DVSRVVLEOH$GYLVH
VHDWHGSDWLHQWVWRUHPDLQDWOHDVWIHHWIURPRQHDQRWKHU
 &RPPXQDORE MHFWVLQHJWR\VUHDGLQJPDWHULDOVHWFVKRXOGEH UHPRYHGR UFOHDQHGUH JXODUO\


,FHUWLI\WKDW,KDYHUHDGDQGDJUHHWRLPSOHPHQWDOOWKHOLVWH G&29,'5LVN&RQWURO0HDVXUHVUHTXLUHGIRUWKH
FRQGXFWRI-RKQVRQ	-RKQVRQ9LVLRQ&DUHVWXGLHV


3ULQFLSDO,QYHVWLJDWR U6LJQDWXUHDQG'DWH


CR-6470, v 2.0  
 
Page 189 of 192JJVC CONFIDENTIAL
7LWOH *XLGHOLQHVIRU&29,'5LVN0LWLJDWLRQ
'RFXPHQW7\SH 
'RFXPHQW1XPEHU  5HYLVLRQ1XPEHU

5(6285&(/,1.6

865HVRXUFH/LQNV

x26+$7UDLQLQJ
KWWSVZZZRVKDJRY6/7&FRYLGFRQWUROSUHYHQWLRQKWPO 

3HUVRQDO3URWHFWLYH(TXLSPHQW33(7UDLQLQJ&'&KWWSVZZZFGFJRYFRURQDYLUXVQFRYKFSXVLQJSSHKWPO

x,	57UDLQLQJ$&898(
/HQV$VVLVW KWWSVZZZDFXYXHFRPOHQVDVVLVW 

x&OLQLF3UHSDUHGQHVV*XLGHV&'&KWWSVZZZFGFJRYF RURQDYLUXVQFRY KFSFOLQLFSUHSDUHGQH VVKWPO
$2$KWWSVDRDXEHUIOLSFRPL DRDJXLGDQFHIRUUHRSHQLQJ SUDFWLFHVFRYLGā"P 
$PHULFDQ2SWRPHWULF$VVRFLDWLRQ KWWSVZZZDRDRUJRSWRPHWU\SUDFWLFHUHDFWLYDWLRQSUHSDUHGQHV V
JXLGH

xOQ2IILFH'LVLQIHFWLRQRI0XOWL3DWLHQW8VH'LDJQRVWLF&RQWDFW /HQVHV
KWWSVZZZJSOLLQIRZSFRQWHQWXSORDGVLQRIILFHGLVLQIHFWLQJRIGLDJQRVWLF
OHQVHVSGI
2865HVRXUFH/LQNV

x8SGDWHVRQORFDOUHJXODWLRQVLQ+RQJ.RQJKWWSVZZZFRURQDYLUXVJRYKNHQJLQGH[KWPO 

x5HVXPSWLRQRIRSWLFDOVHUYLFHVLQ(QJODQG/HWWHUIURP0DWW1HO LJDQDQG3RRQDP6KDUPD
KWWSVZZZHQJODQGQKVXNFRURQDYLUXVZSFRQWHQWXSORDGVVLWHV &UH RSHQLQJRIRSWLFDO
VHUYLFHVOHWWHUMXQHSGI

x1+62SWLFDO/HWWHUKWWSVZZZHQJODQGQKVXNFRURQDYLUXVZSFRQWHQWXSORDGVVLWHV &RSWLFDOOHWWHUDSULO
SGI

x7KH&ROOHJHRI2SWRPHWULVWVSULPDU\H\HFDUH&29,'JXLGDQFH 5HGSKDVH
KWWSVZZZFROOHJHRSWRPHWULVWVRUJWKHFROOHJH PHGLDKXEQHZV OLVWLQJFRURQDYLUXVFRYLGJXLGDQFH
IRURSWRPHWULVWVKWPO 

x7KH&ROOHJHRI2SWRPHWULVWV &29,'&ROOHJHXSGDWHV
KWWSVZZZFROOHJHRSWRPHWULVWVRUJWKHFROOHJH PHGLDKXEQHZV OLVWLQJFRURQDYLUXVDGYLFHIRU
RSWRPHWULVWVKWPO&ROOHJH*XLGHOLQHV

x,QIHFWLRQ&RQWURO*XLGHOLQHVQG 5HWULHYHGIURP&DQDGLDQ$ VVRFLDWLRQ2I2SWRPHWULVWV
KWWSVRSWRFDVLWHVGHIDXOWILOHVUHVRXUFHVGRFXPHQWVLQIHFWL RQBFRQWUROBJXLGHOLQHVBSGI
x,QIHFWLRQSUHYHQWLRQDQGFRQWURO IRU&29,',QWHULPJXLGDQFH IRURXWSDWLHQWDQG DPEXODWRU\FDUH
VHWWLQJV0D\0D\5HWULHYHGIURP*RYH UQPHQWRI&DQD GDKWWSVZZZFDQDGDFDHQSXEOLF
KHDOWKVHUYLFHVGLVHDVHVQRY HOFRURQDYLUXVLQIHFWLRQJXLGD QFHGRFXPHQWVLQWHULPJXLGDQFH
RXWSDWLHQWDPEXODWRU\FDUHVHWWLQJVKWPO
CR-6470, v 2.0  
 
Page 190 of 192JJVC CONFIDENTIAL
7LWOH *XLGHOLQHVIRU&29,'5LVN0LWLJDWLRQ
'RFXPHQW7\SH 
'RFXPHQW1XPEHU  5HYLVLRQ1XPEHU

x,QIRUPDWLRQIRU0HPEHUV2Q&RURQDYLUXV&29,'QG5HWU LHYHGIURP&DQDGLDQ$VVRFLDWLRQ2I
2SWRPHWULVWV
KWWSVRSWRFDVLWHVGHIDXOWILOHV UHVRXUFHVGRFXPHQWVLQIRUPD WLRQBIRUBPHPEHUVBRQBFRURQDYLUXVSGI
x&RURQDYLUXV&29,'UHVRXUFHVIRUKHDOWKSURIHVVLRQDOVLQFO XGLQJDJHGFDUHSURYLGHUVSDWKRORJ\
SURYLGHUVDQGKHDOWKFDUHPDQDJH UV6HSWHPEHU5HWUL HYHGIURP$XVWUDOLDQ*RYHUQPHQW
'HSDUWPHQWRI+HDOWK
KWWSVZZZKHDOWKJRYDXUHVRX UFHVFROOHFWLRQVFRURQDYLUXVFR YLGUHVRXUFHVIRUKHDOWKSURIHVVLRQDOV
LQFOXGLQJDJHGFDUHSURYLGHUVSDWKRORJ\SURYLGHUVDQGKHDOWKFD UHPDQDJHUV

x(QYLURQPHQWDO&OHDQLQJDQG'LVLQI HFWLRQ3ULQFLSOHVIRU&29,' QG5HWULHYHGIURP$XVWUDOLDQ
*RYHUQPHQW'HSDUWPHQWRI+HDOWK
KWWSVZZZKHDOWKJRYDXVLWHVGHIDXOWI LOHVGRFXPHQWV HQYLURQPHQWDOFOHDQ LQJDQGGLVLQIHFWLRQ
SULQFLSOHVIRUFRYLGSGI
x,QIHFWLRQFRQWUROJXLGHOLQHVDQGDGYLFHQG5HWULHYHGIURP 2SWRPHWU\$XVWUDOLD
KWWSVZZZRSWRPHWU\RUJDXSUDFWLFHSURIHVVLRQDOVXSSRUWFRUR QDYLUXVFRYLGZKDWRSWRPHWULVWVQHHG
WRNQRZFRYLGFOLQLFDODGYLFHLQIHFWLRQFRQWUROJXLGHOLQHVD QGDGYLFH


CR-6470, v 2.0  
 
Page 191 of 192JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
PROTOCOL COMPLIANCE INVEST IGATOR(S) SIGNATURE PAGE 
Protocol Number and Title: CR-6470 Validation of senofilcon A with new UV / HEV Filter
Version and Date: 2.0 14 September 2021
I have read and understand the protocol sp ecified above and agree on its content.  
I agree to conduct this study according to ISO 14155:2020,1GCP and ICH guidelines,2the 
Declaration of Helsinki,3United States (US) Code of Federal Regulations (CFR),4and the 
pertinent individual country laws/regulations and to comply with its obligations, subject to 
ethical and safety considerations. The Principal Investigator is responsible for ensuring that all 
clinical site personnel, including Sub-Investigators adhere to all ICH2regulations and GCP 
guidelines regarding clinical trials  during and after study completion.
I will assure that no deviation fr om or changes to the protocol will take place without prior 
agreement from the Sponsor and documented approval from the Institutional Review Board 
(IRB), except where necessary to eliminate an immediate hazard(s) to the trial participants.
I am responsible for ensuring that all clinical site personnel including Sub-Investigators adhere 
to all ICH2regulations and GCP guidelines regarding clinical trials during and after study 
completion.
All clinical site personnel involved in the conduct of this study have completed Human 
Subjects Protection Training. 
I agree to ensure that all clinical site personnel involved in the conduct of this study are 
informed about their obligations in meeting the above commitments.
I shall not disclose the information contained in this protocol or any results obtained from this 
study without written authorization.I have read the suggested guidance provided by JJVCI pertaining to the COVID-19 risk 
mitigation, (COVID-19 Work Instruction in th e Appendix G of this protocol). I agree to 
conduct this study in compliance with local,  state, governmental guidance for COVID-19 risks.
Principal Investigator:
Signature Date
Name and Professional Position (Printed)
Institution/Site:
Institution/Site Name
Institution/Site Address
CR-6470, v 2.0  
 
Page 192 of 192JJVC CONFIDENTIAL